<?xml version="1.0" encoding="UTF-8"?>
<PAPER>

<BODY>
<DIV><P>
</P>
<P>[0001] <ne id="WO2007045867.HC.class-names.1" epochem-id="EPOCHEM:NEW:CLASS:279" name="3-aminoindole" comment="" chebi-id="WO2007045867:337253" relevant="true" type="CLASS">3-AMINOINDOLE</ne> COMPOUNDS AS CRTH2 RECEPTOR LIGANDS
Field of the Invention
This invention relates to a class of <ne id="WO2007045867.HC.class-names.2" epochem-id="EPOCHEM:NEW:CLASS:279" name="3-aminoindole" comment="" chebi-id="WO2007045867:337253" relevant="true" type="CLASS">3-aminoindole</ne> compounds which are ligands of the CRTH2 receptor (Chemoattractant Receptor-homologous molecule expressed on T Helper cells type 2), and their use in the treatment of diseases responsive to modulation of CRTH2 receptor activity, principally diseases having a significant inflammatory component. The invention also relates to novel members of that class of ligands and pharmaceutical compositions containing them. Background of the Invention Mast cells are known to play an important role in allergic and immune responses through the release of a number of mediators, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.5" epochem-id="EPOCHEM:COMPOUND:3720" name="histamine" comment="" chebi-id="CHEBI:18295" relevant="false">histamine</ne>, <ne id="WO2007045867.HC.class-names.73" epochem-id="EPOCHEM:NEW:CLASS:105" name="leukotrienes" comment="" chebi-id="CHEBI:25029" relevant="false" type="CLASS">leukotrienes</ne>, <ne id="WO2007045867.HC.class-names.74" epochem-id="EPOCHEM:NEW:CLASS:905" name="cytokines" comment="" chebi-id="WO2007045867:914767" relevant="false" type="CLASS">cytokines</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.413" epochem-id="EPOCHEM:COMPOUND:2993" name="prostaglandin D2" comment="" chebi-id="CHEBI:15555" relevant="false">prostaglandin D2</ne>, etc (Boyce; Allergy Asthma Proc, 2004, 25, 27-30).
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.414" epochem-id="EPOCHEM:COMPOUND:2993" name="prostaglandin D2" comment="" chebi-id="CHEBI:15555" relevant="false">Prostaglandin D2</ne> (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.415" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne>) is the major cyclooxygenase metabolite of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.7" epochem-id="EPOCHEM:NEW:COMPOUND:1112" name="arachadonic acid" comment="arachidonic acid" chebi-id="CHEBI:15843" relevant="false">arachadonic acid</ne> produced by mast cells in response to allergen challenge (Lewis et al; J. Immunol., 1982, 129, 1627-1631). It has been shown that <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.416" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> production is increased in patients with systemic mastocytosis (Roberts; N. Engl. J. Med., 1980, 303, 1400-1404), allergic rhinitis (Naclerio et al; Am. Rev. Respir. Dis., 1983, 128, 597-602; Brown et al; Arch. Otolarynol. Head Neck Surg., 1987, 113, 179-183; Lebel et al; J. Allergy Clin. Immunol., 1988, 82, 869-877), bronchial asthma (Murray et al; N. Engl. J. Med., 1986, 315, 800-804; Liu et al; Am. Rev. Respir. Dis., 1990, 142, 126-132; Wenzel et al; J. Allergy Clin. Immunol., 1991 , 87, 540-548), ), allergic conjunctivitis (Proud et al; J Allergy Clin Immunol. 1990 May;85(5):896-905) and urticaria (Heavey et al; J. Allergy Clin. Immunol., 1986, 78, 458-461).
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.417" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> mediates it effects through two receptors, the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.418" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> (or DP) receptor (Boie et al; J. Biol. Chem., 1995, 270, 18910-18916) and the chemoattractant receptor-homologous molecule expressed on Th2 (or CRTH2) (Nagata et al; J. Immunol., 1999, 162, 1278-1289; Powell; Prostaglandins Luekot. Essent. Fatty Acids, 2003, 69, 179-185). Therefore, it has been postulated that agents that antagonise the effects of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.419" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> at its receptors may have beneficial effects in a number of disease states. The CRTH2 receptor has been shown to be expressed on cell types associated with allergic inflammation, such as basophils, eosinophils, and Th2-type immune helper cells (Hirai et al; J. Exp. Med., 2001 , 193, 255-261). The CRTH2 receptor has been shown to mediate <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.420" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne>-mediated cell migration in these cell types (Hirai et al; J. Exp.
Med., 2001, 193, 255-261), and also to play a major role in neutrophil and eosinophil cell recruitment in a model of contact dermatitis (Takeshita et al; Int. Immunol., 2004, 16, 947-959). In addition, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.421" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> has been shown to activate human eosinophils and Th2 cells (Gazi et al; Prostaglandins Other Lipid Mediat. 2005 Jan;75(1-4):153-67). <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.3" epochem-id="EPOCHEM:NEW:COMPOUND:1111" name="Ramatroban" comment="" chebi-id="WO2007045867:674477" relevant="true">Ramatroban</ne> {<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.2" epochem-id="EPOCHEM:NEW:COMPOUND:1110" name="(3R)-3-[(4-fluorophenyl)sulfonyl-amino ]-1, 2,3,4-tetrahydro-9H-carbazole-9-propanoicacid" comment="" chebi-id="WO2007045867:658460" relevant="true">(3R)-3-[(4-fluorophenyl)sulfonyl- amino]-1 ,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid</ne>}, a dual CRTH2 and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.345" epochem-id="EPOCHEM:NEW:COMPOUND:1432" name="thromboxane" comment="" chebi-id="CHEBI:26995" relevant="false">thromboxane</ne> A2 receptor antagonist, has been shown to attenuate these responses (Sugimoto et al; J. Pharmacol. Exp. Ther., 2003, 305, 347-352; Takeshita et al; op. 5 cit). The potential of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.422" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> both to enhance allergic inflammation and induce an inflammatory response has been demonstrated in mice and rats. Transgenic mice over expressing <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.423" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> synthase exhibit an enhanced pulmonary eosinophilia and increased levels of Th2 <ne id="WO2007045867.HC.class-names.75" epochem-id="EPOCHEM:NEW:CLASS:905" name="cytokines" comment="" chebi-id="WO2007045867:914767" relevant="false" type="CLASS">cytokines</ne> in response to allergen challenge (Fujitani et al, J. Immunol., 2002, 168, 443-449). In addition, exogenously administered CRTH2
</P>
<P>10 agonists enhance the allergic response in sensitised mice (Spik et al; J. Immunol., 2005, 174, 3703-3708). In rats exogenously applied CRTH2 agonists cause a pulmonary eosinophilia but a DP agonist (BW 245C) or a TP agonist (l-BOP) showed no effect (Shirashi et al; J. Pharmacol. Exp. Ther., 2005, 312, 954-960). These observations suggest that CRTH2 antagonists may have valuable properties for the
</P>
<P>15 treatment of diseases mediated by <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.424" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne>. As there is significant evidence to support a role for <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.425" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> in eosinophil, basophil and lymphocyte recruitment it is anticipated that CRTH2 antagonists can also be used in the treatment of eosinophilic disorders such as Churg-Strauss syndrome and sinusitis; basophil associated diseases such as chronic urticaria; inflammatory diseases associated with T lymphocytes including
</P>
<P>20 psoriasis, eczema, inflammatory bowel disease, Crohn's Disease, Chronic Obstructive Pulmonary Disease and arthritis.
In addition to <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.4" epochem-id="EPOCHEM:NEW:COMPOUND:1111" name="Ramatroban" comment="" chebi-id="WO2007045867:674477" relevant="true">Ramatroban</ne> a number of other CRTH2 antagonists have been described. Examples include: <ne id="WO2007045867.HC.class-names.4" epochem-id="EPOCHEM:NEW:CLASS:281" name="indole" comment="" chebi-id="CHEBI:35581" relevant="false" type="CLASS">indole</ne>-<ne id="WO2007045867.HC.class-names.3" epochem-id="EPOCHEM:NEW:CLASS:280" name="aceticacids" comment="" chebi-id="WO2007045867:696067" relevant="false" type="CLASS">acetic acids</ne> (WO2003/022813; WO2003/066046; WO2003/066047; WO2003/097042; WO2003/097598;
</P>
<P>25 WO2003/101961; WO2003/101981; WO2004/007451; WO2004/078719; WO2004/106302; WO2005/019171 ; GB2407318; WO2005/040112;
WO2005/040114; WO2005/044260); <ne id="WO2007045867.HC.class-names.6" epochem-id="EPOCHEM:NEW:CLASS:282" name="tetrahydroquinolines" comment="" chebi-id="WO2007045867:410570" relevant="false" type="CLASS">tetrahydroquinolines</ne> (EP1413306; EP1435356; WO2004/032848; WO2004/035543; WO2005/007094), and <ne id="WO2007045867.HC.class-names.7" epochem-id="EPOCHEM:NEW:CLASS:283" name="phenylacetic acids" comment="" chebi-id="WO2007045867:498248" relevant="false" type="CLASS">phenylacetic acids</ne> (WO2004/058164; WO2004/089884; WO2004/089885; WO2005/018529).
</P>
<P>30 Recently, International Patent Application No. WO 2006/060535 relating to modulators of PPARs has been published. The general structural formula defined therein encompasses CRTH2 receptor antagonist <ne id="WO2007045867.HC.class-names.8" epochem-id="EPOCHEM:NEW:CLASS:284" name="aminoindoles" comment="" chebi-id="WO2007045867:397080" relevant="false" type="CLASS">aminoindoles</ne> of the kind with which this invention is concerned, but neither their utility nor any specific examples of any such compound are disclosed.
</P>
<P>35. Detailed Description of the invention
One aspect of the invention provides a compound of general formula [I] or a pharmaceutically acceptable salt, <ne id="WO2007045867.HC.class-names.69" epochem-id="EPOCHEM:NEW:CLASS:451" name="N-oxide" comment="" chebi-id="CHEBI:35580" relevant="false" type="CLASS">N-oxide</ne>, <ne id="WO2007045867.HC.class-names.65" epochem-id="EPOCHEM:NEW:CLASS:450" name="hydrate" comment="" chebi-id="CHEBI:35505" relevant="false" type="CLASS">hydrate</ne>, or solvate thereof:
EMI5.1
</P>
<P>[I] in which:
R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt; and R&lt;4&gt; are independently <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.279" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, (CrC6) alkyl, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1005" epochem-id="EPOCHEM:NEW:LIGAND:536" name="halo" comment="" chebi-id="WO2007045867:554182" relevant="false">halo</ne>, -S(O)<ne type="FORMULA" id="WO2007045867.HC.formula-names.66" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="WO2007045867:595830" relevant="false">nR</ne>&lt;10&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.67" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;11&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.11" epochem-id="EPOCHEM:NEW:FORMULA:153" name="SO2R" comment="" chebi-id="CHEBI:29825" relevant="false">SO2R</ne>&lt;10&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.20" epochem-id="EPOCHEM:NEW:FORMULA:155" name="SO2N" comment="" chebi-id="WO2007045867:676309" relevant="false">SO2N</ne>(R&lt;11&gt;)2, -N(R&lt;11&gt;)2, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.68" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;11&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.95" epochem-id="EPOCHEM:NEW:FORMULA:267" name="C(O)R" comment="" chebi-id="WO2007045867:714016" relevant="false">C(O)R</ne>&lt;10&gt;, -C(O)N(R&lt;11&gt;)2, - <ne type="FORMULA" id="WO2007045867.HC.formula-names.16" epochem-id="EPOCHEM:NEW:FORMULA:154" name="CO2R" comment="" chebi-id="WO2007045867:616448" relevant="false">CO2R</ne>&lt;11&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.96" epochem-id="EPOCHEM:NEW:FORMULA:267" name="C(O)R" comment="" chebi-id="WO2007045867:714016" relevant="false">C(O)R</ne>&lt;10&gt;, <ne type="FORMULA" id="WO2007045867.HC.formula-names.6" epochem-id="EPOCHEM:NEW:FORMULA:152" name="CN" comment="" chebi-id="CHEBI:48819" relevant="false">CN</ne> or a group OR&lt;12&gt;; wherein each R&lt;10&gt; is independently (CrC6)alkyl, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.2" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.886" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3341" relevant="false">cycloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.923" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.953" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33471" relevant="false">heteroaryl</ne>;
R&lt;11&gt; is independently <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.280" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.84" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.3" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.887" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3342" relevant="false">cycloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.924" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.954" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33472" relevant="false">heteroaryl</ne>;
R&lt;12&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.281" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.85" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.4" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.888" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3343" relevant="false">cycloalkyl</ne>, or a group - <ne type="FORMULA" id="WO2007045867.HC.formula-names.12" epochem-id="EPOCHEM:NEW:FORMULA:153" name="SO2R" comment="" chebi-id="CHEBI:29825" relevant="false">SO2R</ne>&lt;10&gt;, wherein n is O 1 or 2;
R&lt;5&gt; and R&lt;6&gt; are independently <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.282" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, (CrC6) alkyl or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.82" epochem-id="EPOCHEM:NEW:LIGAND:210" name="(CrC6) haloalkyl" comment="(C1C6) haloalkyl" chebi-id="WO2007045867:195695" relevant="false">(CrC6) haloalkyl</ne>, or R&lt;5&gt; and R&lt;6&gt; together with the atom to which they are attached form a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.889" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3344" relevant="false">cycloalkyl</ne> group; R&lt;7&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.283" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.86" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.5" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>;
R&lt;8&gt; is <ne type="LIGAND" id="WO2007045867.HC.ligand-names.925" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.955" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33473" relevant="false">heteroaryl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.840" epochem-id="EPOCHEM:NEW:LIGAND:523" name="aryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:456700" relevant="false">aryl-fused-heterocycloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.834" epochem-id="EPOCHEM:NEW:LIGAND:522" name="heteroaryl-fused-cycloalkyl" comment="" chebi-id="WO2007045867:476609" relevant="false">heteroaryl-fused-cycloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.681" epochem-id="EPOCHEM:NEW:LIGAND:301" name="heteroaryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:242991" relevant="false">heteroaryl-fused-heterocycloalkyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.880" epochem-id="EPOCHEM:NEW:LIGAND:526" name="aryl-fused- cycloalkyl" comment="" chebi-id="WO2007045867:764181" relevant="false">aryl-fused-cycloalkyl</ne>; and
R&lt;9&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.284" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.87" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.6" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.892" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3345" relevant="false">cycloalkyl</ne>. Compounds with which the invention is concerned are CRTH2 receptor antagonists, and are selective over the DP receptor.
A second aspect of the invention is a pharmaceutical composition comprising a compound (I) as defined above together with one or more pharmaceutically acceptable carriers.
A third aspect of the invention is the use of a compound (I) as defined above, or a pharmaceutically acceptable salt, <ne id="WO2007045867.HC.class-names.70" epochem-id="EPOCHEM:NEW:CLASS:451" name="N-oxide" comment="" chebi-id="CHEBI:35580" relevant="false" type="CLASS">N-oxide</ne>, <ne id="WO2007045867.HC.class-names.66" epochem-id="EPOCHEM:NEW:CLASS:450" name="hydrate" comment="" chebi-id="CHEBI:35505" relevant="false" type="CLASS">hydrate</ne> or solvate thereof, in the manufacture of a composition for treatment of conditions responsive to modulation of CRTH2 receptor activity.
A fourth aspect of the invention is a method of treatment of conditions responsive to modulation of CRTH2 receptor activity, comprising administering to a patient suffering such disease an effective amount of a compound (I) as defined above, or a pharmaceutically acceptable salt, <ne id="WO2007045867.HC.class-names.71" epochem-id="EPOCHEM:NEW:CLASS:451" name="N-oxide" comment="" chebi-id="CHEBI:35580" relevant="false" type="CLASS">N-oxide</ne>, <ne id="WO2007045867.HC.class-names.67" epochem-id="EPOCHEM:NEW:CLASS:450" name="hydrate" comment="" chebi-id="CHEBI:35505" relevant="false" type="CLASS">hydrate</ne> or solvate thereof. Important conditions responsive to modulation of CRTH2 receptor activity include asthma, chronic obstructive pulmonary disease, allergic airway syndrome, bronchitis, cystic fibrosis, emphysema and rhinitis,
Other conditions responsive to modulation of CRTH2 receptor activity include psoriasis, dermatitis (atopic and non-atopic), Crohn's disease, ulcerative colitis, and irritable bowel disease. Terminology
As used herein, the term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.833" epochem-id="EPOCHEM:NEW:LIGAND:521" name="(Ca-Cb)alkyl" comment="" chebi-id="WO2007045867:620992" relevant="false">(Ca-Cb) alkyl</ne>" wherein a and b are integers refers to a straight or <ne id="WO2007045867.HC.class-names.63" epochem-id="EPOCHEM:NEW:CLASS:449" name="branched chain alkyl" comment="" chebi-id="WO2007045867:584211" relevant="false" type="CLASS">branched chain alkyl</ne> radical having from a to b carbon atoms. Thus when a is 1 and b is 6, for example, the term includes <ne type="LIGAND" id="WO2007045867.HC.ligand-names.725" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.209" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.225" epochem-id="EPOCHEM:NEW:LIGAND:15" name="n-propyl" comment="" chebi-id="CHEBI:26308" relevant="false">n-propyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.226" epochem-id="EPOCHEM:NEW:LIGAND:126" name="isopropyl" comment="" chebi-id="CHEBI:30353" relevant="false">isopropyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.227" epochem-id="EPOCHEM:NEW:LIGAND:127" name="n-butyl" comment="" chebi-id="CHEBI:41264" relevant="false">n-butyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.228" epochem-id="EPOCHEM:NEW:LIGAND:212" name="isobutyl" comment="" chebi-id="CHEBI:30356" relevant="false">isobutyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.229" epochem-id="EPOCHEM:NEW:LIGAND:128" name="sec-butyl" comment="" chebi-id="CHEBI:45557" relevant="false">sec-butyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.230" epochem-id="EPOCHEM:NEW:LIGAND:213" name="t-butyl" comment="" chebi-id="CHEBI:30355" relevant="false">t-butyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.231" epochem-id="EPOCHEM:NEW:LIGAND:214" name="n-pentyl" comment="" chebi-id="WO2007045867:848229" relevant="false">n-pentyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.232" epochem-id="EPOCHEM:NEW:LIGAND:215" name="n-hexyl" comment="" chebi-id="WO2007045867:584842" relevant="false">n-hexyl</ne>.
As used herein, the term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.983" epochem-id="EPOCHEM:NEW:LIGAND:532" name="(Ca-Cb)fluoroalkyl" comment="" chebi-id="WO2007045867:49662" relevant="false">(Ca-Cb) fluoroalkyl</ne>" wherein a and b are integers refers to a straight or <ne id="WO2007045867.HC.class-names.64" epochem-id="EPOCHEM:NEW:CLASS:449" name="branched chain alkyl" comment="" chebi-id="WO2007045867:584211" relevant="false" type="CLASS">branched chain alkyl</ne> radical having from a to b carbon atoms in which the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.285" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne> atoms all replaced by <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.441" epochem-id="EPOCHEM:NEW:COMPOUND:512" name="fluorine" comment="" chebi-id="CHEBI:24061" relevant="false">fluorine</ne> (fully fluorinated) or in which some of the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.286" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne> atoms are replaced by <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.442" epochem-id="EPOCHEM:NEW:COMPOUND:512" name="fluorine" comment="" chebi-id="CHEBI:24061" relevant="false">fluorine</ne> (partially fluorinated). The term includes, for example -<ne type="FORMULA" id="WO2007045867.HC.formula-names.1" epochem-id="EPOCHEM:NEW:FORMULA:42" name="CF3" comment="" chebi-id="WO2007045867:425956" relevant="false">CF3</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.2" epochem-id="EPOCHEM:NEW:FORMULA:68" name="CHF2" comment="" chebi-id="WO2007045867:247640" relevant="false">CHF2</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.3" epochem-id="EPOCHEM:NEW:FORMULA:69" name="CFH2" comment="" chebi-id="WO2007045867:691661" relevant="false">CFH2</ne>, and <ne type="FORMULA" id="WO2007045867.HC.formula-names.4" epochem-id="EPOCHEM:NEW:FORMULA:70" name="CF3CH2" comment="" chebi-id="WO2007045867:792389" relevant="false">CF3CH2</ne>-.
As used herein the term "carbocyclic" refers to an optionally substituted mono-, bi- or tricyclic, radical having up to 16 ring atoms, all of which are carbon, and includes <ne type="LIGAND" id="WO2007045867.HC.ligand-names.928" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.893" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3346" relevant="false">cycloalkyl</ne>. As used herein the term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.894" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3347" relevant="false">cycloalkyl</ne>" refers to an optionally substituted monocyclic saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.263" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.276" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.287" epochem-id="EPOCHEM:NEW:LIGAND:104" name="cyclopentyl" comment="" chebi-id="WO2007045867:427337" relevant="false">cyclopentyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.293" epochem-id="EPOCHEM:NEW:LIGAND:106" name="cyclohexyl" comment="" chebi-id="WO2007045867:868001" relevant="false">cyclohexyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.299" epochem-id="EPOCHEM:NEW:LIGAND:149" name="cycloheptyl" comment="" chebi-id="WO2007045867:192174" relevant="false">cycloheptyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.300" epochem-id="EPOCHEM:NEW:LIGAND:150" name="cyclooctyl" comment="" chebi-id="WO2007045867:761138" relevant="false">cyclooctyl</ne>.
As used herein the unqualified term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.929" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne>" refers to an optionally substituted mono-, bi- or tri-cyclic carbocyclic aromatic radical, and includes radicals having two monocyclic carbocyclic aromatic rings which are directly linked by a covalent bond.
<ne type="LIGAND" id="WO2007045867.HC.ligand-names.930" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">Aryl</ne> radicals may have, for example, from 6 to 14 ring carbon atoms, preferably from
</P>
<P>6 to 10 carbon atoms. Illustrative of <ne type="LIGAND" id="WO2007045867.HC.ligand-names.931" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne> radicals are <ne type="LIGAND" id="WO2007045867.HC.ligand-names.791" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1013" epochem-id="EPOCHEM:NEW:LIGAND:603" name="biphenyl" comment="" chebi-id="CHEBI:17097" relevant="false">biphenyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.330" epochem-id="EPOCHEM:NEW:LIGAND:218" name="napthyl" comment="" chebi-id="WO2007045867:771041" relevant="false">napthyl</ne>.
As used herein, the term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.881" epochem-id="EPOCHEM:NEW:LIGAND:526" name="aryl-fused- cycloalkyl" comment="" chebi-id="WO2007045867:764181" relevant="false">aryl-fused-cycloalkyl</ne>" refers to a carbocyclic radical consisting of a monocyclic <ne type="LIGAND" id="WO2007045867.HC.ligand-names.933" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne> ring, such as <ne type="LIGAND" id="WO2007045867.HC.ligand-names.792" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, fused to a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.896" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3348" relevant="false">cycloalkyl</ne> group, in which the <ne type="LIGAND" id="WO2007045867.HC.ligand-names.934" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.897" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3349" relevant="false">cycloalkyl</ne> parts are as defined herein. Exemplary <ne type="LIGAND" id="WO2007045867.HC.ligand-names.882" epochem-id="EPOCHEM:NEW:LIGAND:526" name="aryl-fused- cycloalkyl" comment="" chebi-id="WO2007045867:764181" relevant="false">aryl-fused- cycloalkyl</ne> groups include <ne type="LIGAND" id="WO2007045867.HC.ligand-names.331" epochem-id="EPOCHEM:NEW:LIGAND:219" name="tetrahydronaphthyl" comment="" chebi-id="WO2007045867:131223" relevant="false">tetrahydronaphthyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.334" epochem-id="EPOCHEM:NEW:LIGAND:220" name="indanyl" comment="" chebi-id="WO2007045867:990977" relevant="false">indanyl</ne>. The <ne type="LIGAND" id="WO2007045867.HC.ligand-names.883" epochem-id="EPOCHEM:NEW:LIGAND:526" name="aryl-fused- cycloalkyl" comment="" chebi-id="WO2007045867:764181" relevant="false">aryl-fused-cycloalkyl</ne> radical may be attached to the remainder of the molecule by any available carbon atom. As used herein the unqualified term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.958" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33474" relevant="false">heteroaryl</ne>" refers to an optionally substituted mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O, and includes radicals having two such monocyclic rings, or one such monocyclic ring and one monocyclic <ne type="LIGAND" id="WO2007045867.HC.ligand-names.937" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne> ring, which are directly linked by a covalent bond. Illustrative of such radicals are <ne type="LIGAND" id="WO2007045867.HC.ligand-names.337" epochem-id="EPOCHEM:NEW:LIGAND:221" name="thienyl" comment="" chebi-id="CHEBI:37991" relevant="false">thienyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.345" epochem-id="EPOCHEM:NEW:LIGAND:222" name="benzthienyl" comment="" chebi-id="WO2007045867:162839" relevant="false">benzthienyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.346" epochem-id="EPOCHEM:NEW:LIGAND:223" name="furyl" comment="" chebi-id="WO2007045867:664830" relevant="false">furyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.347" epochem-id="EPOCHEM:NEW:LIGAND:224" name="benzfuryl" comment="" chebi-id="WO2007045867:36066" relevant="false">benzfuryl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.348" epochem-id="EPOCHEM:NEW:LIGAND:225" name="pyrrolyl" comment="" chebi-id="WO2007045867:15411" relevant="false">pyrrolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.350" epochem-id="EPOCHEM:NEW:LIGAND:226" name="imidazolyl" comment="" chebi-id="WO2007045867:176925" relevant="false">imidazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.354" epochem-id="EPOCHEM:NEW:LIGAND:227" name="benzimidazolyl" comment="" chebi-id="WO2007045867:520921" relevant="false">benzimidazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.356" epochem-id="EPOCHEM:NEW:LIGAND:228" name="thiazolyl" comment="" chebi-id="WO2007045867:487041" relevant="false">thiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.360" epochem-id="EPOCHEM:NEW:LIGAND:229" name="benzthiazolyl" comment="" chebi-id="WO2007045867:598126" relevant="false">benzthiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.361" epochem-id="EPOCHEM:NEW:LIGAND:230" name="isothiazolyl" comment="" chebi-id="WO2007045867:237735" relevant="false">isothiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.363" epochem-id="EPOCHEM:NEW:LIGAND:231" name="benzisothiazolyl" comment="" chebi-id="WO2007045867:33930" relevant="false">benzisothiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.364" epochem-id="EPOCHEM:NEW:LIGAND:232" name="pyrazolyl" comment="" chebi-id="WO2007045867:713690" relevant="false">pyrazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.366" epochem-id="EPOCHEM:NEW:LIGAND:233" name="oxazolyl" comment="" chebi-id="WO2007045867:353557" relevant="false">oxazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.368" epochem-id="EPOCHEM:NEW:LIGAND:234" name="benzoxazolyl" comment="" chebi-id="WO2007045867:414768" relevant="false">benzoxazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.369" epochem-id="EPOCHEM:NEW:LIGAND:235" name="isoxazolyl" comment="" chebi-id="WO2007045867:373204" relevant="false">isoxazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.372" epochem-id="EPOCHEM:NEW:LIGAND:236" name="benzisoxazolyl" comment="" chebi-id="WO2007045867:635344" relevant="false">benzisoxazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.362" epochem-id="EPOCHEM:NEW:LIGAND:230" name="isothiazolyl" comment="" chebi-id="WO2007045867:237735" relevant="false">isothiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.373" epochem-id="EPOCHEM:NEW:LIGAND:237" name="triazolyl" comment="" chebi-id="WO2007045867:474385" relevant="false">triazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.374" epochem-id="EPOCHEM:NEW:LIGAND:238" name="benztriazolyl" comment="" chebi-id="WO2007045867:321968" relevant="false">benztriazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.375" epochem-id="EPOCHEM:NEW:LIGAND:239" name="thiadiazolyl" comment="" chebi-id="WO2007045867:260317" relevant="false">thiadiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.377" epochem-id="EPOCHEM:NEW:LIGAND:240" name="oxadiazolyl" comment="" chebi-id="WO2007045867:435565" relevant="false">oxadiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.378" epochem-id="EPOCHEM:NEW:LIGAND:241" name="pyridinyl" comment="" chebi-id="WO2007045867:168902" relevant="false">pyridinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.380" epochem-id="EPOCHEM:NEW:LIGAND:242" name="pyridazinyl" comment="" chebi-id="WO2007045867:725370" relevant="false">pyridazinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.382" epochem-id="EPOCHEM:NEW:LIGAND:243" name="pyrimidinyl" comment="" chebi-id="WO2007045867:440472" relevant="false">pyrimidinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.381" epochem-id="EPOCHEM:NEW:LIGAND:242" name="pyridazinyl" comment="" chebi-id="WO2007045867:725370" relevant="false">pyridazinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.384" epochem-id="EPOCHEM:NEW:LIGAND:244" name="triazinyl" comment="" chebi-id="WO2007045867:619112" relevant="false">triazinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.385" epochem-id="EPOCHEM:NEW:LIGAND:245" name="indolyl" comment="" chebi-id="WO2007045867:946871" relevant="false">indolyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.387" epochem-id="EPOCHEM:NEW:LIGAND:246" name="indazolyl" comment="" chebi-id="WO2007045867:200110" relevant="false">indazolyl</ne>.
As used herein the unqualified term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.990" epochem-id="EPOCHEM:NEW:LIGAND:535" name="heterocycloalkyl" comment="" chebi-id="WO2007045867:93099" relevant="false">heterocycloalkyl</ne>" or "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.1015" epochem-id="EPOCHEM:NEW:LIGAND:604" name="heterocyclyl" comment="" chebi-id="WO2007045867:785843" relevant="false">heterocyclyl</ne>" or "heterocyclic" includes "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.959" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33475" relevant="false">heteroaryl</ne>" as defined above, and in addition means an optionally substituted mono-, bi- or tri-cyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.984" epochem-id="EPOCHEM:NEW:LIGAND:533" name="monocyclic carbocyclic radical" comment="" chebi-id="WO2007045867:228438" relevant="false">monocyclic carbocyclic radical</ne>. Illustrative of such radicals are <ne type="LIGAND" id="WO2007045867.HC.ligand-names.349" epochem-id="EPOCHEM:NEW:LIGAND:225" name="pyrrolyl" comment="" chebi-id="WO2007045867:15411" relevant="false">pyrrolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.388" epochem-id="EPOCHEM:NEW:LIGAND:247" name="furanyl" comment="" chebi-id="CHEBI:24131" relevant="false">furanyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.338" epochem-id="EPOCHEM:NEW:LIGAND:221" name="thienyl" comment="" chebi-id="CHEBI:37991" relevant="false">thienyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.397" epochem-id="EPOCHEM:NEW:LIGAND:248" name="piperidinyl" comment="" chebi-id="WO2007045867:287038" relevant="false">piperidinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.351" epochem-id="EPOCHEM:NEW:LIGAND:226" name="imidazolyl" comment="" chebi-id="WO2007045867:176925" relevant="false">imidazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.367" epochem-id="EPOCHEM:NEW:LIGAND:233" name="oxazolyl" comment="" chebi-id="WO2007045867:353557" relevant="false">oxazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.370" epochem-id="EPOCHEM:NEW:LIGAND:235" name="isoxazolyl" comment="" chebi-id="WO2007045867:373204" relevant="false">isoxazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.357" epochem-id="EPOCHEM:NEW:LIGAND:228" name="thiazolyl" comment="" chebi-id="WO2007045867:487041" relevant="false">thiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.376" epochem-id="EPOCHEM:NEW:LIGAND:239" name="thiadiazolyl" comment="" chebi-id="WO2007045867:260317" relevant="false">thiadiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.365" epochem-id="EPOCHEM:NEW:LIGAND:232" name="pyrazolyl" comment="" chebi-id="WO2007045867:713690" relevant="false">pyrazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.379" epochem-id="EPOCHEM:NEW:LIGAND:241" name="pyridinyl" comment="" chebi-id="WO2007045867:168902" relevant="false">pyridinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.399" epochem-id="EPOCHEM:NEW:LIGAND:249" name="pyrrolidinyl" comment="" chebi-id="WO2007045867:552649" relevant="false">pyrrolidinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.383" epochem-id="EPOCHEM:NEW:LIGAND:243" name="pyrimidinyl" comment="" chebi-id="WO2007045867:440472" relevant="false">pyrimidinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.400" epochem-id="EPOCHEM:NEW:LIGAND:250" name="morpholinyl" comment="" chebi-id="WO2007045867:928950" relevant="false">morpholinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.403" epochem-id="EPOCHEM:NEW:LIGAND:251" name="piperazinyl" comment="" chebi-id="WO2007045867:542502" relevant="false">piperazinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.386" epochem-id="EPOCHEM:NEW:LIGAND:245" name="indolyl" comment="" chebi-id="WO2007045867:946871" relevant="false">indolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.405" epochem-id="EPOCHEM:NEW:LIGAND:252" name="quinolyl" comment="" chebi-id="WO2007045867:158530" relevant="false">quinolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.401" epochem-id="EPOCHEM:NEW:LIGAND:250" name="morpholinyl" comment="" chebi-id="WO2007045867:928950" relevant="false">morpholinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.406" epochem-id="EPOCHEM:NEW:LIGAND:253" name="benzfuranyl" comment="" chebi-id="WO2007045867:513945" relevant="false">benzfuranyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.407" epochem-id="EPOCHEM:NEW:LIGAND:254" name="pyranyl" comment="" chebi-id="WO2007045867:609408" relevant="false">pyranyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.371" epochem-id="EPOCHEM:NEW:LIGAND:235" name="isoxazolyl" comment="" chebi-id="WO2007045867:373204" relevant="false">isoxazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.355" epochem-id="EPOCHEM:NEW:LIGAND:227" name="benzimidazolyl" comment="" chebi-id="WO2007045867:520921" relevant="false">benzimidazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.408" epochem-id="EPOCHEM:NEW:LIGAND:255" name="methylenedioxyphenyl" comment="" chebi-id="WO2007045867:39401" relevant="false">methylenedioxyphenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.409" epochem-id="EPOCHEM:NEW:LIGAND:256" name="ethylenedioxyphenyl" comment="" chebi-id="WO2007045867:130261" relevant="false">ethylenedioxyphenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.410" epochem-id="EPOCHEM:NEW:LIGAND:257" name="maleimido" comment="" chebi-id="WO2007045867:851332" relevant="false">maleimido</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.411" epochem-id="EPOCHEM:NEW:LIGAND:258" name="succinimido" comment="" chebi-id="WO2007045867:787946" relevant="false">succinimido</ne> groups.
As used herein, the term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.835" epochem-id="EPOCHEM:NEW:LIGAND:522" name="heteroaryl-fused-cycloalkyl" comment="" chebi-id="WO2007045867:476609" relevant="false">heteroaryl-fused-cycloalkyl</ne>" means a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.985" epochem-id="EPOCHEM:NEW:LIGAND:534" name="heterocyclic radical" comment="" chebi-id="WO2007045867:391582" relevant="false">heterocyclic radical</ne> consisting of monocyclic <ne type="LIGAND" id="WO2007045867.HC.ligand-names.961" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33476" relevant="false">heteroaryl</ne> group, such as <ne type="LIGAND" id="WO2007045867.HC.ligand-names.439" epochem-id="EPOCHEM:NEW:LIGAND:265" name="pyridyl" comment="" chebi-id="WO2007045867:44079" relevant="false">pyridyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.389" epochem-id="EPOCHEM:NEW:LIGAND:247" name="furanyl" comment="" chebi-id="CHEBI:24131" relevant="false">furanyl</ne>, fused to a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.901" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3350" relevant="false">cycloalkyl</ne> group, in which the <ne type="LIGAND" id="WO2007045867.HC.ligand-names.962" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33477" relevant="false">heteroaryl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.902" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3351" relevant="false">cycloalkyl</ne> parts are as defined herein. Exemplary <ne type="LIGAND" id="WO2007045867.HC.ligand-names.836" epochem-id="EPOCHEM:NEW:LIGAND:522" name="heteroaryl-fused-cycloalkyl" comment="" chebi-id="WO2007045867:476609" relevant="false">heteroaryl-fused-cycloalkyl</ne> groups include <ne type="LIGAND" id="WO2007045867.HC.ligand-names.412" epochem-id="EPOCHEM:NEW:LIGAND:259" name="tetrahydroquinolinyl" comment="" chebi-id="WO2007045867:903584" relevant="false">tetrahydroquinolinyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.879" epochem-id="EPOCHEM:NEW:LIGAND:525" name="tetrahydrobenzofuranyl" comment="" chebi-id="WO2007045867:273755" relevant="false">tetrahydrobenzofuranyl</ne>. The <ne type="LIGAND" id="WO2007045867.HC.ligand-names.837" epochem-id="EPOCHEM:NEW:LIGAND:522" name="heteroaryl-fused-cycloalkyl" comment="" chebi-id="WO2007045867:476609" relevant="false">heteroaryl-fused-cycloalkyl</ne> group may be attached to the remainder of the molecule by any available carbon or nitrogen atom. As used herein, the term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.841" epochem-id="EPOCHEM:NEW:LIGAND:523" name="aryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:456700" relevant="false">aryl-fused-heterocycloalkyl</ne>" refers to a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.986" epochem-id="EPOCHEM:NEW:LIGAND:534" name="heterocyclic radical" comment="" chebi-id="WO2007045867:391582" relevant="false">heterocyclic radical</ne> consisting of a monocyclic <ne type="LIGAND" id="WO2007045867.HC.ligand-names.939" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne> ring, such as <ne type="LIGAND" id="WO2007045867.HC.ligand-names.793" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, fused to a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.992" epochem-id="EPOCHEM:NEW:LIGAND:535" name="heterocycloalkyl" comment="" chebi-id="WO2007045867:93099" relevant="false">heterocycloalkyl</ne> group, in which the <ne type="LIGAND" id="WO2007045867.HC.ligand-names.940" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.993" epochem-id="EPOCHEM:NEW:LIGAND:535" name="heterocycloalkyl" comment="" chebi-id="WO2007045867:93099" relevant="false">heterocycloalkyl</ne> parts are as defined above. Exemplary <ne type="LIGAND" id="WO2007045867.HC.ligand-names.842" epochem-id="EPOCHEM:NEW:LIGAND:523" name="aryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:456700" relevant="false">aryl-fused-heterocycloalkyl</ne> groups include <ne type="LIGAND" id="WO2007045867.HC.ligand-names.413" epochem-id="EPOCHEM:NEW:LIGAND:259" name="tetrahydroquinolinyl" comment="" chebi-id="WO2007045867:903584" relevant="false">tetrahydroquinolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.416" epochem-id="EPOCHEM:NEW:LIGAND:260" name="indolinyl" comment="" chebi-id="WO2007045867:725815" relevant="false">indolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.421" epochem-id="EPOCHEM:NEW:LIGAND:261" name="benzodioxinyl" comment="" chebi-id="WO2007045867:180049" relevant="false">benzodioxinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.426" epochem-id="EPOCHEM:NEW:LIGAND:262" name="benxodioxolyl" comment="" chebi-id="WO2007045867:530861" relevant="false">benxodioxolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.429" epochem-id="EPOCHEM:NEW:LIGAND:263" name="dihydrobenzofuranyl" comment="" chebi-id="WO2007045867:234633" relevant="false">dihydrobenzofuranyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.434" epochem-id="EPOCHEM:NEW:LIGAND:264" name="isoindolonyl" comment="" chebi-id="WO2007045867:590048" relevant="false">isoindolonyl</ne>. The <ne type="LIGAND" id="WO2007045867.HC.ligand-names.843" epochem-id="EPOCHEM:NEW:LIGAND:523" name="aryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:456700" relevant="false">aryl-fused-heterocycloalkyl</ne> radical may be attached to the remainder of molecule by any available carbon or nitrogen atom.
As used herein, the term "<ne type="LIGAND" id="WO2007045867.HC.ligand-names.874" epochem-id="EPOCHEM:NEW:LIGAND:524" name="heteroaryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:242991" relevant="false">heteroaryl-fused-heterocycloalkyl</ne>" refers to a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.987" epochem-id="EPOCHEM:NEW:LIGAND:534" name="heterocyclic radical" comment="" chebi-id="WO2007045867:391582" relevant="false">heterocyclic radical</ne> consisting of a monocyclic <ne type="LIGAND" id="WO2007045867.HC.ligand-names.966" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33478" relevant="false">heteroaryl</ne> group, such as <ne type="LIGAND" id="WO2007045867.HC.ligand-names.440" epochem-id="EPOCHEM:NEW:LIGAND:265" name="pyridyl" comment="" chebi-id="WO2007045867:44079" relevant="false">pyridyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.390" epochem-id="EPOCHEM:NEW:LIGAND:247" name="furanyl" comment="" chebi-id="CHEBI:24131" relevant="false">furanyl</ne>, fused to a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.997" epochem-id="EPOCHEM:NEW:LIGAND:535" name="heterocycloalkyl" comment="" chebi-id="WO2007045867:93099" relevant="false">heterocycloalkyl</ne> group, in which the <ne type="LIGAND" id="WO2007045867.HC.ligand-names.967" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33479" relevant="false">heteroaryl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.998" epochem-id="EPOCHEM:NEW:LIGAND:535" name="heterocycloalkyl" comment="" chebi-id="WO2007045867:93099" relevant="false">heterocycloalkyl</ne> parts are as defined herein. Exemplary <ne type="LIGAND" id="WO2007045867.HC.ligand-names.875" epochem-id="EPOCHEM:NEW:LIGAND:524" name="heteroaryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:242991" relevant="false">heteroaryl-fused- heterocycloalkyl</ne> groups include <ne type="LIGAND" id="WO2007045867.HC.ligand-names.447" epochem-id="EPOCHEM:NEW:LIGAND:266" name="dihydrodioxinopyridinyl" comment="" chebi-id="WO2007045867:228179" relevant="false">dihydrodioxinopyridinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.448" epochem-id="EPOCHEM:NEW:LIGAND:267" name="dihydropyrrolopyridinyl" comment="" chebi-id="WO2007045867:466170" relevant="false">dihydropyrrolopyridinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.449" epochem-id="EPOCHEM:NEW:LIGAND:268" name="dihydrofuranopyridinyl" comment="" chebi-id="WO2007045867:747123" relevant="false">dihydrofuranopyridinyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.450" epochem-id="EPOCHEM:NEW:LIGAND:269" name="dioxolopyridinyl" comment="" chebi-id="WO2007045867:809666" relevant="false">dioxolopyridinyl</ne>. The <ne type="LIGAND" id="WO2007045867.HC.ligand-names.876" epochem-id="EPOCHEM:NEW:LIGAND:524" name="heteroaryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:242991" relevant="false">heteroaryl-fused-heterocycloalkyl</ne> group may be attached to the remainder of the molecule by any available carbon or nitrogen atom.
Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.452" epochem-id="EPOCHEM:NEW:LIGAND:271" name="(Ci-C6) alkyl" comment="(C1-C6) alkyl" chebi-id="WO2007045867:901502" relevant="false">(Ci-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.905" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3352" relevant="false">cycloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.451" epochem-id="EPOCHEM:NEW:LIGAND:270" name="(C1-C6) alkoxy" comment="" chebi-id="WO2007045867:741627" relevant="false">(C1-C6) alkoxy</ne>, hydroxy, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.982" epochem-id="EPOCHEM:NEW:LIGAND:531" name="hydroxy(CrC6) alkyl" comment="" chebi-id="WO2007045867:287792" relevant="false">hydroxy(CrC6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.455" epochem-id="EPOCHEM:NEW:LIGAND:273" name="mercapto" comment="" chebi-id="CHEBI:29312" relevant="false">mercapto</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.457" epochem-id="EPOCHEM:NEW:LIGAND:274" name="mercapto(Ci-C6) alkyl" comment="" chebi-id="WO2007045867:589346" relevant="false">mercapto(Ci-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.454" epochem-id="EPOCHEM:NEW:LIGAND:272" name="(C1-C6) alkylthio" comment="" chebi-id="WO2007045867:120422" relevant="false">(C1-C6) alkylthio</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.794" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, monocyclic <ne type="LIGAND" id="WO2007045867.HC.ligand-names.970" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33480" relevant="false">heteroaryl</ne> having 5 or 6 ring atoms, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1006" epochem-id="EPOCHEM:NEW:LIGAND:536" name="halo" comment="" chebi-id="WO2007045867:554182" relevant="false">halo</ne> (including <ne type="LIGAND" id="WO2007045867.HC.ligand-names.534" epochem-id="EPOCHEM:NEW:LIGAND:296" name="fluoro" comment="" chebi-id="CHEBI:42645" relevant="false">fluoro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.764" epochem-id="EPOCHEM:NEW:LIGAND:378" name="bromo" comment="" chebi-id="WO2007045867:807484" relevant="false">bromo</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.747" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne>), <ne type="LIGAND" id="WO2007045867.HC.ligand-names.772" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.476" epochem-id="EPOCHEM:NEW:LIGAND:276" name="trifluoromethoxy" comment="" chebi-id="WO2007045867:979582" relevant="false">trifluoromethoxy</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.477" epochem-id="EPOCHEM:NEW:LIGAND:202" name="nitro" comment="" chebi-id="CHEBI:29785" relevant="false">nitro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.478" epochem-id="EPOCHEM:NEW:LIGAND:277" name="nitrile" comment="" chebi-id="CHEBI:18379" relevant="false">nitrile</ne> (-<ne type="FORMULA" id="WO2007045867.HC.formula-names.7" epochem-id="EPOCHEM:NEW:FORMULA:152" name="CN" comment="" chebi-id="CHEBI:48819" relevant="false">CN</ne>), <ne type="LIGAND" id="WO2007045867.HC.ligand-names.480" epochem-id="EPOCHEM:NEW:LIGAND:8" name="oxo" comment="" chebi-id="CHEBI:46629" relevant="false">oxo</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.25" epochem-id="EPOCHEM:NEW:FORMULA:28" name="COOH" comment="" chebi-id="WO2007045867:957753" relevant="false">COOH</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.26" epochem-id="EPOCHEM:NEW:FORMULA:156" name="COOR" comment="" chebi-id="WO2007045867:178676" relevant="false">COOR</ne>&lt;A&gt;, -COR&lt;A&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.13" epochem-id="EPOCHEM:NEW:FORMULA:153" name="SO2R" comment="" chebi-id="CHEBI:29825" relevant="false">SO2R</ne>&lt;A&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.29" epochem-id="EPOCHEM:NEW:FORMULA:26" name="CONH2" comment="" chebi-id="WO2007045867:950167" relevant="false">CONH2</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.28" epochem-id="EPOCHEM:NEW:FORMULA:157" name="SO2NH2" comment="" chebi-id="WO2007045867:568717" relevant="false">SO2NH2</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.31" epochem-id="EPOCHEM:NEW:FORMULA:158" name="CONHR" comment="" chebi-id="WO2007045867:47499" relevant="false">CONHR</ne>&lt;A&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.61" epochem-id="EPOCHEM:NEW:FORMULA:250" name="SO2NHR" comment="" chebi-id="WO2007045867:252187" relevant="false">SO2NHR</ne>&lt;A&gt;,
-<ne type="FORMULA" id="WO2007045867.HC.formula-names.62" epochem-id="EPOCHEM:NEW:FORMULA:251" name="CONR" comment="" chebi-id="WO2007045867:848510" relevant="false">CONR</ne>&lt;A&gt;R&lt;B&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.63" epochem-id="EPOCHEM:NEW:FORMULA:252" name="SO2NR" comment="" chebi-id="WO2007045867:433153" relevant="false">SO2NR</ne>&lt;A&gt;R&lt;B&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.64" epochem-id="EPOCHEM:NEW:FORMULA:24" name="NH2" comment="" chebi-id="CHEBI:46882" relevant="false">NH2</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.65" epochem-id="EPOCHEM:NEW:FORMULA:253" name="NHR" comment="" chebi-id="WO2007045867:141444" relevant="false">NHR</ne>&lt;A&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.69" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;A&gt;R&lt;B&gt;, - <ne type="FORMULA" id="WO2007045867.HC.formula-names.83" epochem-id="EPOCHEM:NEW:FORMULA:255" name="OCONH2" comment="" chebi-id="WO2007045867:622815" relevant="false">OCONH2</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.84" epochem-id="EPOCHEM:NEW:FORMULA:256" name="OCONHR" comment="" chebi-id="WO2007045867:864336" relevant="false">OCONHR</ne>&lt;A&gt; , -<ne type="FORMULA" id="WO2007045867.HC.formula-names.85" epochem-id="EPOCHEM:NEW:FORMULA:257" name="OCONR" comment="" chebi-id="WO2007045867:980801" relevant="false">OCONR</ne>&lt;A&gt;R&lt;B&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.86" epochem-id="EPOCHEM:NEW:FORMULA:258" name="NHC0R" comment="NHCOR" chebi-id="WO2007045867:472147" relevant="false">NHC0R</ne>&lt;A&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.87" epochem-id="EPOCHEM:NEW:FORMULA:259" name="NHCOOR" comment="" chebi-id="WO2007045867:161945" relevant="false">NHCOOR</ne>&lt;A&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.70" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;B&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.27" epochem-id="EPOCHEM:NEW:FORMULA:156" name="COOR" comment="" chebi-id="WO2007045867:178676" relevant="false">COOR</ne>&lt;A&gt;, - <ne type="FORMULA" id="WO2007045867.HC.formula-names.88" epochem-id="EPOCHEM:NEW:FORMULA:260" name="NHSO2OR" comment="" chebi-id="WO2007045867:663505" relevant="false">NHSO2OR</ne>&lt;A&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.71" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;6&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.89" epochem-id="EPOCHEM:NEW:FORMULA:261" name="SO2OH" comment="" chebi-id="WO2007045867:806205" relevant="false">SO2OH</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.72" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;B&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.90" epochem-id="EPOCHEM:NEW:FORMULA:262" name="SO2OR" comment="" chebi-id="WO2007045867:205106" relevant="false">SO2OR</ne>&lt;A&gt;,-<ne type="FORMULA" id="WO2007045867.HC.formula-names.91" epochem-id="EPOCHEM:NEW:FORMULA:263" name="NHCONH2" comment="" chebi-id="WO2007045867:257897" relevant="false">NHCONH2</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.73" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;A&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.30" epochem-id="EPOCHEM:NEW:FORMULA:26" name="CONH2" comment="" chebi-id="WO2007045867:950167" relevant="false">CONH2</ne>, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.92" epochem-id="EPOCHEM:NEW:FORMULA:264" name="NHCONHR" comment="" chebi-id="WO2007045867:249603" relevant="false">NHCONHR</ne>&lt;6&gt; - <ne type="FORMULA" id="WO2007045867.HC.formula-names.74" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;A&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.32" epochem-id="EPOCHEM:NEW:FORMULA:158" name="CONHR" comment="" chebi-id="WO2007045867:47499" relevant="false">CONHR</ne>&lt;B&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.93" epochem-id="EPOCHEM:NEW:FORMULA:265" name="NHC0NR" comment="NHCONR" chebi-id="WO2007045867:856384" relevant="false">NHC0NR</ne>&lt;A&gt;R&lt;B&gt; or -<ne type="FORMULA" id="WO2007045867.HC.formula-names.75" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;A&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.94" epochem-id="EPOCHEM:NEW:FORMULA:266" name="C0NR" comment="CONR" chebi-id="WO2007045867:782259" relevant="false">C0NR</ne>&lt;A&gt;R&lt;6&gt; wherein R&lt;A&gt; and R&lt;B&gt; are independently a (CrC6) alkyl, (C3-C6) <ne type="LIGAND" id="WO2007045867.HC.ligand-names.906" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3353" relevant="false">cycloalkyl</ne> , <ne type="LIGAND" id="WO2007045867.HC.ligand-names.795" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.981" epochem-id="EPOCHEM:NEW:LIGAND:530" name="monocyclic heterocyclic group" comment="" chebi-id="WO2007045867:488443" relevant="false">monocyclic heterocyclic group</ne> having 5 or 6 ring atoms, or R&lt;A&gt; and R&lt;B&gt; when attached to the same nitrogen atom may form a ring with that nitrogen of 5 or 6 ring atoms, optionally containing further heteroatoms selected from N, O or S (examples being <ne type="LIGAND" id="WO2007045867.HC.ligand-names.402" epochem-id="EPOCHEM:NEW:LIGAND:250" name="morpholinyl" comment="" chebi-id="WO2007045867:928950" relevant="false">morpholinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.398" epochem-id="EPOCHEM:NEW:LIGAND:248" name="piperidinyl" comment="" chebi-id="WO2007045867:287038" relevant="false">piperidinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.404" epochem-id="EPOCHEM:NEW:LIGAND:251" name="piperazinyl" comment="" chebi-id="WO2007045867:542502" relevant="false">piperazinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.832" epochem-id="EPOCHEM:NEW:LIGAND:391" name="4-methylpiperazinyl" comment="" chebi-id="WO2007045867:154928" relevant="false">4-methylpiperazinyl</ne>, and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.412" epochem-id="EPOCHEM:NEW:COMPOUND:1446" name="tetrahydropyrrole" comment="" chebi-id="CHEBI:33135" relevant="false">tetrahydropyrrole</ne>). An "optional substituent" may be one of the foregoing substituent groups. As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as <ne id="WO2007045867.HC.class-names.79" epochem-id="EPOCHEM:NEW:CLASS:908" name="alkali metal hydroxides" comment="" chebi-id="CHEBI:33978" relevant="false" type="CLASS">alkali metal hydroxides</ne>, e.g. <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.395" epochem-id="EPOCHEM:COMPOUND:7085" name="sodium" comment="" chebi-id="CHEBI:26708" relevant="false">sodium</ne> and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.443" epochem-id="EPOCHEM:COMPOUND:7084" name="potassium" comment="" chebi-id="CHEBI:26216" relevant="false">potassium</ne> hydroxides; <ne id="WO2007045867.HC.class-names.62" epochem-id="EPOCHEM:NEW:CLASS:448" name="alkaline earth metal hydroxides" comment="" chebi-id="WO2007045867:399393" relevant="false" type="CLASS">alkaline earth metal hydroxides</ne> e.g. <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.377" epochem-id="EPOCHEM:COMPOUND:7090" name="calcium" comment="" chebi-id="CHEBI:22984" relevant="false">calcium</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.409" epochem-id="EPOCHEM:COMPOUND:7094" name="barium" comment="" chebi-id="CHEBI:32594" relevant="false">barium</ne> and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.410" epochem-id="EPOCHEM:NEW:COMPOUND:1444" name="magnesium hydroxides" comment="" chebi-id="CHEBI:35149" relevant="false">magnesium hydroxides</ne>; with <ne type="ONT" id="WO2007045867.HC.class-names.85" epochem-id="EPOCHEM:NEW:CLASS:1080" name="organic bases" comment="" chebi-id="WO2007045867:122648" relevant="false">organic bases</ne> e.g. <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.408" epochem-id="EPOCHEM:NEW:COMPOUND:1443" name="N-methyl- D-glucamine" comment="" chebi-id="WO2007045867:811548" relevant="false">N-methyl- D-glucamine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.407" epochem-id="EPOCHEM:NEW:COMPOUND:1442" name="choline tris(hydroxymethyl)amino-methane" comment="" chebi-id="WO2007045867:897787" relevant="false">choline tris(hydroxymethyl)amino-methane</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.406" epochem-id="EPOCHEM:COMPOUND:1074" name="L-arginine" comment="" chebi-id="WO2007045867:751758" relevant="false">L-arginine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.405" epochem-id="EPOCHEM:COMPOUND:1038" name="L-lysine" comment="" chebi-id="WO2007045867:184387" relevant="false">L-lysine</ne><ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.374" epochem-id="EPOCHEM:NEW:COMPOUND:1436" name=",N-ethyl piperidine" comment="" chebi-id="WO2007045867:46339" relevant="false">, N-ethyl piperidine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.375" epochem-id="EPOCHEM:NEW:COMPOUND:1437" name="dibenzylamine" comment="" chebi-id="WO2007045867:677469" relevant="false">dibenzylamine</ne> and the like. Specific salts with bases include the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.376" epochem-id="EPOCHEM:NEW:COMPOUND:1438" name="benzathine" comment="" chebi-id="WO2007045867:74830" relevant="false">benzathine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.378" epochem-id="EPOCHEM:COMPOUND:7090" name="calcium" comment="" chebi-id="CHEBI:22984" relevant="false">calcium</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.380" epochem-id="EPOCHEM:NEW:COMPOUND:1439" name="diolamine" comment="" chebi-id="WO2007045867:604303" relevant="false">diolamine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.381" epochem-id="EPOCHEM:NEW:COMPOUND:1440" name="meglumine" comment="" chebi-id="WO2007045867:136392" relevant="false">meglumine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.382" epochem-id="EPOCHEM:NEW:COMPOUND:1441" name="olamine" comment="" chebi-id="WO2007045867:370069" relevant="false">olamine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.384" epochem-id="EPOCHEM:COMPOUND:7084" name="potassium" comment="" chebi-id="CHEBI:26216" relevant="false">potassium</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.394" epochem-id="EPOCHEM:NEW:COMPOUND:460" name="procaine" comment="" chebi-id="WO2007045867:646382" relevant="false">procaine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.396" epochem-id="EPOCHEM:COMPOUND:7085" name="sodium" comment="" chebi-id="CHEBI:26708" relevant="false">sodium</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.404" epochem-id="EPOCHEM:NEW:COMPOUND:262" name="tromethamine" comment="" chebi-id="CHEBI:9754" relevant="false">tromethamine</ne> and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.273" epochem-id="EPOCHEM:NEW:COMPOUND:1191" name="Zinc" comment="" chebi-id="CHEBI:27363" relevant="false">zinc</ne> salts.
Those compounds (I) which are basic can form salts, including pharmaceutically acceptable salts with <ne type="ONT" id="WO2007045867.HC.class-names.58" epochem-id="EPOCHEM:NEW:CLASS:445" name="inorganic acids" comment="" chebi-id="WO2007045867:873764" relevant="false">inorganic acids</ne>, e.g. with <ne id="WO2007045867.HC.class-names.59" epochem-id="EPOCHEM:NEW:CLASS:446" name="hydrohalic acids" comment="" chebi-id="WO2007045867:541863" relevant="false" type="CLASS">hydrohalic acids</ne> such as <ne type="LIGAND" id="WO2007045867.HC.ligand-names.816" epochem-id="EPOCHEM:NEW:LIGAND:385" name="hydrochloric" comment="" chebi-id="WO2007045867:636808" relevant="false">hydrochloric</ne> or <ne id="WO2007045867.HC.class-names.60" epochem-id="EPOCHEM:NEW:CLASS:447" name="hydrobromic acids" comment="" chebi-id="WO2007045867:252960" relevant="false" type="CLASS">hydrobromic acids</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.372" epochem-id="EPOCHEM:NEW:COMPOUND:394" name="sulphuric acid" comment="" chebi-id="CHEBI:26836" relevant="false">sulphuric acid</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.116" epochem-id="EPOCHEM:COMPOUND:1167" name="nitric acid" comment="" chebi-id="CHEBI:25545" relevant="false">nitric acid</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.373" epochem-id="EPOCHEM:COMPOUND:1185" name="phosphoric acid" comment="" chebi-id="CHEBI:26078" relevant="false">phosphoric acid</ne> and the like, and with <ne type="ONT" id="WO2007045867.HC.class-names.61" epochem-id="EPOCHEM:NEW:CLASS:370" name="organic acids" comment="" chebi-id="WO2007045867:147411" relevant="false">organic acids</ne> e.g. with <ne type="LIGAND" id="WO2007045867.HC.ligand-names.817" epochem-id="EPOCHEM:NEW:LIGAND:76" name="acetic" comment="" chebi-id="WO2007045867:79985" relevant="false">acetic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.819" epochem-id="EPOCHEM:NEW:LIGAND:81" name="tartaric" comment="" chebi-id="WO2007045867:179009" relevant="false">tartaric</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.820" epochem-id="EPOCHEM:NEW:LIGAND:83" name="succinic" comment="" chebi-id="WO2007045867:706143" relevant="false">succinic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.821" epochem-id="EPOCHEM:NEW:LIGAND:161" name="fumaric" comment="" chebi-id="WO2007045867:375632" relevant="false">fumaric</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.822" epochem-id="EPOCHEM:NEW:LIGAND:386" name="maleic" comment="" chebi-id="WO2007045867:536994" relevant="false">maleic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.823" epochem-id="EPOCHEM:NEW:LIGAND:79" name="malic" comment="" chebi-id="WO2007045867:278894" relevant="false">malic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.824" epochem-id="EPOCHEM:NEW:LIGAND:387" name="salicylic" comment="" chebi-id="WO2007045867:545961" relevant="false">salicylic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.825" epochem-id="EPOCHEM:NEW:LIGAND:78" name="citric" comment="" chebi-id="WO2007045867:231302" relevant="false">citric</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.826" epochem-id="EPOCHEM:NEW:LIGAND:388" name="methanesulphonic" comment="" chebi-id="WO2007045867:188083" relevant="false">methanesulphonic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.827" epochem-id="EPOCHEM:NEW:LIGAND:389" name="p-toluenesulphonic" comment="" chebi-id="WO2007045867:550641" relevant="false">p-toluenesulphonic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.828" epochem-id="EPOCHEM:NEW:LIGAND:84" name="benzoic" comment="" chebi-id="WO2007045867:518497" relevant="false">benzoic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.829" epochem-id="EPOCHEM:NEW:LIGAND:390" name="benzenesunfonic" comment="" chebi-id="WO2007045867:541234" relevant="false">benzenesunfonic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.830" epochem-id="EPOCHEM:NEW:LIGAND:163" name="glutamic" comment="" chebi-id="WO2007045867:2412" relevant="false">glutamic</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.831" epochem-id="EPOCHEM:NEW:LIGAND:77" name="lactic" comment="" chebi-id="WO2007045867:384524" relevant="false">lactic</ne>, and mandelic acids and the like. Additional salt forms are detailed in the "Handbook of Pharmaceutical Salts. Properties, selection and use", P. Heinrich Stahl &amp; Camille G. Wermuth, Wiley-VCH, 2002. Compounds with which the invention is concerned which may exist in one or more stereoisomer^ form, because of the presence of asymmetric atoms or rotational restrictions, and in such cases can exist as a number of stereoisomers with R or S stereochemistry at each chiral centre or as atropisomeres with R or S stereochemistry at each chiral axis. The invention includes all such enantiomers and diastereoisomers and mixtures thereof.
Use of prodrugs, such as <ne id="WO2007045867.HC.class-names.55" epochem-id="EPOCHEM:NEW:CLASS:338" name="esters" comment="" chebi-id="CHEBI:35701" relevant="false" type="CLASS">esters</ne>, of compounds with which the invention is concerned is also part of the invention. "Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of formula (I). For example an ester prodrug of a compound of formula (I) may be convertible by hydrolysis in vivo to the parent molecule. Suitable <ne id="WO2007045867.HC.class-names.56" epochem-id="EPOCHEM:NEW:CLASS:338" name="esters" comment="" chebi-id="CHEBI:35701" relevant="false" type="CLASS">esters</ne> of compounds of formula (I) are for example <ne id="WO2007045867.HC.class-names.34" epochem-id="EPOCHEM:NEW:CLASS:424" name="acetates" comment="" chebi-id="WO2007045867:521094" relevant="false" type="CLASS">acetates</ne>, <ne id="WO2007045867.HC.class-names.35" epochem-id="EPOCHEM:NEW:CLASS:425" name="citrates" comment="" chebi-id="WO2007045867:246853" relevant="false" type="CLASS">citrates</ne>, <ne id="WO2007045867.HC.class-names.36" epochem-id="EPOCHEM:NEW:CLASS:426" name="lactates" comment="" chebi-id="WO2007045867:888272" relevant="false" type="CLASS">lactates</ne>, <ne id="WO2007045867.HC.class-names.37" epochem-id="EPOCHEM:NEW:CLASS:427" name="tartrates" comment="" chebi-id="WO2007045867:774119" relevant="false" type="CLASS">tartrates</ne>, <ne id="WO2007045867.HC.class-names.38" epochem-id="EPOCHEM:NEW:CLASS:428" name="malonates" comment="" chebi-id="WO2007045867:224825" relevant="false" type="CLASS">malonates</ne>, <ne id="WO2007045867.HC.class-names.39" epochem-id="EPOCHEM:NEW:CLASS:429" name="oxalates" comment="" chebi-id="WO2007045867:631122" relevant="false" type="CLASS">oxalates</ne>, <ne id="WO2007045867.HC.class-names.40" epochem-id="EPOCHEM:NEW:CLASS:430" name="salicylates" comment="" chebi-id="WO2007045867:915546" relevant="false" type="CLASS">salicylates</ne>, <ne id="WO2007045867.HC.class-names.41" epochem-id="EPOCHEM:NEW:CLASS:431" name="propionates" comment="" chebi-id="WO2007045867:407966" relevant="false" type="CLASS">propionates</ne>, <ne id="WO2007045867.HC.class-names.42" epochem-id="EPOCHEM:NEW:CLASS:432" name="succinates" comment="" chebi-id="WO2007045867:610582" relevant="false" type="CLASS">succinates</ne>, <ne id="WO2007045867.HC.class-names.43" epochem-id="EPOCHEM:NEW:CLASS:433" name="fumarates" comment="" chebi-id="WO2007045867:855142" relevant="false" type="CLASS">fumarates</ne>, <ne id="WO2007045867.HC.class-names.44" epochem-id="EPOCHEM:NEW:CLASS:434" name="maleates" comment="" chebi-id="WO2007045867:373798" relevant="false" type="CLASS">maleates</ne>, <ne id="WO2007045867.HC.class-names.45" epochem-id="EPOCHEM:NEW:CLASS:435" name="methylene-bis-[beta]-hydroxynaphthoates" comment="" chebi-id="WO2007045867:497264" relevant="false" type="CLASS">methylene-bis-[beta]-hydroxynaphthoates</ne>, <ne id="WO2007045867.HC.class-names.46" epochem-id="EPOCHEM:NEW:CLASS:436" name="gentisates" comment="" chebi-id="WO2007045867:467908" relevant="false" type="CLASS">gentisates</ne>, <ne id="WO2007045867.HC.class-names.47" epochem-id="EPOCHEM:NEW:CLASS:437" name="isethionates" comment="" chebi-id="WO2007045867:503132" relevant="false" type="CLASS">isethionates</ne>, <ne id="WO2007045867.HC.class-names.48" epochem-id="EPOCHEM:NEW:CLASS:438" name="di-p-toluoyltartrates" comment="" chebi-id="WO2007045867:816948" relevant="false" type="CLASS">di-p-toluoyltartrates</ne>, <ne type="ONT" id="WO2007045867.HC.class-names.49" epochem-id="EPOCHEM:NEW:CLASS:439" name="methanesulphonates" comment="" chebi-id="WO2007045867:318256" relevant="false">methanesulphonates</ne>, <ne id="WO2007045867.HC.class-names.50" epochem-id="EPOCHEM:NEW:CLASS:440" name="ethanesulphonates" comment="" chebi-id="WO2007045867:800404" relevant="false" type="CLASS">ethanesulphonates</ne>, <ne id="WO2007045867.HC.class-names.51" epochem-id="EPOCHEM:NEW:CLASS:441" name="benzenesulphonates" comment="" chebi-id="WO2007045867:95243" relevant="false" type="CLASS">benzenesulphonates</ne>, <ne id="WO2007045867.HC.class-names.54" epochem-id="EPOCHEM:NEW:CLASS:444" name="jOtoluene- sulphonates" comment="" chebi-id="WO2007045867:487272" relevant="false" type="CLASS">jOtoluene- sulphonates</ne>, <ne id="WO2007045867.HC.class-names.52" epochem-id="EPOCHEM:NEW:CLASS:442" name="cyclohexylsulphamates" comment="" chebi-id="WO2007045867:546610" relevant="false" type="CLASS">cyclohexylsulphamates</ne> and <ne id="WO2007045867.HC.class-names.53" epochem-id="EPOCHEM:NEW:CLASS:443" name="quinates" comment="" chebi-id="WO2007045867:108342" relevant="false" type="CLASS">quinates</ne>. Examples of ester prodrugs are those described by F. J. Leinweber, Drug Metab. Res., 1987, 18, 379. As used in herein, references to the compounds of formula (I) are meant to also include the prodrug forms. The variables Ff '-R&lt;9&gt;
In compounds with which the invention is concerned, the following structural characteristics are currently preferred, in any compatible combination:
R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt; and R&lt;4&gt; are independently <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.287" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.88" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.727" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.211" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, or n- or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.683" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.812" epochem-id="EPOCHEM:NEW:LIGAND:383" name="(C1-C6) fluoroalkyl" comment="" chebi-id="WO2007045867:777766" relevant="false">(C1-C6) fluoroalkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.773" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.516" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.907" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3354" relevant="false">cycloalkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.264" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.277" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1007" epochem-id="EPOCHEM:NEW:LIGAND:536" name="halo" comment="" chebi-id="WO2007045867:554182" relevant="false">halo</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.535" epochem-id="EPOCHEM:NEW:LIGAND:296" name="fluoro" comment="" chebi-id="CHEBI:42645" relevant="false">fluoro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.748" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.765" epochem-id="EPOCHEM:NEW:LIGAND:378" name="bromo" comment="" chebi-id="WO2007045867:807484" relevant="false">bromo</ne>; -S(O)<ne type="FORMULA" id="WO2007045867.HC.formula-names.76" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="WO2007045867:595830" relevant="false">nR</ne>&lt;10&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.21" epochem-id="EPOCHEM:NEW:FORMULA:155" name="SO2N" comment="" chebi-id="WO2007045867:676309" relevant="false">SO2N</ne>(R&lt;11&gt;)2, -N(R&lt;11&gt;)2, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.77" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;11&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.97" epochem-id="EPOCHEM:NEW:FORMULA:267" name="C(O)R" comment="" chebi-id="WO2007045867:714016" relevant="false">C(O)R</ne>&lt;10&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.17" epochem-id="EPOCHEM:NEW:FORMULA:154" name="CO2R" comment="" chebi-id="WO2007045867:616448" relevant="false">CO2R</ne>&lt;11&gt;, - <ne type="FORMULA" id="WO2007045867.HC.formula-names.98" epochem-id="EPOCHEM:NEW:FORMULA:267" name="C(O)R" comment="" chebi-id="WO2007045867:714016" relevant="false">C(O)R</ne>&lt;10&gt;, <ne type="FORMULA" id="WO2007045867.HC.formula-names.8" epochem-id="EPOCHEM:NEW:FORMULA:152" name="CN" comment="" chebi-id="CHEBI:48819" relevant="false">CN</ne> or a group OR&lt;12&gt;; wherein each R&lt;10&gt; is independently d-C-6 alkyl, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.728" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.212" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, or n- or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.684" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>; fully or partially fluorinated <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1009" epochem-id="EPOCHEM:NEW:LIGAND:444" name="C1-C6 alkyl" comment="" chebi-id="WO2007045867:573716" relevant="false">C1-C6 alkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.774" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.517" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.908" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3355" relevant="false">cycloalkyl</ne> for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.265" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.278" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.288" epochem-id="EPOCHEM:NEW:LIGAND:104" name="cyclopentyl" comment="" chebi-id="WO2007045867:427337" relevant="false">cyclopentyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.294" epochem-id="EPOCHEM:NEW:LIGAND:106" name="cyclohexyl" comment="" chebi-id="WO2007045867:868001" relevant="false">cyclohexyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.943" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.796" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>; or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.971" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33481" relevant="false">heteroaryl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.441" epochem-id="EPOCHEM:NEW:LIGAND:265" name="pyridyl" comment="" chebi-id="WO2007045867:44079" relevant="false">pyridyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.339" epochem-id="EPOCHEM:NEW:LIGAND:221" name="thienyl" comment="" chebi-id="CHEBI:37991" relevant="false">thienyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.391" epochem-id="EPOCHEM:NEW:LIGAND:247" name="furanyl" comment="" chebi-id="CHEBI:24131" relevant="false">furanyl</ne>; each R11 is independently <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1010" epochem-id="EPOCHEM:NEW:LIGAND:444" name="C1-C6 alkyl" comment="" chebi-id="WO2007045867:573716" relevant="false">C1-C6 alkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.729" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.213" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, or n- or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.685" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso- propyl</ne>; fully or partially fluorinated <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1011" epochem-id="EPOCHEM:NEW:LIGAND:444" name="C1-C6 alkyl" comment="" chebi-id="WO2007045867:573716" relevant="false">C1-C6 alkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.775" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.518" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.909" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3356" relevant="false">cycloalkyl</ne> for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.266" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.279" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.289" epochem-id="EPOCHEM:NEW:LIGAND:104" name="cyclopentyl" comment="" chebi-id="WO2007045867:427337" relevant="false">cyclopentyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.295" epochem-id="EPOCHEM:NEW:LIGAND:106" name="cyclohexyl" comment="" chebi-id="WO2007045867:868001" relevant="false">cyclohexyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.910" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3357" relevant="false">cycloalkyl</ne>-(CrC6 alkyl)-, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.695" epochem-id="EPOCHEM:NEW:LIGAND:303" name="cyclopropylmethyl" comment="" chebi-id="WO2007045867:77384" relevant="false">cyclopropylmethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.697" epochem-id="EPOCHEM:NEW:LIGAND:304" name="cyclopentylmethyl" comment="" chebi-id="WO2007045867:191940" relevant="false">cyclopentylmethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.699" epochem-id="EPOCHEM:NEW:LIGAND:305" name="cyclohexylmethyl" comment="" chebi-id="WO2007045867:83357" relevant="false">cyclohexylmethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.701" epochem-id="EPOCHEM:NEW:LIGAND:306" name="cyclopropylethyl" comment="" chebi-id="WO2007045867:960526" relevant="false">cyclopropylethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.703" epochem-id="EPOCHEM:NEW:LIGAND:307" name="cyclopentylethyl" comment="" chebi-id="WO2007045867:676448" relevant="false">cyclopentylethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.705" epochem-id="EPOCHEM:NEW:LIGAND:308" name="cyclohexylethyl" comment="" chebi-id="WO2007045867:954418" relevant="false">cyclohexylethyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.944" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.797" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>; or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.972" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33482" relevant="false">heteroaryl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.442" epochem-id="EPOCHEM:NEW:LIGAND:265" name="pyridyl" comment="" chebi-id="WO2007045867:44079" relevant="false">pyridyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.340" epochem-id="EPOCHEM:NEW:LIGAND:221" name="thienyl" comment="" chebi-id="CHEBI:37991" relevant="false">thienyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.392" epochem-id="EPOCHEM:NEW:LIGAND:247" name="furanyl" comment="" chebi-id="CHEBI:24131" relevant="false">furanyl</ne>; or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.288" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>;
Currently preferred instances of R&lt;1&gt;-R&lt;4&gt; are:
R&lt;1&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.289" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>; 5 R&lt;2&gt; is <ne type="LIGAND" id="WO2007045867.HC.ligand-names.749" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne>;
R&lt;3&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.290" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>;
R&lt;4&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.291" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>.
R&lt;5&gt; and R&lt;6&gt; are independently <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.292" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.89" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.730" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.214" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, or n- or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.686" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.814" epochem-id="EPOCHEM:NEW:LIGAND:384" name="(CrC6) fluoroalkyl" comment="(C1-C6) fluoroalkyl" chebi-id="WO2007045867:444598" relevant="false">(CrC6) fluoroalkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.776" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne> or
</P>
<P>10 <ne type="LIGAND" id="WO2007045867.HC.ligand-names.519" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.911" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3358" relevant="false">cycloalkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.267" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.280" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>, or R&lt;5&gt; and R&lt;6&gt; together with the atom to which they are attached form a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.912" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3359" relevant="false">cycloalkyl</ne> ring such as a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.268" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne> ring. Presently it is preferred that both of R&lt;5&gt; and R&lt;6&gt; are <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.293" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>.
R&lt;7&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.294" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.90" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.731" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.215" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, or n- or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.687" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.815" epochem-id="EPOCHEM:NEW:LIGAND:384" name="(CrC6) fluoroalkyl" comment="(C1-C6) fluoroalkyl" chebi-id="WO2007045867:444598" relevant="false">(CrC6) fluoroalkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.777" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.520" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>. Presently it is 15 preferred that R&lt;7&gt; be <ne type="LIGAND" id="WO2007045867.HC.ligand-names.732" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>.
R&lt;8&gt; is optionally substituted <ne type="LIGAND" id="WO2007045867.HC.ligand-names.945" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne> such as <ne type="LIGAND" id="WO2007045867.HC.ligand-names.798" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1016" epochem-id="EPOCHEM:NEW:LIGAND:605" name="naphthy" comment="naphthyl" chebi-id="WO2007045867:321276" relevant="false">naphthy</ne>); <ne type="LIGAND" id="WO2007045867.HC.ligand-names.973" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33483" relevant="false">heteroaryl</ne> for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.716" epochem-id="EPOCHEM:NEW:LIGAND:309" name="quinolinyl" comment="" chebi-id="WO2007045867:478166" relevant="false">quinolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.443" epochem-id="EPOCHEM:NEW:LIGAND:265" name="pyridyl" comment="" chebi-id="WO2007045867:44079" relevant="false">pyridyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.341" epochem-id="EPOCHEM:NEW:LIGAND:221" name="thienyl" comment="" chebi-id="CHEBI:37991" relevant="false">thienyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.393" epochem-id="EPOCHEM:NEW:LIGAND:247" name="furanyl" comment="" chebi-id="CHEBI:24131" relevant="false">furanyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.722" epochem-id="EPOCHEM:NEW:LIGAND:310" name="azolyl" comment="" chebi-id="WO2007045867:653414" relevant="false">azolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.358" epochem-id="EPOCHEM:NEW:LIGAND:228" name="thiazolyl" comment="" chebi-id="WO2007045867:487041" relevant="false">thiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.760" epochem-id="EPOCHEM:NEW:LIGAND:376" name="diazolyl" comment="" chebi-id="WO2007045867:486335" relevant="false">diazolyl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.352" epochem-id="EPOCHEM:NEW:LIGAND:226" name="imidazolyl" comment="" chebi-id="WO2007045867:176925" relevant="false">imidazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.844" epochem-id="EPOCHEM:NEW:LIGAND:523" name="aryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:456700" relevant="false">aryl-fused-heterocycloalkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.414" epochem-id="EPOCHEM:NEW:LIGAND:259" name="tetrahydroquinolinyl" comment="" chebi-id="WO2007045867:903584" relevant="false">tetrahydroquinolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.417" epochem-id="EPOCHEM:NEW:LIGAND:260" name="indolinyl" comment="" chebi-id="WO2007045867:725815" relevant="false">indolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.422" epochem-id="EPOCHEM:NEW:LIGAND:261" name="benzodioxinyl" comment="" chebi-id="WO2007045867:180049" relevant="false">benzodioxinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.427" epochem-id="EPOCHEM:NEW:LIGAND:262" name="benxodioxolyl" comment="" chebi-id="WO2007045867:530861" relevant="false">benxodioxolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.430" epochem-id="EPOCHEM:NEW:LIGAND:263" name="dihydrobenzofuranyl" comment="" chebi-id="WO2007045867:234633" relevant="false">dihydrobenzofuranyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.435" epochem-id="EPOCHEM:NEW:LIGAND:264" name="isoindolonyl" comment="" chebi-id="WO2007045867:590048" relevant="false">isoindolonyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.838" epochem-id="EPOCHEM:NEW:LIGAND:522" name="heteroaryl-fused-cycloalkyl" comment="" chebi-id="WO2007045867:476609" relevant="false">heteroaryl-fused-cycloalkyl</ne>, for 20 example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.790" epochem-id="EPOCHEM:NEW:LIGAND:381" name="tetrahydroquinolyl" comment="" chebi-id="WO2007045867:785179" relevant="false">tetrahydroquinolyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.877" epochem-id="EPOCHEM:NEW:LIGAND:524" name="heteroaryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:242991" relevant="false">heteroaryl-fused-heterocycloalkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.418" epochem-id="EPOCHEM:NEW:LIGAND:260" name="indolinyl" comment="" chebi-id="WO2007045867:725815" relevant="false">indolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.423" epochem-id="EPOCHEM:NEW:LIGAND:261" name="benzodioxinyl" comment="" chebi-id="WO2007045867:180049" relevant="false">benzodioxinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.762" epochem-id="EPOCHEM:NEW:LIGAND:377" name="benzodioxolyl" comment="" chebi-id="WO2007045867:434800" relevant="false">benzodioxolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.431" epochem-id="EPOCHEM:NEW:LIGAND:263" name="dihydrobenzofuranyl" comment="" chebi-id="WO2007045867:234633" relevant="false">dihydrobenzofuranyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.436" epochem-id="EPOCHEM:NEW:LIGAND:264" name="isoindolonyl" comment="" chebi-id="WO2007045867:590048" relevant="false">isoindolonyl</ne>; or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.884" epochem-id="EPOCHEM:NEW:LIGAND:526" name="aryl-fused- cycloalkyl" comment="" chebi-id="WO2007045867:764181" relevant="false">aryl-fused- cycloalkyl</ne> group such as <ne type="LIGAND" id="WO2007045867.HC.ligand-names.332" epochem-id="EPOCHEM:NEW:LIGAND:219" name="tetrahydronaphthyl" comment="" chebi-id="WO2007045867:131223" relevant="false">tetrahydronaphthyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.335" epochem-id="EPOCHEM:NEW:LIGAND:220" name="indanyl" comment="" chebi-id="WO2007045867:990977" relevant="false">indanyl</ne>. One currently preferred R&lt;8&gt; is optionally substituted <ne type="LIGAND" id="WO2007045867.HC.ligand-names.799" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>. Optional substituents in R&lt;8&gt; include: <ne type="LIGAND" id="WO2007045867.HC.ligand-names.536" epochem-id="EPOCHEM:NEW:LIGAND:296" name="fluoro" comment="" chebi-id="CHEBI:42645" relevant="false">fluoro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.750" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.800" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.485" epochem-id="EPOCHEM:NEW:LIGAND:280" name="methanesulfonyl" comment="" chebi-id="WO2007045867:560731" relevant="false">methanesulfonyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.487" epochem-id="EPOCHEM:NEW:LIGAND:281" name="4-ethanesulfonylphenyl" comment="" chebi-id="WO2007045867:89974" relevant="false">4-ethanesulfonylphenyl</ne>, 25 <ne type="LIGAND" id="WO2007045867.HC.ligand-names.778" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.481" epochem-id="EPOCHEM:NEW:LIGAND:278" name="morpholine-4-sulfonyl" comment="" chebi-id="WO2007045867:954655" relevant="false">morpholine-4-sulfonyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.483" epochem-id="EPOCHEM:NEW:LIGAND:279" name="pyrrolidine-1-carbonyl" comment="" chebi-id="WO2007045867:270811" relevant="false">pyrrolidine- 1-carbonyl</ne>, and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.489" epochem-id="EPOCHEM:NEW:LIGAND:282" name="cyclobutylcarbamoyl" comment="" chebi-id="WO2007045867:828402" relevant="false">cyclobutylcarbamoyl</ne>. Currently preferred R&lt;8&gt; radicals include <ne type="LIGAND" id="WO2007045867.HC.ligand-names.528" epochem-id="EPOCHEM:NEW:LIGAND:293" name="4-chlorophenyl" comment="" chebi-id="WO2007045867:173177" relevant="false">4-chlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.491" epochem-id="EPOCHEM:NEW:LIGAND:283" name="2-chlorophenyl" comment="" chebi-id="WO2007045867:60121" relevant="false">2- chlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.771" epochem-id="EPOCHEM:NEW:LIGAND:284" name="4-(trifluoromethyl)phenyl" comment="" chebi-id="WO2007045867:81738" relevant="false">4-(trifluoromethyl)phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.770" epochem-id="EPOCHEM:NEW:LIGAND:285" name="4-(methylsulfonyl)phenyl" comment="" chebi-id="WO2007045867:303620" relevant="false">4-(methylsulfonyl)phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.641" epochem-id="EPOCHEM:NEW:LIGAND:298" name="4-fluorophenyl" comment="" chebi-id="WO2007045867:53461" relevant="false">4-fluorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.496" epochem-id="EPOCHEM:NEW:LIGAND:286" name="2-naphthyl" comment="" chebi-id="WO2007045867:92913" relevant="false">2- naphthyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.499" epochem-id="EPOCHEM:NEW:LIGAND:287" name="1 -naphthyl" comment="" chebi-id="WO2007045867:273857" relevant="false">1-naphthyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.503" epochem-id="EPOCHEM:NEW:LIGAND:288" name="2,3-dichlorophenyl" comment="" chebi-id="WO2007045867:371207" relevant="false">2,3-dichlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.506" epochem-id="EPOCHEM:NEW:LIGAND:289" name="8-quinolinyl" comment="" chebi-id="WO2007045867:2417" relevant="false">8-quinolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.510" epochem-id="EPOCHEM:NEW:LIGAND:290" name="3,5- dichlorophenyl" comment="" chebi-id="WO2007045867:704605" relevant="false">3,5-dichlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.513" epochem-id="EPOCHEM:NEW:LIGAND:291" name="3,4-dichlorophenyl" comment="" chebi-id="WO2007045867:840420" relevant="false">3,4- dichlorophenyl</ne>.
</P>
<P>30 R&lt;9&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.295" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.91" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.733" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.216" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, or n- or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.688" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>;
<ne type="LIGAND" id="WO2007045867.HC.ligand-names.813" epochem-id="EPOCHEM:NEW:LIGAND:383" name="(C1-C6) fluoroalkyl" comment="" chebi-id="WO2007045867:777766" relevant="false">(C1-C6) fluoroalkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.780" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.521" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.915" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3360" relevant="false">cycloalkyl</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.269" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.281" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>. Currently it is preferred that R&lt;9&gt; be <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.296" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>.
Specific compounds with which the invention is concerned include those of the Examples herein, and pharmaceutically acceptable salts, <ne id="WO2007045867.HC.class-names.29" epochem-id="EPOCHEM:NEW:CLASS:419" name="N-oxides" comment="" chebi-id="CHEBI:35580" relevant="false" type="CLASS">N-oxides</ne>, <ne id="WO2007045867.HC.class-names.28" epochem-id="EPOCHEM:NEW:CLASS:418" name="hydrates" comment="" chebi-id="CHEBI:35505" relevant="false" type="CLASS">hydrates</ne> or 35. solvates thereof. Compositions
As mentioned above, the compounds with which the invention, is concerned are CRTH2 receptor antagonists, and are useful in the treatment of diseases which benefit from such modulation. Examples of such diseases are referred to above, and include asthma, rhinitis, allergic airway syndrome, and bronchitis.
It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art. In general, the daily dose range will lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a mammal, often 0.01 mg to about 50 mg per kg, for example 0.1 to 10 mg per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. Orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions.
Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.350" epochem-id="EPOCHEM:NEW:COMPOUND:990" name="sorbitol" comment="" chebi-id="CHEBI:30911" relevant="false">sorbitol</ne>, tragacanth, or <ne type="CHEMICAL" id="WO2007045867.HC.substance-names.2" epochem-id="EPOCHEM:NEW:SUBSTANCE:140" name="polyvinyl-pyrrolidone" comment="" chebi-id="WO2007045867:888327" relevant="false">polyvinyl-pyrrolidone</ne>; <ne type="ONT" id="WO2007045867.HC.class-names.26" epochem-id="EPOCHEM:NEW:CLASS:224" name="fillers" comment="" chebi-id="WO2007045867:821928" relevant="false">fillers</ne> for example <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.357" epochem-id="EPOCHEM:COMPOUND:2313" name="lactose" comment="" chebi-id="CHEBI:17716" relevant="false">lactose</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.358" epochem-id="EPOCHEM:NEW:COMPOUND:1433" name="sugar" comment="" chebi-id="WO2007045867:728107" relevant="false">sugar</ne>, maize-<ne type="CHEMICAL" id="WO2007045867.HC.substance-names.3" epochem-id="EPOCHEM:NEW:SUBSTANCE:127" name="starch" comment="" chebi-id="CHEBI:28017" relevant="false">starch</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.356" epochem-id="EPOCHEM:NEW:COMPOUND:373" name="calcium phosphate" comment="" chebi-id="CHEBI:9679" relevant="false">calcium phosphate</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.351" epochem-id="EPOCHEM:NEW:COMPOUND:990" name="sorbitol" comment="" chebi-id="CHEBI:30911" relevant="false">sorbitol</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.353" epochem-id="EPOCHEM:COMPOUND:1017" name="glycine" comment="" chebi-id="CHEBI:15428" relevant="false">glycine</ne>; <ne type="ONT" id="WO2007045867.HC.class-names.27" epochem-id="EPOCHEM:NEW:CLASS:417" name="tabletting lubricant" comment="" chebi-id="WO2007045867:317561" relevant="false">tabletting lubricant</ne>, for example <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.354" epochem-id="EPOCHEM:NEW:COMPOUND:85" name="magnesium stearate" comment="" chebi-id="CHEBI:9254" relevant="false">magnesium stearate</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.substance-names.5" epochem-id="EPOCHEM:NEW:SUBSTANCE:313" name="talc" comment="" chebi-id="WO2007045867:53143" relevant="false">talc</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.substance-names.1" epochem-id="EPOCHEM:NEW:SUBSTANCE:2" name="polyethylene glycol" comment="" chebi-id="CHEBI:46793" relevant="false">polyethylene glycol</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.359" epochem-id="EPOCHEM:NEW:COMPOUND:1434" name="silica" comment="" chebi-id="CHEBI:30563" relevant="false">silica</ne>; <ne type="ONT" id="WO2007045867.HC.class-names.86" epochem-id="EPOCHEM:NEW:CLASS:1042" name="disintegrants" comment="" chebi-id="WO2007045867:993219" relevant="false">disintegrants</ne> for example potato <ne type="CHEMICAL" id="WO2007045867.HC.substance-names.4" epochem-id="EPOCHEM:NEW:SUBSTANCE:127" name="starch" comment="" chebi-id="CHEBI:28017" relevant="false">starch</ne>, or acceptable <ne id="WO2007045867.HC.class-names.25" epochem-id="EPOCHEM:NEW:CLASS:127" name="wetting agents" comment="" chebi-id="WO2007045867:887463" relevant="false" type="CLASS">wetting agents</ne> such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.355" epochem-id="EPOCHEM:NEW:COMPOUND:425" name="sodium lauryl sulfate" comment="" chebi-id="CHEBI:8984" relevant="false">sodium lauryl sulfate</ne>. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.127" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> or other suitable vehicle before use.
Such liquid preparations may contain conventional additives such as <ne type="ONT" id="WO2007045867.HC.class-names.31" epochem-id="EPOCHEM:NEW:CLASS:421" name="suspending agents" comment="" chebi-id="WO2007045867:201522" relevant="false">suspending agents</ne>, for example <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.352" epochem-id="EPOCHEM:NEW:COMPOUND:990" name="sorbitol" comment="" chebi-id="CHEBI:30911" relevant="false">sorbitol</ne>, syrup, <ne type="CHEMICAL" id="WO2007045867.HC.substance-names.6" epochem-id="EPOCHEM:NEW:SUBSTANCE:114" name="methyl cellulose" comment="" chebi-id="WO2007045867:444212" relevant="false">methyl cellulose</ne>, glucose syrup, gelatin hydrogenated edible fats; <ne type="ONT" id="WO2007045867.HC.class-names.32" epochem-id="EPOCHEM:NEW:CLASS:422" name="emulsifying agents" comment="" chebi-id="WO2007045867:283309" relevant="false">emulsifying agents</ne>, for example <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.367" epochem-id="EPOCHEM:NEW:COMPOUND:441" name="lecithin" comment="" chebi-id="CHEBI:16110" relevant="false">lecithin</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.368" epochem-id="EPOCHEM:NEW:COMPOUND:1435" name="sorbitan monooleate" comment="" chebi-id="WO2007045867:427379" relevant="false">sorbitan monooleate</ne>, or acacia; <ne type="ONT" id="WO2007045867.HC.class-names.33" epochem-id="EPOCHEM:NEW:CLASS:423" name="nonaqueous vehicles" comment="" chebi-id="WO2007045867:633938" relevant="false">nonaqueous vehicles</ne> (which may include edible oils), for example almond oil, fractionated coconut oil, oily <ne id="WO2007045867.HC.class-names.57" epochem-id="EPOCHEM:NEW:CLASS:338" name="esters" comment="" chebi-id="CHEBI:35701" relevant="false" type="CLASS">esters</ne> such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.369" epochem-id="EPOCHEM:NEW:COMPOUND:875" name="glycerine" comment="" chebi-id="CHEBI:17754" relevant="false">glycerine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.370" epochem-id="EPOCHEM:NEW:COMPOUND:25" name="propylene glycol" comment="" chebi-id="CHEBI:16997" relevant="false">propylene glycol</ne>, or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.371" epochem-id="EPOCHEM:NEW:COMPOUND:426" name="ethyl alcohol" comment="" chebi-id="CHEBI:16236" relevant="false">ethyl alcohol</ne>; <ne type="ONT" id="WO2007045867.HC.class-names.30" epochem-id="EPOCHEM:NEW:CLASS:420" name="preservatives" comment="" chebi-id="WO2007045867:331823" relevant="false">preservatives</ne>, for example <ne type="LIGAND" id="WO2007045867.HC.ligand-names.735" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.349" epochem-id="EPOCHEM:NEW:COMPOUND:993" name="propyl p-hydroxybenzoate" comment="" chebi-id="WO2007045867:537290" relevant="false">propyl p-hydroxybenzoate</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.348" epochem-id="EPOCHEM:COMPOUND:726" name="sorbic acid" comment="" chebi-id="CHEBI:35962" relevant="false">sorbic acid</ne>, and if desired conventional flavouring or colouring agents. For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
The drug may also be formulated for inhalation, for example as a nasal spray, or dry powder or aerosol inhalers. For delivery by inhalation, the active compound is preferably in the form of microparticles. They may be prepared by a variety of techniques, including spray-drying, freeze-drying and micronisation. Aerosol generation can be carried out using, for example, pressure-driven jet atomizers or ultrasonic atomizers, preferably using propellant-driven metered aerosols or propellant-free administration of micronized active compounds from, for example, inhalation capsules or other "dry powder" delivery systems.
The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
Other compounds may be combined with compounds of this invention of formula [I] for the prevention and treatment of prostaglandin-mediated diseases. Thus the present invention is also concerned with pharmaceutical compositions for preventing and treating <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.426" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne>-mediated diseases comprising a therapeutically effective amount of a compound of the invention of formula [I] and one or more other therapeutic agents. Suitable therapeutic agents for a combination therapy with compounds of formula [I] include, but are not limited to: (1) <ne type="ONT" id="WO2007045867.HC.class-names.14" epochem-id="EPOCHEM:NEW:CLASS:20" name="corticosteroids" comment="" chebi-id="CHEBI:36699" relevant="false">corticosteroids</ne>, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.330" epochem-id="EPOCHEM:NEW:COMPOUND:1418" name="fluticasone" comment="" chebi-id="WO2007045867:189496" relevant="false">fluticasone</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.331" epochem-id="EPOCHEM:NEW:COMPOUND:1419" name="ciclesonide" comment="" chebi-id="WO2007045867:933189" relevant="false">ciclesonide</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.332" epochem-id="EPOCHEM:NEW:COMPOUND:1420" name="budesonide" comment="" chebi-id="WO2007045867:627208" relevant="false">budesonide</ne>; (2) <ne type="ONT" id="WO2007045867.HC.class-names.15" epochem-id="EPOCHEM:NEW:CLASS:408" name="[beta]2-adrenoreceptor agonists" comment="" chebi-id="WO2007045867:726202" relevant="false">[beta]2-adrenoreceptor agonists</ne>, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.333" epochem-id="EPOCHEM:NEW:COMPOUND:1421" name="salmeterol" comment="" chebi-id="WO2007045867:479904" relevant="false">salmeterol</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.334" epochem-id="EPOCHEM:NEW:COMPOUND:1422" name="indacaterol" comment="" chebi-id="WO2007045867:913577" relevant="false">indacaterol</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.335" epochem-id="EPOCHEM:NEW:COMPOUND:1423" name="formoterol" comment="" chebi-id="WO2007045867:272801" relevant="false">formoterol</ne>; (3) <ne type="ONT" id="WO2007045867.HC.class-names.20" epochem-id="EPOCHEM:NEW:CLASS:412" name="leukotriene modulators" comment="" chebi-id="WO2007045867:797382" relevant="false">leukotriene modulators</ne>, for example <ne type="ONT" id="WO2007045867.HC.class-names.19" epochem-id="EPOCHEM:NEW:CLASS:411" name="leukotriene antagonists" comment="" chebi-id="CHEBI:49159" relevant="false">leukotriene antagonists</ne> such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.338" epochem-id="EPOCHEM:NEW:COMPOUND:1426" name="montelukast" comment="" chebi-id="CHEBI:6992" relevant="false">montelukast</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.339" epochem-id="EPOCHEM:NEW:COMPOUND:1427" name="zafirulast" comment="" chebi-id="WO2007045867:346867" relevant="false">zafirulast</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.340" epochem-id="EPOCHEM:NEW:COMPOUND:1428" name="pranlukast" comment="" chebi-id="WO2007045867:695743" relevant="false">pranlukast</ne> or <ne type="ONT" id="WO2007045867.HC.class-names.21" epochem-id="EPOCHEM:NEW:CLASS:413" name="leukotriene biosynthesis inhibitors" comment="" chebi-id="WO2007045867:52743" relevant="false">leukotriene biosynthesis inhibitors</ne> such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.341" epochem-id="EPOCHEM:NEW:COMPOUND:1429" name="Zileuton" comment="" chebi-id="CHEBI:10112" relevant="false">Zileuton</ne> or BAY-1005; (4) <ne type="ONT" id="WO2007045867.HC.class-names.16" epochem-id="EPOCHEM:NEW:CLASS:409" name="anticholinergic" comment="" chebi-id="WO2007045867:642196" relevant="false">anticholinergic</ne> agents, for example <ne type="ONT" id="WO2007045867.HC.class-names.22" epochem-id="EPOCHEM:NEW:CLASS:414" name="muscarinic-3 (M3) receptor antagonists" comment="" chebi-id="WO2007045867:580595" relevant="false">muscarinic-3 (M3) receptor antagonists</ne> such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.342" epochem-id="EPOCHEM:NEW:COMPOUND:1430" name="tiotropium" comment="" chebi-id="WO2007045867:597051" relevant="false">tiotropium</ne> <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.343" epochem-id="EPOCHEM:COMPOUND:5" name="bromide" comment="" chebi-id="CHEBI:15858" relevant="false">bromide</ne>; (5) <ne type="ONT" id="WO2007045867.HC.class-names.17" epochem-id="EPOCHEM:NEW:CLASS:410" name="phosphodiesterase-IV (PDE-IV) inhibitors" comment="" chebi-id="WO2007045867:556161" relevant="false">phosphodiesterase-IV (PDE-IV) inhibitors</ne>, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.336" epochem-id="EPOCHEM:NEW:COMPOUND:1424" name="roflumilast" comment="" chebi-id="WO2007045867:454338" relevant="false">roflumilast</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.337" epochem-id="EPOCHEM:NEW:COMPOUND:1425" name="cilomilast" comment="" chebi-id="WO2007045867:288603" relevant="false">cilomilast</ne>; (6) <ne type="ONT" id="WO2007045867.HC.class-names.18" epochem-id="EPOCHEM:NEW:CLASS:246" name="antihistamines" comment="" chebi-id="CHEBI:37956" relevant="false">antihistamines</ne>, for example selective <ne type="ONT" id="WO2007045867.HC.class-names.9" epochem-id="EPOCHEM:NEW:CLASS:404" name="histamine-1 (H1) receptor antagonists" comment="" chebi-id="WO2007045867:486097" relevant="false">histamine-1 (H1) receptor antagonists</ne>, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.320" epochem-id="EPOCHEM:NEW:COMPOUND:1411" name="fexofenadine" comment="" chebi-id="CHEBI:5050" relevant="false">fexofenadine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.323" epochem-id="EPOCHEM:NEW:COMPOUND:1414" name="citirizine" comment="" chebi-id="WO2007045867:685308" relevant="false">citirizine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.321" epochem-id="EPOCHEM:NEW:COMPOUND:1412" name="loratidine" comment="" chebi-id="WO2007045867:805941" relevant="false">loratidine</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.322" epochem-id="EPOCHEM:NEW:COMPOUND:1413" name="astemizole" comment="" chebi-id="WO2007045867:537831" relevant="false">astemizole</ne>; (7) <ne type="ONT" id="WO2007045867.HC.class-names.10" epochem-id="EPOCHEM:NEW:CLASS:405" name="antitussive" comment="" chebi-id="WO2007045867:918399" relevant="false">antitussive</ne> agents, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.324" epochem-id="EPOCHEM:COMPOUND:5764" name="codeine" comment="" chebi-id="CHEBI:16714" relevant="false">codeine</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.325" epochem-id="EPOCHEM:NEW:COMPOUND:1415" name="dextramorphan" comment="" chebi-id="WO2007045867:891609" relevant="false">dextramorphan</ne>; (8) <ne type="ONT" id="WO2007045867.HC.class-names.11" epochem-id="EPOCHEM:NEW:CLASS:406" name="non-selective COX-1 / COX-2 inhibitors" comment="" chebi-id="WO2007045867:611828" relevant="false">non-selective COX-1 / COX-2 inhibitors</ne>, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.326" epochem-id="EPOCHEM:NEW:COMPOUND:1416" name="ibuprofen" comment="" chebi-id="WO2007045867:40409" relevant="false">ibuprofen</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.327" epochem-id="EPOCHEM:COMPOUND:5053" name="ketoprofen" comment="" chebi-id="CHEBI:6128" relevant="false">ketoprofen</ne>; (9) <ne type="ONT" id="WO2007045867.HC.class-names.13" epochem-id="EPOCHEM:NEW:CLASS:407" name="COX-2 inhibitors" comment="" chebi-id="WO2007045867:374353" relevant="false">COX-2 inhibitors</ne>, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.328" epochem-id="EPOCHEM:NEW:COMPOUND:1417" name="celecoxib" comment="" chebi-id="CHEBI:41423" relevant="false">celecoxib</ne> and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.329" epochem-id="EPOCHEM:COMPOUND:4349" name="rofecoxib" comment="" chebi-id="CHEBI:8887" relevant="false">rofecoxib</ne>; (10) VLA-4 antagonists, such as those described in WO97/03094 and WO97/02289; (11) <ne type="ONT" id="WO2007045867.HC.class-names.87" epochem-id="EPOCHEM:NEW:CLASS:1081" name="TACE inhibitors" comment="" chebi-id="WO2007045867:997835" relevant="false">TACE inhibitors</ne> and <ne type="ONT" id="WO2007045867.HC.class-names.23" epochem-id="EPOCHEM:NEW:CLASS:415" name="TNF-[alpha] inhibitors" comment="" chebi-id="WO2007045867:67701" relevant="false">TNF-[alpha] inhibitors</ne>, for example <ne type="ONT" id="WO2007045867.HC.class-names.24" epochem-id="EPOCHEM:NEW:CLASS:416" name="anti-TNF monoclonal antibodies" comment="" chebi-id="WO2007045867:90984" relevant="false">anti-TNF monoclonal antibodies</ne>, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.344" epochem-id="EPOCHEM:NEW:COMPOUND:1431" name="Remicade" comment="" chebi-id="WO2007045867:534192" relevant="false">Remicade</ne> and CDP-870 and TNF receptor immunoglobulin molecules, such as Enbrel; (12) inhibitors of matrix metalloprotease, for example MMP12; (13) human neutrophil elastase inhibitors, such as those described in WO2005/026124, WO2003/053930 and WO06/082412; (14) A2a agonists such as those described in EP1052264 and EP1241176 (15) A2b antagonists such as those described in WO2002/42298; (16) modulators of chemokine receptor function, for example antagonists of CCR3 and CCR8; (17) compounds which modulate the action of other prostanoid receptors, for example a DP receptor antagonist or a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.346" epochem-id="EPOCHEM:NEW:COMPOUND:1432" name="thromboxane" comment="" chebi-id="CHEBI:26995" relevant="false">thromboxane</ne> A2 antagonist; and (18) agents that modulate Th2 function, such as PPAR agonists
The weight ratio of the compound of the invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Methods of Synthesis
The present invention is also concerned with processes for preparing the compounds of this invention. The compounds can be prepared according to the procedures of the following schemes and examples, using appropriate materials, and are further exemplified by the following specific examples.
Moreover, by utilizing the procedures described with the disclosure contained herein, one of ordinary skill in the art can readily prepare additional compounds of the present invention claimed herein. The compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention. The examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. Compounds of formula [l-a], wherein R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;7&gt;, R&lt;8&gt; and R&lt;9&gt; are as defined for formula [I] above, may be prepared from compounds of formula [ll-a] wherein X represents an appropriate ester protecting group. Suitable ester protecting groups include, for example, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.736" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.218" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, which may be removed by acid- or base-catalysed aqueous hydrolysis or by treatment with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.79" epochem-id="EPOCHEM:NEW:COMPOUND:1129" name="potassium trimethylsilanoate" comment="" chebi-id="WO2007045867:427365" relevant="false">potassium trimethylsilanoate</ne> in a solvent such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.347" epochem-id="EPOCHEM:NEW:COMPOUND:791" name="THF" comment="" chebi-id="WO2007045867:88378" relevant="false">THF</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.768" epochem-id="EPOCHEM:NEW:LIGAND:109" name="benzyl" comment="" chebi-id="CHEBI:22744" relevant="false">benzyl</ne>, which may be removed by catalytic hydrogenation, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.769" epochem-id="EPOCHEM:NEW:LIGAND:379" name="te/f-butyl" comment="tert-butyl" chebi-id="WO2007045867:168028" relevant="false">te/f-butyl</ne>, which may be removed by treatment with a strong acid such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.111" epochem-id="EPOCHEM:NEW:COMPOUND:1136" name="trifluoroacetic acid" comment="" chebi-id="CHEBI:45892" relevant="false">trifluoroacetic acid</ne>/<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.113" epochem-id="EPOCHEM:COMPOUND:5443" name="dichloromethane" comment="" chebi-id="CHEBI:15767" relevant="false">dichloromethane</ne> mixtures, or a solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.115" epochem-id="EPOCHEM:COMPOUND:4" name="hydrogen chloride" comment="" chebi-id="CHEBI:17883" relevant="false">hydrogen chloride</ne> in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.467" epochem-id="EPOCHEM:NEW:COMPOUND:2089" name="dioxane" comment="" chebi-id="CHEBI:46923" relevant="false">dioxane</ne>.
</P>
<P>[0056]
EMI14.1
Compounds of formula [ll-a] may be prepared from compounds of formula [III- a], wherein R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;7&gt;, R&lt;9&gt; and X are as defined above, by reaction with a compound of formula [VIII] wherein R&lt;8&gt; is as defined above for general formula [I].
</P>
<P>[0058]
EMI14.2
</P>
<P>[VIII]
The reaction solvent may be a <ne type="ONT" id="WO2007045867.HC.class-names.77" epochem-id="EPOCHEM:NEW:CLASS:906" name="polar organic solvent" comment="" chebi-id="WO2007045867:74378" relevant="false">polar organic solvent</ne> such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.94" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> or <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.16" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne>. Compounds of formula [VIlI] are well known and are either readily available or can be prepared by methods well known to those skilled in the art.
Compounds of formula [lll-a] may be prepared by the reaction between a compound of formula [IV-a], wherein R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt;, R&lt;4&gt; R&lt;5&gt;, R&lt;6&gt;, R&lt;7&gt; and X are as defined above, and an appropriate compound of formula [IX], wherein R&lt;9&gt; is as defined above, and LG represents a suitable leaving group (for example, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.751" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.766" epochem-id="EPOCHEM:NEW:LIGAND:378" name="bromo" comment="" chebi-id="WO2007045867:807484" relevant="false">bromo</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.724" epochem-id="EPOCHEM:NEW:LIGAND:311" name="methanesulfonyloxy" comment="" chebi-id="WO2007045867:315252" relevant="false">methanesulfonyloxy</ne>).
R-LG
</P>
<P>[IX]
The transformation of compounds of formula [V-a], wherein R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt;, R&lt;4&gt; R&lt;5&gt;,
R&lt;6&gt;, R&lt;7&gt; and X are as defined above, into those of formula [IV-a] may conveniently be achieved by reduction with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.274" epochem-id="EPOCHEM:NEW:COMPOUND:1191" name="Zinc" comment="" chebi-id="CHEBI:27363" relevant="false">zinc</ne>/<ne type="LIGAND" id="WO2007045867.HC.ligand-names.818" epochem-id="EPOCHEM:NEW:LIGAND:76" name="acetic" comment="" chebi-id="WO2007045867:79985" relevant="false">acetic</ne> acid or with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.298" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne> in the presence of a suitable <ne type="ONT" id="WO2007045867.HC.class-names.76" epochem-id="EPOCHEM:NEW:CLASS:581" name="catalyst" comment="" chebi-id="CHEBI:35223" relevant="false">catalyst</ne>, such as <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.434" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne> supported on carbon.
Compounds of formula [V-a] may be prepared from compounds of formula [Vl-a], wherein R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt;, R&lt;4&gt; R&lt;5&gt;, R&lt;6&gt; R&lt;7&gt; and X are as defined above, by nitration with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.117" epochem-id="EPOCHEM:COMPOUND:1167" name="nitric acid" comment="" chebi-id="CHEBI:25545" relevant="false">nitric acid</ne> and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.119" epochem-id="EPOCHEM:COMPOUND:5418" name="acetic anhydride" comment="" chebi-id="CHEBI:36610" relevant="false">acetic anhydride</ne>, at a temperature between -8O&lt;0&gt;C and room temperature.
Compounds of formula [Vl-a] may be prepared from compounds of formula [Vll-a], wherein R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt;, R&lt;4&gt; and R&lt;7&gt; are as defined above, by reaction with a compound of general formula [X], wherein R&lt;5&gt; and R&lt;6&gt; are as defined in formula [I], X is as defined above and LG is a leaving group, such as a <ne id="WO2007045867.HC.class-names.80" epochem-id="EPOCHEM:NEW:CLASS:132" name="halogen" comment="" chebi-id="CHEBI:24473" relevant="false" type="CLASS">halogen</ne>, particularly <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.461" epochem-id="EPOCHEM:NEW:COMPOUND:513" name="chlorine" comment="" chebi-id="CHEBI:23116" relevant="false">chlorine</ne>, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.462" epochem-id="EPOCHEM:NEW:COMPOUND:514" name="bromine" comment="" chebi-id="CHEBI:22927" relevant="false">bromine</ne> or an <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.463" epochem-id="EPOCHEM:NEW:COMPOUND:515" name="iodine" comment="" chebi-id="CHEBI:24859" relevant="false">iodine</ne> atom. Typically, the alkylation reaction is carried out in the presence of a base (for example, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.122" epochem-id="EPOCHEM:NEW:COMPOUND:1137" name="potassium carbonate" comment="" chebi-id="WO2007045867:587620" relevant="false">potassium carbonate</ne>) in an inert solvent (for example<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.124" epochem-id="EPOCHEM:NEW:COMPOUND:1138" name=",[ Lambda]/,[Lambda]/-dimethylformamide" comment="N-N-dimethylformamide" chebi-id="WO2007045867:80993" relevant="false">, [Lambda]/,[Lambda]/-dimethylformamide</ne>).
</P>
<P>[0068]
EMI15.1
M
Compounds of general formula [Vll-a] are well known and are either readily available or can be prepared by methods well known to those skilled in the art. Examples The invention will now be described in detail with reference to the following examples. It will be appreciated that the invention is described by way of example only and modification of detail may be made without departing from the scope of the invention. <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.444" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR spectra were recorded at ambient temperature using a Varian Unity
Inova (400MHz) spectrometer with a triple resonance 5 mm probe spectrometer.
Chemical shifts are expressed in ppm relative to <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.142" epochem-id="EPOCHEM:NEW:COMPOUND:1139" name="tetramethylsilane" comment="" chebi-id="WO2007045867:561301" relevant="false">tetramethylsilane</ne>. The following abbreviations have been used: br s = broad singlet, s = singlet, d = doublet, dd = double doublet, t = triplet, q = quartet, m = multiplet.
Mass Spectrometry (LCMS) experiments to determine retention times and associated mass ions were performed using the following methods: Method A: experiments were performed on a Micromass Platform LCT spectrometer with positive ion electrospray and single wavelength UV 254 nm detection using a Higgins Clipeus C18 5 [mu]m 100 x 3.0 mm column and a 2 mL/minute flow rate. The initial solvent system was 95% <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.128" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> containing 0.1% <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.140" epochem-id="EPOCHEM:COMPOUND:601" name="formic acid" comment="" chebi-id="CHEBI:30751" relevant="false">formic acid</ne> (solvent A) and 5% <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.468" epochem-id="EPOCHEM:NEW:COMPOUND:2090" name="acetonithle" comment="acetonitrile" chebi-id="WO2007045867:832516" relevant="false">acetonithle</ne> containing 0.1% <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.141" epochem-id="EPOCHEM:COMPOUND:601" name="formic acid" comment="" chebi-id="CHEBI:30751" relevant="false">formic acid</ne> (solvent B) for the first minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 14 minutes. The final solvent system was held constant for a further 2 minutes. Method B: experiments were performed on a Micromass Platform LC spectrometer with positive and negative ion electrospray and ELS/Diode array detection using a Phenomenex Luna C18(2) 30 x 4.6 mm column and a 2 mL/minute flow rate. The solvent system was 95% solvent A and 5% solvent B for the first 0.50 minutes followed by a gradient up to 5% solvent A and 95% solvent B over the next 4 minutes. The final solvent system was held constant for a further 0.50 minutes
Microwave experiments were carried out using a Personal Chemistry Smith Synthesizer(TM), which uses a single-mode resonator and dynamic field tuning, both of which give reproducibility and control. Temperatures from 40-250&lt;0&gt;C can be achieved, and pressures of up to 20 bar can be reached. Two types of vial are available for this processor, 0.5-2.0 mL and 2.0-5.0 mL
Reverse-phase preparative HPLC purifications were carried out using Genesis 7 micron C-18 bonded <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.360" epochem-id="EPOCHEM:NEW:COMPOUND:1434" name="silica" comment="" chebi-id="CHEBI:30563" relevant="false">silica</ne> stationary phase in columns 10 cm in le[eta]gth and 2 cm internal diameter. The mobile phase used was mixtures of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.125" epochem-id="EPOCHEM:NEW:COMPOUND:776" name="acetonitrile" comment="" chebi-id="CHEBI:38472" relevant="false">acetonitrile</ne> and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.129" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (both buffered with 01% v/v <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.112" epochem-id="EPOCHEM:NEW:COMPOUND:1136" name="trifluoroacetic acid" comment="" chebi-id="CHEBI:45892" relevant="false">trifluoroacetic acid</ne>) with a flow rate of 10 mL per minute and typical gradients of 40 to 90% organic modifier ramped up over 30 to 40 minutes. Fractions containing the required product (identified by LC-MS analysis) were pooled, the organic fraction removed by evaporation, and the remaining aqueous fraction lyophilised, to give the final product. Example 1 : <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.143" epochem-id="EPOCHEM:NEW:COMPOUND:1140" name="[5-chloro-3-(4-chlorobenzenesulf onylamino)-2-methylindol-1 - yl]acetic acid" comment="5-chloro-3-(4-chlorobenzenesulfonylamino)-2 methylindol-1-yl] acetic acid" chebi-id="WO2007045867:637539" relevant="true">[5-chloro-3-(4-chlorobenzenesulf onylamino)-2-methylindol-1 - yl]acetic acid</ne> (l-a: R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H, R&lt;2&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.45" epochem-id="EPOCHEM:NEW:FORMULA:21" name="Cl" comment="" chebi-id="CHEBI:23116" relevant="false">Cl</ne>, R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.33" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.55" epochem-id="EPOCHEM:NEW:FORMULA:161" name="4-CIPh" comment="4-ClPh" chebi-id="WO2007045867:999154" relevant="false">4-CIPh</ne>)
</P>
<P>[0076]
EMI17.1
Preparation 1a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.152" epochem-id="EPOCHEM:NEW:COMPOUND:1143" name="([delta]-chloro^-methylindol-i-yljacetic acid methyl ester" comment="5-chloro-3-(4-chlorobenzenesulfonylamino)-2 methylindol-1-yl] acetic acid" chebi-id="WO2007045867:58403" relevant="false">([delta]-chloro^-methylindol-i-yljacetic acid methyl ester</ne>
A mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.153" epochem-id="EPOCHEM:NEW:COMPOUND:1144" name="5-chloro-2-methyl-1 H-indole" comment="" chebi-id="WO2007045867:762194" relevant="false">5-chloro-2-methyl-1 H-indole</ne> (1.0 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.154" epochem-id="EPOCHEM:NEW:COMPOUND:1145" name="bromoacetic acid methyl ester" comment="" chebi-id="WO2007045867:29980" relevant="false">bromoacetic acid methyl ester</ne> (0.83 mL), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.123" epochem-id="EPOCHEM:NEW:COMPOUND:1137" name="potassium carbonate" comment="" chebi-id="WO2007045867:587620" relevant="false">potassium carbonate</ne> (2.5 g) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.155" epochem-id="EPOCHEM:NEW:COMPOUND:1146" name="[Lambda]/,/V-dimethylformamide" comment="N-N-dimethylformamide" chebi-id="WO2007045867:353730" relevant="false">[Lambda]/,/V-dimethylformamide</ne> (7.0 ml_) was stirred at 45&lt;0&gt;C overnight. The reaction mixture was diluted with 1.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.172" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne> and the resulting precipitate collected by filtration and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.156" epochem-id="EPOCHEM:NEW:COMPOUND:1147" name="(5-chloro-2-methyl-indol-1-yl)acetic acid methyl ester" comment="" chebi-id="WO2007045867:259290" relevant="true">(5-chloro-2-methyl-indol-1-yl)acetic acid methyl ester</ne>, 1.3 g.
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.445" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.52" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 2.30 (d, J = 0.9 Hz, 3H), 3.70 (s, 3H), 5.10 (s, 2H), 6.25 (t, J = 0.9 Hz, 1H), 7.05 (dd, J = 1.9, 8.7 Hz, 1H), 7.40 (d, J = 8.7 Hz, 1H), 7.45 (d, J = 1.9 Hz, 1H). Preparation 1 b <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.158" epochem-id="EPOCHEM:NEW:COMPOUND:1148" name="(5-chloro-2-methyl-3-nitroindol-1-yl)acetic acid methyl ester" comment="" chebi-id="WO2007045867:989377" relevant="false">(5-chloro-2-methyl-3-nitroindol-1-yl)acetic acid methyl ester</ne>
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.118" epochem-id="EPOCHEM:COMPOUND:1167" name="nitric acid" comment="" chebi-id="CHEBI:25545" relevant="false">Nitric acid</ne> (90%, 0.74 mL) was added to stirred <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.120" epochem-id="EPOCHEM:COMPOUND:5418" name="acetic anhydride" comment="" chebi-id="CHEBI:36610" relevant="false">acetic anhydride</ne> (11 mL) at O&lt;0&gt;C and the resulting solution was left to stand at room temperature for ten minutes. This solution was added slowly to a solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.157" epochem-id="EPOCHEM:NEW:COMPOUND:1147" name="(5-chloro-2-methyl-indol-1-yl)acetic acid methyl ester" comment="" chebi-id="WO2007045867:259290" relevant="true">(5-chloro-2-methyl-indol-1-yl)acetic acid methyl ester</ne> (1.3 g) in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.121" epochem-id="EPOCHEM:COMPOUND:5418" name="acetic anhydride" comment="" chebi-id="CHEBI:36610" relevant="false">acetic anhydride</ne> (27 mL) at -7O&lt;0&gt;C and the resulting mixture was allowed to warm to room temperature over three hours. The reaction mixture was poured onto a mixture of ice and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.130" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> and stirred for one hour. The resulting precipitate was collected by filtration and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.159" epochem-id="EPOCHEM:NEW:COMPOUND:1148" name="(5-chloro-2-methyl-3-nitroindol-1-yl)acetic acid methyl ester" comment="" chebi-id="WO2007045867:989377" relevant="false">(5-chloro-2-methyl- 3-nitroindol-1-yl)acetic acid methyl ester</ne> (1.4 g).
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.446" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.53" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 2.75 (s, 3H), 3.75 (s, 3H), 5.40 (s, 2H), 7.40 (dd, J = 2.2, 8.8 Hz, 1H), 7.75 (dd, J = 0.4, 8.8 Hz, 1H), 8.10 (dd, J = 0.4, 2.2 Hz, 1H).
MS: ESI (+ve) (Method B): 283 (M+H)&lt;+&gt;, Retention time 3.6 min. Preparation 1c <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.146" epochem-id="EPOCHEM:NEW:COMPOUND:1142" name="(3-amino-5-chloro-2- methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:454933" relevant="false">(3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne>
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.275" epochem-id="EPOCHEM:NEW:COMPOUND:1191" name="Zinc" comment="" chebi-id="CHEBI:27363" relevant="false">Zinc</ne> dust (3.0 g) was added to a solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.160" epochem-id="EPOCHEM:NEW:COMPOUND:1148" name="(5-chloro-2-methyl-3-nitroindol-1-yl)acetic acid methyl ester" comment="" chebi-id="WO2007045867:989377" relevant="false">(5-chloro-2-methyl-3-nitroindol-1- yl)acetic acid methyl ester</ne> (2.7 g) in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.161" epochem-id="EPOCHEM:NEW:COMPOUND:525" name="glacial acetic acid" comment="" chebi-id="WO2007045867:252166" relevant="false">glacial acetic acid</ne> (150 mL) and the resulting mixture was stirred at room temperature for three hours. The reaction mixture was filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.469" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> and treated with 1.25 M <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.173" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne> in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.470" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> and the resulting precipitate was collected by filtration and triturated with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.162" epochem-id="EPOCHEM:NEW:COMPOUND:866" name="diethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false">diethyl ether</ne> to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.164" epochem-id="EPOCHEM:NEW:COMPOUND:1149" name="(S-amino-[delta]-chloro-a-methylindol-i-yOacetic acid methyl ester hydrochloride" comment="(3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride" chebi-id="WO2007045867:846353" relevant="false">(S-amino-[delta]-chloro-a-methylindol-i-yOacetic acid methyl ester hydrochloride</ne> as a brown solid, 2.7 g. MS: ESI (+ve) (Method B): 253 (M+H)&lt;+&gt;, Retention time 1.9 min.
Preparation 1d <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.165" epochem-id="EPOCHEM:NEW:COMPOUND:1150" name="[5-chloro-3-(4-chlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:555916" relevant="false">[5-chloro-3-(4-chlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester</ne>
A mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.145" epochem-id="EPOCHEM:NEW:COMPOUND:1141" name="4-chlorobenzenesulfonyl chloride" comment="" chebi-id="WO2007045867:949817" relevant="false">4-chlorobenzenesulfonyl chloride</ne> (0.26 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.147" epochem-id="EPOCHEM:NEW:COMPOUND:1142" name="(3-amino-5-chloro-2- methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:454933" relevant="false">(3-amino-5-chloro-2- methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (0.28 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.10" epochem-id="EPOCHEM:COMPOUND:4239" name="triethylamine" comment="" chebi-id="CHEBI:35026" relevant="false">triethylamine</ne> (0.47 imL) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.114" epochem-id="EPOCHEM:COMPOUND:5443" name="dichloromethane" comment="" chebi-id="CHEBI:15767" relevant="false">dichloromethane</ne> (10 ml_) was stirred at O&lt;0&gt;C for seventy five minutes. The solvent was removed under reduced pressure and purification of the residue by column chromatography on <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.361" epochem-id="EPOCHEM:NEW:COMPOUND:1434" name="silica" comment="" chebi-id="CHEBI:30563" relevant="false">silica</ne> gel, eluting with a mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.163" epochem-id="EPOCHEM:NEW:COMPOUND:866" name="diethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false">diethyl ether</ne> and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.167" epochem-id="EPOCHEM:COMPOUND:5548" name="cyclohexane" comment="" chebi-id="CHEBI:29005" relevant="false">cyclohexane</ne> (2:3 by volume) gave <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.166" epochem-id="EPOCHEM:NEW:COMPOUND:1150" name="[5-chloro-3-(4-chlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:555916" relevant="false">[5-chloro-3-(4-chlorobenzenesulfonylamino)-2- methylindol-1-yl]acetic acid methyl ester</ne>, 0.17 g. MS: ESI (+ve) (Method B): 425 (M-H)&lt;"&gt;, Retention time 3.6 min.
Preparation 1 e <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.168" epochem-id="EPOCHEM:NEW:COMPOUND:1151" name="[5-chloro-3-(4-ch!orobenzenesulf onyIamino)-2-methylindol-1 - yl]acetic acid" comment="[5-chloro-3-(4-chlorobenzenesulf onylamino)-2-methylindol-1 - yl]acetic acid" chebi-id="WO2007045867:438377" relevant="false">[5-chloro-3-(4-ch!orobenzenesulf onyIamino)-2-methylindol-1 - yl]acetic acid</ne>
A solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.169" epochem-id="EPOCHEM:NEW:COMPOUND:1152" name="[5-chloro-3-(4-chlorobenzenesulfonylamino)-2-methylindol-1- yljacetic acid methyl ester" comment="[5-chloro-3-(4-chlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester" chebi-id="WO2007045867:896231" relevant="false">[5-chloro-3-(4-chlorobenzenesulfonylamino)-2-methylindol-1- yljacetic acid methyl ester</ne> (0.43 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.170" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne> (2.0 mL) and 4.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.44" epochem-id="EPOCHEM:COMPOUND:7174" name="sodium hydroxide" comment="" chebi-id="CHEBI:32145" relevant="false">sodium hydroxide</ne> solution (2.0 mL) was stirred at room temperature for one hour. The <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.171" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne> was removed under reduced pressure and the pH of the residue adjusted to pH1 by the addition of 1.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.174" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration and washed with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.131" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> to afford after drying, <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.144" epochem-id="EPOCHEM:NEW:COMPOUND:1140" name="[5-chloro-3-(4-chlorobenzenesulf onylamino)-2-methylindol-1 - yl]acetic acid" comment="5-chloro-3-(4-chlorobenzenesulfonylamino)-2 methylindol-1-yl] acetic acid" chebi-id="WO2007045867:637539" relevant="true">[5-chloro-3-(4- chlorobenzenesulf onylamino)-2-methylindol-1 -yl]acetic acid</ne>, 0.34 g <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.447" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.54" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 1.95 (s, 3H), 4.95 (s, 2H), 6.80 (m, 1 H), 7.00 (m, 1 H),
</P>
<P>7.35 (d, J = 8.8 Hz, 1 H), 7.55 (m, 4H), 9.50 (s, 1 H), 13.1 (br s, 1 H).
MS: ESI (+ve) (Method A): 413 (M+H)&lt;+&gt;, Retention time 10.3 min. Example 2: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.202" epochem-id="EPOCHEM:NEW:COMPOUND:1157" name="[5-chloro-3-(2-chlorobenzenesulf onylamino)-2-methylindol-1 - yl]acetic acid" comment="" chebi-id="WO2007045867:331016" relevant="true">[5-chloro-3-(2-chlorobenzenesulf onylamino)-2-methylindol-1 - yl]acetic acid</ne> (l-a: R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H, R&lt;2&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.46" epochem-id="EPOCHEM:NEW:FORMULA:21" name="Cl" comment="" chebi-id="CHEBI:23116" relevant="false">Cl</ne>, R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.34" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.56" epochem-id="EPOCHEM:NEW:FORMULA:162" name="2-CIPh" comment="2-ClPh" chebi-id="WO2007045867:262460" relevant="false">2-CIPh</ne>)
</P>
<P>[0090]
EMI18.1
Preparation 2a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.192" epochem-id="EPOCHEM:NEW:COMPOUND:1153" name="[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1 - yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:261532" relevant="false">[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1 - yl]acetic acid methyl ester</ne>
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.195" epochem-id="EPOCHEM:NEW:COMPOUND:1154" name="2-Chlorobenzenesulfonyl chloride" comment="" chebi-id="WO2007045867:875882" relevant="false">2-Chlorobenzenesulfonyl chloride</ne> (0.05 g) was added to a stirred solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.148" epochem-id="EPOCHEM:NEW:COMPOUND:1142" name="(3-amino-5-chloro-2- methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:454933" relevant="false">(3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.05 g) in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.95" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> (5.0 ml_) at room temperature. After one hour and thirty minutes the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.96" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> was removed under reduced pressure. The residue was washed with 1.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.175" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne> and then <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.132" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.193" epochem-id="EPOCHEM:NEW:COMPOUND:1153" name="[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1 - yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:261532" relevant="true">[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1-yl]acetic acid methyl ester</ne>, 0.06 g. MS: ESI (+ve) (Method B): 425 (M-H)&lt;"&gt;, Retention time 3.7 min.
Preparation 2b <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.198" epochem-id="EPOCHEM:NEW:COMPOUND:1155" name="[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid" comment="" chebi-id="WO2007045867:68841" relevant="false">[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid</ne>
A mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.194" epochem-id="EPOCHEM:NEW:COMPOUND:1153" name="[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1 - yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:261532" relevant="false">[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester</ne> (0.06 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.80" epochem-id="EPOCHEM:NEW:COMPOUND:1129" name="potassium trimethylsilanoate" comment="" chebi-id="WO2007045867:427365" relevant="false">potassium trimethylsilanoate</ne> (0.05 g) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.17" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 ml_) was heated by microwave irradiation at 100&lt;0&gt;C for five minutes. The solvent was removed under reduced pressure and the pH of the residue adjusted to 1 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.176" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration, washed with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.133" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.200" epochem-id="EPOCHEM:NEW:COMPOUND:1155" name="[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid" comment="" chebi-id="WO2007045867:68841" relevant="false">[5-chloro- 3-(2-chlorobenzenesulfonylamino)-2-methylindol-1-yl]acetic acid</ne>, 0.035 g. <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.448" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.55" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 2.05 (s, 3H), 4.90 (s, 2H), 7.00 (m, 2H), 7.30-7.40 (m,
</P>
<P>2H), 7.60-7.70 (m, 3H), 9.70 (s, 1 H), 13.00 (br s, 1H).
MS: ESI (+ve) (Method A): 413 (M+H)&lt;+&gt;, Retention time 9.8 min. Example 3<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.201" epochem-id="EPOCHEM:NEW:COMPOUND:1156" name=":[ 5-chloro-2-methyl-3-(4-trifluoromethylbenzenesulfonylamino)indol-1 -yl]aceticacid" comment="" chebi-id="WO2007045867:643825" relevant="false">: [5-chloro-2-methyl-3-(4-trifluoromethylbenzenesulfonylamino)indol- 1-yl]acetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H, R&lt;2&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.47" epochem-id="EPOCHEM:NEW:FORMULA:21" name="Cl" comment="" chebi-id="CHEBI:23116" relevant="false">Cl</ne>, R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.35" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.57" epochem-id="EPOCHEM:NEW:FORMULA:163" name="4-CF3Ph" comment="" chebi-id="WO2007045867:508633" relevant="false">4-CF3Ph</ne>)
</P>
<P>[0096]
EMI19.1
Preparation 3a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.203" epochem-id="EPOCHEM:NEW:COMPOUND:1158" name="[5-chloro-2-methyl-3-(4- trifluoromethylbenzenesulfonylamino)indol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:271208" relevant="false">[5-chloro-2-methyl-3-(4- trifluoromethylbenzenesulfonylamino)indol-1-yl]acetic acid methyl ester</ne> To a mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.208" epochem-id="EPOCHEM:NEW:COMPOUND:1159" name="3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:362738" relevant="false">3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.15 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.11" epochem-id="EPOCHEM:COMPOUND:4239" name="triethylamine" comment="" chebi-id="CHEBI:35026" relevant="false">triethylamine</ne> (0.21 ml_) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.18" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 ml_) at -55&lt;0&gt;C was added <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.215" epochem-id="EPOCHEM:NEW:COMPOUND:1160" name="4-trifluoromethylbenzenesulf[omicron]nyl chloride" comment="4-trifluoromethylbenzenesulfonyl chloride" chebi-id="WO2007045867:128011" relevant="false">4-trifluoromethylbenzenesulf[omicron]nyl chloride</ne> (0.13 g) and the resulting mixture was stirred at -5O&lt;0&gt;C for thirty minutes. The reaction mixture was filtered and the filtrate concentrated under reduced pressure. Purification of the residue by column chromatography on <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.362" epochem-id="EPOCHEM:NEW:COMPOUND:1434" name="silica" comment="" chebi-id="CHEBI:30563" relevant="false">silica</ne> gel gave <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.204" epochem-id="EPOCHEM:NEW:COMPOUND:1158" name="[5-chloro-2-methyl-3-(4- trifluoromethylbenzenesulfonylamino)indol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:271208" relevant="false">[5-chloro-2- methyl-3-(4-trifluoromethylbenzenesulfonylamino)indol-1-yl]acetic acid methyl ester</ne>, 0.13 g.
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.449" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (CD3OD): [delta] 2.10 (s, 3H), 3.75 (s, 3H), 4.95 (s, 2H), 6.70 (d, J = 2.0 Hz, 1 H), 6.95 (dd, J = 2.0, 8.7 Hz, 1 H), 7.20 (d, J = 8.7 Hz, 1 H), 7.70-7.80 (m, 4H).
MS: ESI (+ve) (Method B): 459 (M-H)-, Retention time 3.7 min. Preparation <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.216" epochem-id="EPOCHEM:NEW:COMPOUND:1161" name="3b [5-chloro-2-methyl-3-(4- trifluoromethylbenzenesulfonylamino)indol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:192235" relevant="false">3b [5-chloro-2-methyl-3-(4- trifluoromethylbenzenesulfonylamino)indol-1-yl]acetic acid</ne>
A solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.217" epochem-id="EPOCHEM:NEW:COMPOUND:1162" name="[5-chloro-2-methyl-3-(4-trifluoromethylbenzenesulfonylamino)- indol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:141149" relevant="false">[5-chloro-2-methyl-3-(4-trifluoromethylbenzenesulfonylamino)- indol-1-yl]acetic acid methyl ester</ne> (0.12 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.19" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (5.0 mL) and 4.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.45" epochem-id="EPOCHEM:COMPOUND:7174" name="sodium hydroxide" comment="" chebi-id="CHEBI:32145" relevant="false">sodium hydroxide</ne> solution (2.0 mL) was stirred at room temperature for one hour. The <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.20" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> was removed under reduced pressure and pH of the residue adjusted to -3-4 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.177" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.222" epochem-id="EPOCHEM:NEW:COMPOUND:1163" name="[5-chloro-2-methyl- 3-(4-trifluoromethylbenzenesulfonylamino)indol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:135676" relevant="false">[5-chloro-2-methyl- 3-(4-trifluoromethylbenzenesulfonylamino)indol-1-yl]acetic acid</ne>, 0.05 g.
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.450" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.56" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 2.00 (s, 3H), 4.65 (s, 2H), 6.60 (d, J = 2.0 Hz, 1 H), 6.90 (dd, J = 2.0, 8.8 Hz, 1 H), 7.30 (d, J = 8.8 Hz, 1 H), 7.75-7.85 (m, 4H), 9.65 (s, 1 H).
MS: ESI (+ve) (Method A): 447 (M+H)&lt;+&gt;, Retention time 10.6 min. Example 4: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.227" epochem-id="EPOCHEM:NEW:COMPOUND:1167" name="[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- methylindol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:315419" relevant="true">[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- methylindol-1-yl]acetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H, R&lt;2&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.48" epochem-id="EPOCHEM:NEW:FORMULA:21" name="Cl" comment="" chebi-id="CHEBI:23116" relevant="false">Cl</ne>, R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.36" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.59" epochem-id="EPOCHEM:NEW:FORMULA:165" name="4- CH3SO2Ph" comment="4-CH3SO2Ph" chebi-id="WO2007045867:890595" relevant="false">4- CH3SO2Ph</ne>)
</P>
<P>[0103]
EMI20.1
Preparation 4a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.223" epochem-id="EPOCHEM:NEW:COMPOUND:1164" name="[5-chloro-3-(4-methanesulfonylbenzenesulfonyIamino)-2- methylindol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:10828" relevant="true">[5-chloro-3-(4-methanesulfonylbenzenesulfonyIamino)-2- methylindol-1-yl]acetic acid methyl ester</ne> To a mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.209" epochem-id="EPOCHEM:NEW:COMPOUND:1159" name="3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:362738" relevant="false">3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.15 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.12" epochem-id="EPOCHEM:COMPOUND:4239" name="triethylamine" comment="" chebi-id="CHEBI:35026" relevant="false">triethylamine</ne> (0.21 mL) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.21" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) at -55&lt;0&gt;C was added <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.224" epochem-id="EPOCHEM:NEW:COMPOUND:1165" name="4-methanesulfonylbenzenesulfonyl chloride" comment="" chebi-id="WO2007045867:821801" relevant="false">4-methanesulfonylbenzenesulfonyl chloride</ne> (0.13 g) and the resulting mixture was stirred at -50&lt;0&gt;C for thirty minutes. The reaction mixture was filtered and the filtrate concentrated under reduced pressure. Purification of the residue by column chromatography on <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.363" epochem-id="EPOCHEM:NEW:COMPOUND:1434" name="silica" comment="" chebi-id="CHEBI:30563" relevant="false">silica</ne> gel gave <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.225" epochem-id="EPOCHEM:NEW:COMPOUND:1166" name="5-chloro-3- (4-methanesulfonylbenzenesulfonylamino)-2-methylindol-1 -yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:261689" relevant="false">5-chloro-3- (4-methanesulfonylbenzenesulfonylamino)-2-methylindol-1 -yl]acetic acid methyl ester</ne>, 0.13 g.
MS: ESI (+ve) (Method B): 469 (M-H)&lt;"&gt;, Retention time 3.1 min. Preparation 4b <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.228" epochem-id="EPOCHEM:NEW:COMPOUND:1167" name="[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- methylindol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:315419" relevant="true">[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- methylindol-1-yl]acetic acid</ne>
A solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.229" epochem-id="EPOCHEM:NEW:COMPOUND:1167" name="[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- methylindol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:315419" relevant="true">[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- methylindol-1-yl]acetic acid</ne> methyl ester (0.13 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.22" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (5.0 ml_) and 4.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.46" epochem-id="EPOCHEM:COMPOUND:7174" name="sodium hydroxide" comment="" chebi-id="CHEBI:32145" relevant="false">sodium hydroxide</ne> solution (2.0 ml_) was stirred at room temperature for one hour. The <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.23" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> was removed under reduced pressure and pH of the residue adjusted to -3-4 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.178" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.230" epochem-id="EPOCHEM:NEW:COMPOUND:1167" name="[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- methylindol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:315419" relevant="true">[5-chloro-3-(4- methanesulfonylbenzenesulfonylamino)-2-methylindol-1-yl]acetic acid</ne>, 0.20 g.
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.451" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.57" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 1.90 (s, 3H), 3.25 (s, 3H), 4.95 (s, 2H), 6.80 (d, J = 2.2 Hz, 1 H), 7.00 (dd, J = 2.2, 8.8 Hz, 1 H), 7.40 (d, J = 8.8 Hz, 1 H), 7.8 (m, 2H), 8.05 (m, 2H), 9.95 (s, 1 H), 13.10 (br s, 1 H).
MS: ESI (+V[Theta]) (Method A): 457 (M+H)&lt;+&gt;, Retention time 8.8 min. Example 5: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.276" epochem-id="EPOCHEM:NEW:COMPOUND:1192" name="[5-chloro-3-(4-fluorobenzenesulfonyIamino)-2-methylindol-1- yl]acetic acid" comment="" chebi-id="WO2007045867:785302" relevant="true">[5-chloro-3-(4-fluorobenzenesulfonyIamino)-2-methylindol-1- yl]acetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H, R&lt;2&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.49" epochem-id="EPOCHEM:NEW:FORMULA:21" name="Cl" comment="" chebi-id="CHEBI:23116" relevant="false">Cl</ne>, R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.37" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.58" epochem-id="EPOCHEM:NEW:FORMULA:164" name="4-FPh" comment="" chebi-id="WO2007045867:353739" relevant="false">4-FPh</ne>)
</P>
<P>[0109]
EMI21.1
Preparation 5a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.231" epochem-id="EPOCHEM:NEW:COMPOUND:1168" name="[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:196712" relevant="false">[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester</ne>
To a mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.210" epochem-id="EPOCHEM:NEW:COMPOUND:1159" name="3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:362738" relevant="false">3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.15 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.13" epochem-id="EPOCHEM:COMPOUND:4239" name="triethylamine" comment="" chebi-id="CHEBI:35026" relevant="false">triethylamine</ne> (0.21 ml_) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.24" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 ml_) at -55&lt;0&gt;C was added <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.233" epochem-id="EPOCHEM:NEW:COMPOUND:1169" name="4-fluorobenzenesulfonyl chloride" comment="" chebi-id="WO2007045867:558089" relevant="false">4-fluorobenzenesulfonyl chloride</ne> (0.10 g) and the resulting mixture was stirred at -50&lt;0&gt;C for thirty minutes. The reaction mixture was filtered and the filtrate concentrated under reduced pressure. Purification of the residue by column chromatography on <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.364" epochem-id="EPOCHEM:NEW:COMPOUND:1434" name="silica" comment="" chebi-id="CHEBI:30563" relevant="false">silica</ne> gel gave <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.471" epochem-id="EPOCHEM:NEW:COMPOUND:2091" name="[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:730988" relevant="false">[5-chloro-3-
(4-fluorobenzenesulfonylamino)-2-methylindol-1-yl]acetic acid methyl ester</ne>, 0.1O g.
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.452" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (CD3OD): [delta] 2.10 (s, 3H), 3.75 (s, 3H), 4.95 (s, 2H), 6.80 (d, J = 1.9
Hz, 1 H), 7.00 (dd, J = 1.9, 8.7 Hz, 1H), 7.10-7.20 (m, 3H), 7.65 (m, 2H). MS: ESI (+ve) (Method B): 409 (M-H)&lt;"&gt;, Retention time 3.4 min.
Preparation 5b: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.236" epochem-id="EPOCHEM:NEW:COMPOUND:1171" name="[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid" comment="" chebi-id="WO2007045867:635725" relevant="false">[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid</ne>
A solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.232" epochem-id="EPOCHEM:NEW:COMPOUND:1168" name="[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:196712" relevant="true">[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester</ne> (0.09 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.25" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (5.0 ml_) and 4.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.47" epochem-id="EPOCHEM:COMPOUND:7174" name="sodium hydroxide" comment="" chebi-id="CHEBI:32145" relevant="false">sodium hydroxide</ne> solution (2.0 ml_) was stirred at room temperature for one hour.
The <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.26" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> was removed under reduced pressure and pH of the residue adjusted to -3-4 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.179" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.238" epochem-id="EPOCHEM:NEW:COMPOUND:1171" name="[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid" comment="" chebi-id="WO2007045867:635725" relevant="false">[5-chloro-3-(4- fluorobenzenesulfonylamino)-2-methylindol-1-yl]acetic acid</ne>, 0.07 g. <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.453" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.58" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 1.95 (s, 3H), 4.95 (s, 2H), 6.80 (d, J = 2.1 Hz, 1 H),
</P>
<P>7.00 (dd, J = 2.1 , 8.6 Hz1 1 H), 7.30 (m, 2H), 7.35 (d, J = 8.6 Hz, 1 H), 9.45 (s, 1 H),
</P>
<P>13.05 (br s, 1 H).
MS: ESI (+ve) (Method A): 397 (M+H)&lt;+&gt;, Retention time 9.7 min.
Example 6: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.239" epochem-id="EPOCHEM:NEW:COMPOUND:1172" name="[S^BiphenyM-sulfonylaminoJ-S-chloro^-methylindol-i-ylfocetic acid" comment="[3-(Biphenyl-4-sulfonylamino)-5-chloro-2-methylindol-1-yl]acetic acid" chebi-id="WO2007045867:768238" relevant="false">[S^BiphenyM-sulfonylaminoJ-S-chloro^-methylindol-i-ylfocetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H5 R&lt;2&gt; = Cl5 R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.38" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1012" epochem-id="EPOCHEM:NEW:LIGAND:537" name="4-Biphenyl" comment="" chebi-id="WO2007045867:319935" relevant="false">4-Biphenyl</ne>)
</P>
<P>[0122]
EMI22.1
Preparation 6a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.240" epochem-id="EPOCHEM:NEW:COMPOUND:1173" name="[3-(Biphenyl-4-sulf onylamino)-5-chloro-2-methylindol-1 -yl]acetic acid methyl ester" comment="[3-(Biphenyl-4-sulfonylamino)-5-chloro-2-methylindol-1 -yl]acetic acid methyl ester" chebi-id="WO2007045867:499455" relevant="true">[3-(Biphenyl-4-sulf onylamino)-5-chloro-2-methylindol-1 -yl]acetic acid methyl ester</ne>
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.241" epochem-id="EPOCHEM:NEW:COMPOUND:1174" name="Biphenyl-4-sulfonyl chloride" comment="" chebi-id="WO2007045867:110334" relevant="false">Biphenyl-4-sulfonyl chloride</ne> (0.12 g) was added to a stirred solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.242" epochem-id="EPOCHEM:NEW:COMPOUND:1175" name="(3- amino-5-chloro~2-methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="(3- amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride" chebi-id="WO2007045867:579594" relevant="false">(3- amino-5-chloro~2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.10 g) in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.97" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> (5.0 ml_) at room temperature. After thirty minutes the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.98" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> was removed under reduced pressure and the residue washed with 1.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.180" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne> to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.243" epochem-id="EPOCHEM:NEW:COMPOUND:1176" name="[3-(biphenyl-4-sulfonylamino)-5- chloro-2-methylindol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:624501" relevant="false">[3-(biphenyl-4-sulfonylamino)-5- chloro-2-methylindol-1-yl]acetic acid methyl ester</ne>, 0.17 g.
MS: ESI (+ve) (Method B): 467 (M-H)&lt;"&gt;, Retention time 3.8 min. Preparation 6b <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.246" epochem-id="EPOCHEM:NEW:COMPOUND:1177" name="[3-(biphenyl-4-sulfonylamino)-5-chloro-2-methylindol-1 -yl]acetic acid" comment="" chebi-id="WO2007045867:606290" relevant="true">[3-(biphenyl-4-sulfonylamino)-5-chloro-2-methylindol-1 -yl]acetic acid</ne>
A mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.244" epochem-id="EPOCHEM:NEW:COMPOUND:1176" name="[3-(biphenyl-4-sulfonylamino)-5- chloro-2-methylindol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:624501" relevant="false">[3-(biphenyl-4-sulfonylamino)-5-chloro-2-methylindol-1-yl]acetic acid methyl ester</ne> (0.17 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.81" epochem-id="EPOCHEM:NEW:COMPOUND:1129" name="potassium trimethylsilanoate" comment="" chebi-id="WO2007045867:427365" relevant="false">potassium trimethylsilanoate</ne> (0.14 g) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.27" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) was heated by microwave irradiation at 100&lt;0&gt;C for five minutes. The solvent was removed under reduced pressure and the pH of the residue adjusted to 1 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.181" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration, washed with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.134" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.248" epochem-id="EPOCHEM:NEW:COMPOUND:1177" name="[3-(biphenyl-4-sulfonylamino)-5-chloro-2-methylindol-1 -yl]acetic acid" comment="" chebi-id="WO2007045867:606290" relevant="true">[3-(biphenyl-4-sulfonylamino)-5- chloro-2-methylindol-1-yl]acetic acid</ne>, 0.070 g. <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.454" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.59" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 1.95 (s, 3H), 4.95 (s, 2H), 6.80 (d, J = 2.2 Hz, 1 H),
</P>
<P>6.95 (dd, J = 2.2, 8.8 Hz, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.40-7.50 (m, 3H), 7.60-7.70 (m, 4H), 7.75 (m, 2H), 9.45 (s, 1 H), 13.05 (br s, 1H).
MS: ESI (+ve) (Method A): 455 (M+H)&lt;+&gt;, Retention time 11.0 min. Example 7: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.253" epochem-id="EPOCHEM:NEW:COMPOUND:1180" name="[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1 - yl]acetic acid" comment="" chebi-id="WO2007045867:64822" relevant="true">[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1-yl]acetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H, R&lt;2&gt; = Cl5 R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.39" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="LIGAND" id="WO2007045867.HC.ligand-names.497" epochem-id="EPOCHEM:NEW:LIGAND:286" name="2-naphthyl" comment="" chebi-id="WO2007045867:92913" relevant="false">2-naphthyl</ne>)
</P>
<P>[0129]
EMI23.1
Preparation 7a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.249" epochem-id="EPOCHEM:NEW:COMPOUND:1178" name="[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1 - yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:721046" relevant="true">[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1 - yl]acetic acid methyl ester</ne>
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.252" epochem-id="EPOCHEM:NEW:COMPOUND:1179" name="Naphthalene-2-sulfonyl chloride" comment="" chebi-id="WO2007045867:290268" relevant="false">Naphthalene-2-sulfonyl chloride</ne> (0.11 g) was added to a stirred solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.149" epochem-id="EPOCHEM:NEW:COMPOUND:1142" name="(3-amino-5-chloro-2- methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:454933" relevant="false">(3- amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.10 g) in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.99" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> (5.0 mL) at room temperature. After thirty minutes the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.100" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> was removed under reduced pressure and the residue washed with 1.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.182" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne> to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.250" epochem-id="EPOCHEM:NEW:COMPOUND:1178" name="[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1 - yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:721046" relevant="true">[5-chloro-2-methyl-3-(naphthalene-2- sulfonylamino)indol-1-yl]acetic acid methyl ester</ne>, 0.18 g.
MS: ESI (+ve) (Method B): 441 (M-H)-, Retention time 3.6 min.
Preparation 7b <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.256" epochem-id="EPOCHEM:NEW:COMPOUND:1180" name="[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1 - yl]acetic acid" comment="" chebi-id="WO2007045867:64822" relevant="true">[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1 - yl]acetic acid</ne> A mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.251" epochem-id="EPOCHEM:NEW:COMPOUND:1178" name="[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1 - yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:721046" relevant="false">[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1- yl]acetic acid methyl ester</ne> (0.18 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.82" epochem-id="EPOCHEM:NEW:COMPOUND:1129" name="potassium trimethylsilanoate" comment="" chebi-id="WO2007045867:427365" relevant="false">potassium trimethylsilanoate</ne> (0.16 g) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.28" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) was heated by microwave irradiation at 100&lt;0&gt;C for five minutes. The solvent was removed under reduced pressure and the pH of the residue adjusted to 1 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.183" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration, washed with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.135" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.258" epochem-id="EPOCHEM:NEW:COMPOUND:1180" name="[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino)indol-1 - yl]acetic acid" comment="" chebi-id="WO2007045867:64822" relevant="true">[5-chloro- 2-methyl-3-(naphthalene-2-sulfonylamino)indol-1-yl]acetic acid</ne>, 0.080 g. <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.455" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.60" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d[theta]): [delta] 1.90 (s, 3H), 4.90 (s, 2H), 6.80 (d, J = 2.1 Hz, 1 H),
</P>
<P>6.90 (dd. J = 2.1 , 8.7 Hz, 1 H), 7.35 (d, J = 8.7 Hz, 1 H), 7.60 (m, 1 H), 7.65 (m, 1 H), 7.75 (dd, J = 1.9, 8.7 Hz, 1H)1 8.00 (m, 2H), 8.05 (d, J = 8.7 Hz, 1H), 8.20 (d, J = 1.5 Hz, 1 H), 9.50 (s, 1 H), 13.05 (br s, 1 H).
MS: ESI (+ve) (Method A): 429 (M+H)&lt;+&gt;, Retention time 10.5 min. Example 8: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.259" epochem-id="EPOCHEM:NEW:COMPOUND:1181" name="[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid" comment="" chebi-id="WO2007045867:756586" relevant="true">[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H, R&lt;2&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.50" epochem-id="EPOCHEM:NEW:FORMULA:21" name="Cl" comment="" chebi-id="CHEBI:23116" relevant="false">Cl</ne>, R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.40" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.53" epochem-id="EPOCHEM:NEW:FORMULA:159" name="2,3-CI2Ph" comment="2,3-Cl2Ph" chebi-id="WO2007045867:554408" relevant="false">2,3-CI2Ph</ne>)
</P>
<P>[0135]
EMI24.1
Preparation 8a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.264" epochem-id="EPOCHEM:NEW:COMPOUND:1182" name="[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:58208" relevant="true">[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol- 1-yl]acetic acid methyl ester</ne>
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.265" epochem-id="EPOCHEM:NEW:COMPOUND:1183" name="2,3-Dichlorobenzenesulfonyl chloride" comment="" chebi-id="WO2007045867:401971" relevant="false">2,3-Dichlorobenzenesulfonyl chloride</ne> (0.12 g) was added to a stirred solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.150" epochem-id="EPOCHEM:NEW:COMPOUND:1142" name="(3-amino-5-chloro-2- methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:454933" relevant="false">(3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.10 g) in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.101" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> (5.0 mL) at room temperature. After thirty minutes the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.102" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> was removed under reduced pressure and the residue washed with 1.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.184" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne> to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.266" epochem-id="EPOCHEM:NEW:COMPOUND:1184" name="[5-chloro-3-(2,3-dichloro- benzenesulfonylamino)-2-methylindol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:601537" relevant="false">[5-chloro-3-(2,3-dichloro- benzenesulfonylamino)-2-methylindol-1-yl]acetic acid methyl ester</ne>, 0.18 g.
MS: ESI (+ve) (Method B): 459 (M-H)&lt;"&gt;, Retention time 3.7 min. Preparation 8b <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.261" epochem-id="EPOCHEM:NEW:COMPOUND:1181" name="[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid" comment="" chebi-id="WO2007045867:756586" relevant="true">[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol- 1-yl]acetic acid</ne> A mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.267" epochem-id="EPOCHEM:NEW:COMPOUND:1182" name="[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:58208" relevant="true">[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester</ne> (0.18 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.83" epochem-id="EPOCHEM:NEW:COMPOUND:1129" name="potassium trimethylsilanoate" comment="" chebi-id="WO2007045867:427365" relevant="false">potassium trimethylsilanoate</ne> (0.15 g) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.29" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) was heated by microwave irradiation at 100&lt;0&gt;C for five minutes. The solvent was removed under reduced pressure and the pH of the residue adjusted to 1 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.185" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration, washed with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.136" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.263" epochem-id="EPOCHEM:NEW:COMPOUND:1181" name="[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid" comment="" chebi-id="WO2007045867:756586" relevant="true">[5-chloro- 3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1-yl]acetic acid</ne>, 0.096 g. <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.456" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.61" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 2.05 (s, 3H)1 4.95 (s, 2H), 6.90 (d, J = 2.1 Hz, 1H), 7.00 (dd, J = 2.1, 8.7 Hz, 1H), 7.35 (m, 2H), 7.65 (dd, J = 1.5, 7.9 Hz, 1 H), 7.90 (dd, J = 1.5, 7.9 Hz, 1H), 9.90 (s, 1H), 13.05 (br s, 1H).
MS: ESI (+ve) (Method A): 447 (M+H)&lt;+&gt;, Retention time 10.6 min. Example 9: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.268" epochem-id="EPOCHEM:NEW:COMPOUND:1186" name="[5-Chloro-2-methyl-3-(naphthalene-1 -sulf onylamino)indol-1 - yl]acetic acid" comment="[5-Chloro-2-methyl-3-(naphthalene-1 -sulfonylamino)indol-1 - yl]acetic acid" chebi-id="WO2007045867:916542" relevant="true">[5-Chloro-2-methyl-3-(naphthalene-1 -sulf onylamino)indol-1 - yl]acetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H5 R&lt;2&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.51" epochem-id="EPOCHEM:NEW:FORMULA:21" name="Cl" comment="" chebi-id="CHEBI:23116" relevant="false">Cl</ne>, R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.41" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="LIGAND" id="WO2007045867.HC.ligand-names.500" epochem-id="EPOCHEM:NEW:LIGAND:287" name="1 -naphthyl" comment="" chebi-id="WO2007045867:273857" relevant="false">1-naphthyl</ne>)
</P>
<P>[0140]
EMI25.1
Preparation 9a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.76" epochem-id="EPOCHEM:NEW:COMPOUND:1128" name="[5-chloro-2-methyl-3-(naphthalene-1-sulfonylamino)indol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:104431" relevant="true">[5-chloro-2-methyl-3-(naphthalene-1-sulfonylamino)indol-1- yl]acetic acid methyl ester</ne>
Naphthalene- 1 -sulf onyl chloride (0.11 g) was added to a stirred solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.151" epochem-id="EPOCHEM:NEW:COMPOUND:1142" name="(3-amino-5-chloro-2- methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:454933" relevant="false">(3- amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.10 g) in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.103" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> (5.0 ml_) at room temperature. After thirty minutes the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.104" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> was removed under reduced pressure and the residue washed with 1.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.186" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne> to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.77" epochem-id="EPOCHEM:NEW:COMPOUND:1128" name="[5-chloro-2-methyl-3-(naphthalene-1-sulfonylamino)indol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:104431" relevant="false">[5-chloro-2-methyl-3-(naphthalene-1- sulfonylamino)indol-1-yl]acetic acid methyl ester</ne>, 0.15 g.
MS: ESI (+ve) (Method B): 441 (M-H)&lt;"&gt;, Retention time 3.6 min. Preparation 9b <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.88" epochem-id="EPOCHEM:NEW:COMPOUND:1130" name="[5-chloro- 2-methyl-3-(naphthalene-1-sulfonylamino)indol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:404089" relevant="false">[5-chloro-2-methyl-3-(naphthalene-1 -sulfonylamino)indol-1- yl]acetic acid</ne>
A mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.78" epochem-id="EPOCHEM:NEW:COMPOUND:1128" name="[5-chloro-2-methyl-3-(naphthalene-1-sulfonylamino)indol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:104431" relevant="false">[5-chloro-2-methyl-3-(naphthalene-1-sulfonylamino)indol-1- yl]acetic acid methyl ester</ne> (0.15 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.84" epochem-id="EPOCHEM:NEW:COMPOUND:1129" name="potassium trimethylsilanoate" comment="" chebi-id="WO2007045867:427365" relevant="false">potassium trimethylsilanoate</ne> (0.13 g) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.30" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) was heated by microwave irradiation at 100&lt;0&gt;C for five minutes. The solvent was removed under reduced pressure and the pH of the residue adjusted to 1 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.187" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration, washed with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.137" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.90" epochem-id="EPOCHEM:NEW:COMPOUND:1130" name="[5-chloro- 2-methyl-3-(naphthalene-1-sulfonylamino)indol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:404089" relevant="false">[5-chloro- 2-methyl-3-(naphthalene-1-sulfonylamino)indol-1-yl]acetic acid</ne>, 0.083 g.
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.457" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.62" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 1.80 (s, 3H), 4.85 (s, 2H), 6.40 (d, J = 2.0 Hz, 1H), 6.90 (dd, J = 2.0, 8.6 Hz, 1 H), 7.30 (d, J = 8.6 Hz, 1 H), 7.45 (dd, J = 7.4, 8.1 Hz, 1H), 7.65-7.75 (m, 2H), 7.85 (dd, J = 1.2, 7.4 Hz, 1H), 8.10 (dd, J = 2.0, 7.9 Hz, 1H), 8.15 (d, J = 8.1 Hz, 1H), 8.80 (dd, J = 1.2, 8.1 Hz, 1 H), 9.65 (s, 1 H), 13.00 (br s, 1H). MS: ESl (+ve) (Method A): 429 (M+H)&lt;+&gt;, Retention time 10.4 min. Example 10: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.272" epochem-id="EPOCHEM:NEW:COMPOUND:1190" name="[S-Chloro^-methyl-S-tquinoline-[delta]-sulfonylaminoJindoH-y[pi]acetic acid" comment="[5-Chloro-2-methyl-3-(quinoline-8-sulfonylamino)indol-1-y l]acetic acid" chebi-id="WO2007045867:864117" relevant="true">[S-Chloro^-methyl-S-tquinoline-[delta]-sulfonylaminoJindoH-y[pi]acetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H, R&lt;2&gt; =. Ci, R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.42" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="LIGAND" id="WO2007045867.HC.ligand-names.507" epochem-id="EPOCHEM:NEW:LIGAND:289" name="8-quinolinyl" comment="" chebi-id="WO2007045867:2417" relevant="false">8-quinolinyl</ne>)
</P>
<P>[0146]
EMI26.1
Preparation 10a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.91" epochem-id="EPOCHEM:NEW:COMPOUND:1131" name="[5-chloro-2-methyl-3-(quinoline-8-sulfonylamino)indol-1- yljacetic acid methyl ester" comment="" chebi-id="WO2007045867:514330" relevant="true">[5-chloro-2-methyl-3-(quinoline-8-sulfonylamino)indol-1- yljacetic acid methyl ester</ne>
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.92" epochem-id="EPOCHEM:NEW:COMPOUND:1132" name="Quinoline-8-sulfonyl chloride" comment="" chebi-id="WO2007045867:492379" relevant="false">Quinoline-8-sulfonyl chloride</ne> (0.11 g) was added to a stirred solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.93" epochem-id="EPOCHEM:NEW:COMPOUND:1133" name="(3- amino-5-chloro-2-methy\indo\-&lt;'&gt;i-[gamma]i)acet\c acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:56624" relevant="false">(3- amino-5-chloro-2-methy\indo\-&lt;'&gt;i-[gamma]i)acet\c acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.10 g) in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.105" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> (5.0 mL) at room temperature. After thirty minutes the <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.106" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> was removed under reduced pressure and the residue washed with 1.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.188" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne> to <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.107" epochem-id="EPOCHEM:NEW:COMPOUND:1134" name="afford [5-chloro-2-methyl-3-(quinoline-8- sulfonylamino)indol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:390093" relevant="false">afford [5-chloro-2-methyl-3-(quinoline-8- sulfonylamino)indol-1-yl]acetic acid methyl ester</ne>, 0.09 g. MS: ESI (+ve) (Method B): 442 (M-H)&lt;"&gt;, Retention time 3.4 min.
Preparation 10b <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.270" epochem-id="EPOCHEM:NEW:COMPOUND:1188" name="(5-cWoro-2-rnethyl-3-(quinoline-8-sulf onylamino)indol-1 - yl]acetic acid" comment="(5-chloro-2-methyl-3-(quinoline-8-sulfonylamino)indol-1 -yl]acetic acid" chebi-id="WO2007045867:669554" relevant="false">(5-cWoro-2-rnethyl-3-(quinoline-8-sulf onylamino)indol-1 - yl]acetic acid</ne>
A mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.269" epochem-id="EPOCHEM:NEW:COMPOUND:1187" name="[5-chloro-2-methyl-3-(quinoline-8-sulfonylamino)indol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:709138" relevant="false">[5-chloro-2-methyl-3-(quinoline-8-sulfonylamino)indol-1-yl]acetic acid methyl ester</ne> (0.09 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.85" epochem-id="EPOCHEM:NEW:COMPOUND:1129" name="potassium trimethylsilanoate" comment="" chebi-id="WO2007045867:427365" relevant="false">potassium trimethylsilanoate</ne> (0.08 g) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.31" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) was heated by microwave irradiation at 100&lt;0&gt;C for five minutes. The solvent was removed under reduced pressure and the pH of the residue adjusted to 1 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.189" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration, washed with <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.138" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> and purified by preparative reverse-phase HPLC using a gradient over 30 minutes of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.126" epochem-id="EPOCHEM:NEW:COMPOUND:776" name="acetonitrile" comment="" chebi-id="CHEBI:38472" relevant="false">acetonitrile</ne> in <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.139" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (40 to 90 % of organic modifier) to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.110" epochem-id="EPOCHEM:NEW:COMPOUND:1135" name="[5-chloro-2-methyl-3-(quinoline-8-sulfonylamino)indol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:702854" relevant="false">[5-chloro-2-methyl-3-(quinoline-8-sulfonylamino)indol-1-yl]acetic acid</ne>, 0.020 g.
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.458" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.63" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): S 1.95 (s, 3H), 4.85 (s, 2H), 6.20 (d, J = 2.1 Hz, 1H),
</P>
<P>6.85 (dd, J = 2.1 , 8.7 Hz, 1H), 7.25 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 7.4, 8.2 Hz, 1H)
</P>
<P>7.80 (dd, J = 4.2, 8.2 Hz, 1H), 8.05 (dd, J = 1.4, 7.4 Hz, 1 H), 8.25 (dd, J = 1.4, 8.3
Hz, 1H), 8.60 (dd, J = 1.8, 8.3 Hz, 1H)1 9.25 (dd, J = 1.8, 4.2 Hz, 1H), 9.30 (s, 1H), 13.0 br s, 1 H).
MS: ESI (+VB) (Method A): 430 (M+H)&lt;+&gt;, Retention time 9.5 min. Example 11 : <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.319" epochem-id="EPOCHEM:NEW:COMPOUND:1410" name="[delta]-Chloro-S-[beta]jS-dichloro-benzenesulfonylamino^-methyl-indol-i- yl]-acetic acid" comment="" chebi-id="WO2007045867:840219" relevant="false">[delta]-Chloro-S-[beta]jS-dichloro-benzenesulfonylamino^-methyl-indol-i- yl]-acetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H, R&lt;2&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.52" epochem-id="EPOCHEM:NEW:FORMULA:21" name="Cl" comment="" chebi-id="CHEBI:23116" relevant="false">Cl</ne>, R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.43" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.54" epochem-id="EPOCHEM:NEW:FORMULA:160" name="3,5-CI2Ph" comment="3,5-Cl2Ph" chebi-id="WO2007045867:603807" relevant="false">3,5-CI2Ph</ne>).
</P>
<P>[0156]
EMI27.1
Preparation 11a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.277" epochem-id="EPOCHEM:NEW:COMPOUND:1193" name="[5-Chloro-3-(3,5-dichloro-benzenesulfonylamino)-2-methyl- indol-1-yl]-acetic acid methyl ester" comment="" chebi-id="WO2007045867:490409" relevant="true">[5-Chloro-3-(3,5-dichloro-benzenesulfonylamino)-2-methyl- indol-1-yl]-acetic acid methyl ester</ne>.
To a mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.214" epochem-id="EPOCHEM:NEW:COMPOUND:1159" name="3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:362738" relevant="false">3-amino-5-chloro-2-methylindol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.15 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.14" epochem-id="EPOCHEM:COMPOUND:4239" name="triethylamine" comment="" chebi-id="CHEBI:35026" relevant="false">triethylamine</ne> (0.20 mL) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.32" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) at -55&lt;0&gt;C was added <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.317" epochem-id="EPOCHEM:NEW:COMPOUND:1408" name="3,5-dichloro-benzenesulfonyl chloride" comment="" chebi-id="WO2007045867:165806" relevant="false">3,5-dichloro-benzenesulfonyl chloride</ne>
(0.13 g) and the resulting mixture was stirred at -5O&lt;0&gt;C for thirty minutes. The reaction mixture was filtered and the filtrate concentrated under reduced pressure.
Purification of the residue by column chromatography on <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.365" epochem-id="EPOCHEM:NEW:COMPOUND:1434" name="silica" comment="" chebi-id="CHEBI:30563" relevant="false">silica</ne> gel gave <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.318" epochem-id="EPOCHEM:NEW:COMPOUND:1409" name="[5-chloro-3- S.[delta]-dichloro-benzenesulfonylamino^-methylindol-i-yOacetic acid methyl ester" comment="" chebi-id="WO2007045867:942154" relevant="false">[5-chloro-3-
(S.[delta]-dichloro-benzenesulfonylamino^-methylindol-i-yOacetic acid methyl ester</ne>, 0.08 g.
MS: ESI (+ve) (Method B): 459 (M-H)&lt;'&gt;, Retention time 3.8 min. Preparation 11b: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.73" epochem-id="EPOCHEM:NEW:COMPOUND:1126" name="[5-chloro-3-(3,5-dichlorobenzenesulfonylamino)-2- methylindol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:986509" relevant="true">[5-chloro-3-(3,5-dichlorobenzenesulfonylamino)-2- methylindol-1-yl]acetic acid</ne>.
A solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.72" epochem-id="EPOCHEM:NEW:COMPOUND:1125" name="[5-chloro-3-(3,5-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:739792" relevant="false">[5-chloro-3-(3,5-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester</ne> (0.08 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.33" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) and 4.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.48" epochem-id="EPOCHEM:COMPOUND:7174" name="sodium hydroxide" comment="" chebi-id="CHEBI:32145" relevant="false">sodium hydroxide</ne> solution (2.0 mL) was stirred at room temperature for one hour.
The <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.34" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> was removed under reduced pressure and pH of the residue adjusted to -3-4 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.190" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.315" epochem-id="EPOCHEM:NEW:COMPOUND:1407" name="[5-chloro-3-(3,4- dichlorobenzenesulfonylamino)-2-methylindol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:335012" relevant="false">[5-chloro-3-(3,4- dichlorobenzenesulfonylamino)-2-methylindol-1-yl]acetic acid</ne>, 0.06 g.
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.459" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.64" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 2.07 (s, 3H), 4.96 (s, 2H)1 6.75 (d, J = 2.1 Hz, 1 H), 7.01 (dd, J = 2.1 , 8.7 Hz, 1H), 7.40 (d, J = 8.7 Hz, 1 H), 7.54 (d, J = 1.9 Hz, 1 H), 7.94 (t, J = 1.9 Hz, 1 H), 9.73 (s, 1H), 13.10 (v.br s, 1 H).
. MS: ESI (+ve) (Method A): 448 (M+H)\ Retention time 11.12 min. Example 12: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.278" epochem-id="EPOCHEM:NEW:COMPOUND:1194" name="S-Chloro-S-[beta]^-dichloro-benzenesulfonylamino^-methyl-indol-i- yl]-acetic acid" comment="5-Chloro-3-(3,4-dichloro-benzenesulfonylamino)-2-methylindol-1- yl]-acetic acid" chebi-id="WO2007045867:164500" relevant="true">S-Chloro-S-[beta]^-dichloro-benzenesulfonylamino^-methyl-indol-i- yl]-acetic acid</ne> (R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt;, R&lt;9&gt; = H5 R&lt;2&gt; = Cl5 R&lt;7&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.44" epochem-id="EPOCHEM:NEW:FORMULA:29" name="CH3" comment="" chebi-id="WO2007045867:745797" relevant="false">CH3</ne>, R&lt;8&gt; = <ne type="FORMULA" id="WO2007045867.HC.formula-names.60" epochem-id="EPOCHEM:NEW:FORMULA:166" name="3,4-CI2Ph" comment="3,4-Cl2Ph" chebi-id="WO2007045867:263664" relevant="false">3,4-CI2Ph</ne>).
</P>
<P>[0167]
EMI28.1
Preparation 12a <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.69" epochem-id="EPOCHEM:NEW:COMPOUND:1123" name="[5-Chloro&quot;3-(3,4-dichloro-benzenesulfonylamino)-2-methyl- indol-1-yl]-acetic acid methyl ester" comment="" chebi-id="WO2007045867:486339" relevant="false">[5-Chloro"3-(3,4-dichloro-benzenesulfonylamino)-2-methyl- indol-1-yl]-acetic acid methyl ester</ne>.
To a mixture of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.71" epochem-id="EPOCHEM:NEW:COMPOUND:1124" name="3-amino-5-chloro-2-methylinclol-1-yl)acetic acid methyl ester hydrochloride" comment="" chebi-id="WO2007045867:900147" relevant="false">3-amino-5-chloro-2-methylinclol-1-yl)acetic acid methyl ester hydrochloride</ne> (compound of Preparation 1c, 0.15 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.15" epochem-id="EPOCHEM:COMPOUND:4239" name="triethylamine" comment="" chebi-id="CHEBI:35026" relevant="false">triethylamine</ne> (0.20 mL) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.35" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) at -55&lt;0&gt;C was added <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.38" epochem-id="EPOCHEM:NEW:COMPOUND:1115" name="3,4-dichlorobenzenesulfonyl chloride" comment="" chebi-id="WO2007045867:156683" relevant="false">3,4-dichlorobenzenesulfonyl chloride</ne>
(0.13 g) and the resulting mixture was stirred at -5O&lt;0&gt;C for thirty minutes. The reaction mixture was filtered and the filtrate concentrated under reduced pressure.
Purification of the residue by column chromatography on <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.366" epochem-id="EPOCHEM:NEW:COMPOUND:1434" name="silica" comment="" chebi-id="CHEBI:30563" relevant="false">silica</ne> gel gave <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.43" epochem-id="EPOCHEM:NEW:COMPOUND:1120" name="[5-chloro-3- (3,4-dichloro-benzenesulfonylamino)-2-methylindol-1-yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:429091" relevant="true">[5-chloro-3-
(3,4-dichloro-benzenesulfonylamino)-2-methylindol-1-yl]acetic acid methyl ester</ne>, 0.08 g.
MS: ESI (+ve) (Method B): 459 (M-H)&lt;"&gt;, Retention time 3.8 min. Preparation 12b: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.42" epochem-id="EPOCHEM:NEW:COMPOUND:1119" name="[5-chloro-3-(3,4-dichlorobenzenesulf onylamino)-2- methylindol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:973071" relevant="false">[5-chloro-3-(3,4-dichlorobenzenesulf onylamino)-2- methylindol-1-yl]acetic acid</ne>.
A solution of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.41" epochem-id="EPOCHEM:NEW:COMPOUND:1118" name="[5-chloro-3-(3,4-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester" comment="" chebi-id="WO2007045867:963349" relevant="false">[5-chloro-3-(3,4-dichlorobenzenesulfonylamino)-2-methylindol-1- yl]acetic acid methyl ester</ne> (0.08 g), <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.36" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (2.0 mL) and 4.0 M aqueous <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.49" epochem-id="EPOCHEM:COMPOUND:7174" name="sodium hydroxide" comment="" chebi-id="CHEBI:32145" relevant="false">sodium hydroxide</ne> solution (2.0 mL) was stirred at room temperature for one hour.
The <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.37" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> was removed under reduced pressure and pH of the residue adjusted to -3-4 by the addition of concentrated <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.191" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. The resulting precipitate was collected by filtration and dried to afford <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.50" epochem-id="EPOCHEM:NEW:COMPOUND:1121" name="[5-chloro-3-(3,4-dichloro- benzenesulfonylamino)-2-methylindol-1-yl]acetic acid" comment="" chebi-id="WO2007045867:953679" relevant="true">[5-chloro-3-(3,4-dichloro- benzenesulfonylamino)-2-methylindol-1-yl]acetic acid</ne>, 0.06 g.
<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.460" epochem-id="EPOCHEM:NEW:COMPOUND:2008" name="&lt;1&gt;H" comment="" chebi-id="CHEBI:29236" relevant="false">&lt;1&gt;H</ne> NMR (<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.65" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>-d6): [delta] 2.05 (s, 3H), 4.96 (s, 2H), 6.70 (d, J = 2.1 Hz, 1 H), 7.00 (dd, J = 2.1 , 8.7 Hz, 1 H), 7.39 (d, J = 8.8 Hz, 1 H), 7.51 (dd, J = 2.1 , 8.4 Hz, 1 H), 7.71 (d, J = 2.1 Hz, 1 H), 7.76 (t, J = 8.4 Hz, 1 H), 9.65 (s, 1H), 13.10 (v.br s, 1H).
MS: ESI (+ve) (Method A): 448 (M+H)&lt;+&gt;, Retention time 10.94 min. Biological Methods
Compounds of the invention were tested using the following biological test methods to determine their ability to displace <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.427" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> from the CRTH2 receptor and for their ability to antagonise the functional effects of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.428" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> at the CRTH2 receptor. Radioligand Binding Assay
The receptor binding assay is performed in a final volume of 200 [mu]l_ binding <ne type="ONT" id="WO2007045867.HC.class-names.81" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> [10 mM <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.473" epochem-id="EPOCHEM:NEW:COMPOUND:2092" name="BES" comment="" chebi-id="WO2007045867:117341" relevant="false">BES</ne> (pH 7.4), 1 mM <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.472" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007045867:534406" relevant="false">EDTA</ne>, 10 mM <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.51" epochem-id="EPOCHEM:NEW:COMPOUND:1122" name="manganese chloride" comment="" chebi-id="WO2007045867:987678" relevant="false">manganese chloride</ne>, 0.01 % <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.474" epochem-id="EPOCHEM:NEW:COMPOUND:2093" name="BSA" comment="" chebi-id="WO2007045867:183058" relevant="false">BSA</ne>] and 1 nM [<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.464" epochem-id="EPOCHEM:NEW:COMPOUND:2009" name="&lt;3&gt;H" comment="" chebi-id="CHEBI:29238" relevant="false">&lt;3&gt;H</ne>]-<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.429" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> (Amersham Biosciences UK Ltd). Ligands are added in assay <ne type="ONT" id="WO2007045867.HC.class-names.82" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> containing a constant amount of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.66" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne> (1% by volume). Total binding is determined using 1 % by volume of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.67" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne> in assay <ne type="ONT" id="WO2007045867.HC.class-names.83" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> and non-specific binding is determined using 10 [mu]M of unlabeled <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.430" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> (Sigma). Human embryonic kidney (HEK) cell membranes (3.5 [mu]g) expressing the CRTH2 receptor are incubated with 1.5 mg wheatgerm agglutinin SPA beads and 1 nM [<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.465" epochem-id="EPOCHEM:NEW:COMPOUND:2009" name="&lt;3&gt;H" comment="" chebi-id="CHEBI:29238" relevant="false">&lt;3&gt;H</ne>]-<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.431" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> (Amersham Biosciences UK Ltd) and the mixture incubated for 3 hours at room temperature. Bound [<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.466" epochem-id="EPOCHEM:NEW:COMPOUND:2009" name="&lt;3&gt;H" comment="" chebi-id="CHEBI:29238" relevant="false">&lt;3&gt;H</ne>]-<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.432" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> is detected using a Microbeta TRILUX liquid scintillation counter (Perkin Elmer). Compound IC50 value is determined using a 6-point dose response curve in duplicate with a semi-log compound dilution series. IC50 calculations are performed using Excel and XLfit (Microsoft), and this value is used to determine a Ki value for the test compound using the Cheng-Prusoff equation. Compounds of the invention that have been tested in the binding assay are illustrated below in the following Table.
</P>
<P>[0180]
EMI29.1
Key: "+++" CRTH2 Ki &lt; 10OnM; "++" Ki &lt; 1[mu]M; V Ki &lt; 10[mu]M Functional Assay: <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.435" epochem-id="EPOCHEM:NEW:COMPOUND:2005" name="GTP[gamma]S" comment="" chebi-id="CHEBI:43000" relevant="false">GTP[gamma]S</ne> Assay
The <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.436" epochem-id="EPOCHEM:NEW:COMPOUND:2005" name="GTP[gamma]S" comment="" chebi-id="CHEBI:43000" relevant="false">GTP[gamma]S</ne> Assay is performed in a final volume of 200 ml_ assay <ne type="ONT" id="WO2007045867.HC.class-names.84" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> (2OmM <ne id="WO2007045867.HC.class-names.78" epochem-id="EPOCHEM:NEW:CLASS:907" name="HEPES" comment="" chebi-id="CHEBI:46756" relevant="false" type="CLASS">HEPES</ne> pH 7.4, 1OmM <ne type="FORMULA" id="WO2007045867.HC.formula-names.5" epochem-id="EPOCHEM:NEW:FORMULA:110" name="MgCI2" comment="MgCl2" chebi-id="CHEBI:6636" relevant="false">MgCI2</ne>, 10OmM <ne type="FORMULA" id="WO2007045867.HC.formula-names.24" epochem-id="EPOCHEM:NEW:FORMULA:12" name="NaCI" comment="NaCl" chebi-id="CHEBI:26710" relevant="false">NaCI</ne>, 10[mu]g/ml_ saponin). <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.68" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne> concentrations are kept constant at 1% by volume.
Human embryonic kidney (HEK) cell membranes (3.5 [mu]g) expressing the CRTH2 receptor are incubated with the compounds for 15 min at 3O&lt;0&gt;C prior to addition of <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.433" epochem-id="EPOCHEM:NEW:COMPOUND:2004" name="PGD2" comment="" chebi-id="CHEBI:15555" relevant="false">PGD2</ne> (3OnM final concentration) and <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.477" epochem-id="EPOCHEM:COMPOUND:2751" name="GTP" comment="" chebi-id="WO2007045867:303809" relevant="false">GTP</ne> (10[mu]M final concentration). The assay solutions are then incubated for 30 minutes at 3O&lt;0&gt;C, followed by addition of [<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.439" epochem-id="EPOCHEM:NEW:COMPOUND:2007" name="&lt;35&gt;S" comment="" chebi-id="CHEBI:37983" relevant="false">&lt;35&gt;S</ne>]-<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.437" epochem-id="EPOCHEM:NEW:COMPOUND:2006" name="GTPyS" comment="GTP-gamma-S" chebi-id="CHEBI:43000" relevant="false">GTPyS</ne> (0.1 nM final concentration). The assay plate is than shaken and incubated for 5 minutes at 3O&lt;0&gt;C. Finally, SPA beads (Amersham Biosciences, UK) are added to a final concentration of 1.5mg/well and the plate shaken and incubated for 30 minute at 3O&lt;0&gt;C. The sealed plate is centrifuged at 1000g for 10 mins at 30&lt;0&gt;C and the bound [<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.440" epochem-id="EPOCHEM:NEW:COMPOUND:2007" name="&lt;35&gt;S" comment="" chebi-id="CHEBI:37983" relevant="false">&lt;35&gt;S</ne>]-<ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.438" epochem-id="EPOCHEM:NEW:COMPOUND:2006" name="GTPyS" comment="GTP-gamma-S" chebi-id="CHEBI:43000" relevant="false">GTPyS</ne> is detected on Microbeta scintillation counter (Perkin Elmer). Compound IC50 value is determined using a 6-point dose response curve in duplicate with a semi-log compound dilution series. IC5O calculations are performed using Excel and XLfit (Microsoft), and this value is used to determine a Ki value for the test compound using the Cheng-Prusoff equation. As an illustration, Examples 1 and 9 had a Ki of &lt;1 [mu]M in this assay, and Example 8 was shown to have a Ki &lt; 10OnM in this assay.
</P></DIV>
<DIV><P>
CLAIMS
</P>
<P>1. A compound of general formula [I] or a pharmaceutically acceptable salt, <ne id="WO2007045867.HC.class-names.72" epochem-id="EPOCHEM:NEW:CLASS:451" name="N-oxide" comment="" chebi-id="CHEBI:35580" relevant="false" type="CLASS">N- oxide</ne>, <ne id="WO2007045867.HC.class-names.68" epochem-id="EPOCHEM:NEW:CLASS:450" name="hydrate" comment="" chebi-id="CHEBI:35505" relevant="false" type="CLASS">hydrate</ne>, or solvate thereof:
EMI31.1
</P>
<P>[I] in which:
R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt; and R&lt;4&gt; are independently <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.299" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.92" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.7" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.1008" epochem-id="EPOCHEM:NEW:LIGAND:536" name="halo" comment="" chebi-id="WO2007045867:554182" relevant="false">halo</ne>, -S(O)<ne type="FORMULA" id="WO2007045867.HC.formula-names.78" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="WO2007045867:595830" relevant="false">nR</ne>&lt;10&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.79" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;11&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.14" epochem-id="EPOCHEM:NEW:FORMULA:153" name="SO2R" comment="" chebi-id="CHEBI:29825" relevant="false">SO2R</ne>&lt;10&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.22" epochem-id="EPOCHEM:NEW:FORMULA:155" name="SO2N" comment="" chebi-id="WO2007045867:676309" relevant="false">SO2N</ne>(R&lt;11&gt;)2, -N(R&lt;11&gt;)2, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.80" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;11&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.99" epochem-id="EPOCHEM:NEW:FORMULA:267" name="C(O)R" comment="" chebi-id="WO2007045867:714016" relevant="false">C(O)R</ne>&lt;10&gt;, -C(O)N(R&lt;11&gt;)2, <ne type="FORMULA" id="WO2007045867.HC.formula-names.18" epochem-id="EPOCHEM:NEW:FORMULA:154" name="CO2R" comment="" chebi-id="WO2007045867:616448" relevant="false">CO2R</ne>&lt;11&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.100" epochem-id="EPOCHEM:NEW:FORMULA:267" name="C(O)R" comment="" chebi-id="WO2007045867:714016" relevant="false">C(O)R</ne>&lt;10&gt;, <ne type="FORMULA" id="WO2007045867.HC.formula-names.9" epochem-id="EPOCHEM:NEW:FORMULA:152" name="CN" comment="" chebi-id="CHEBI:48819" relevant="false">CN</ne> or a group OR&lt;12&gt;; wherein each R&lt;10&gt; is independently <ne type="LIGAND" id="WO2007045867.HC.ligand-names.93" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.8" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.916" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3361" relevant="false">cycloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.948" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.976" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33484" relevant="false">heteroaryl</ne>;
R&lt;11&gt; is independently <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.300" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.94" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.682" epochem-id="EPOCHEM:NEW:LIGAND:302" name="(Ci-C6) haloalkyl" comment="(C1-C6) haloalkyl" chebi-id="WO2007045867:72216" relevant="false">(Ci-C6) haloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.917" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3362" relevant="false">cycloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.949" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.977" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33485" relevant="false">heteroaryl</ne>;
R&lt;12&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.301" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.95" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.9" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.918" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3363" relevant="false">cycloalkyl</ne>, or a group <ne type="FORMULA" id="WO2007045867.HC.formula-names.15" epochem-id="EPOCHEM:NEW:FORMULA:153" name="SO2R" comment="" chebi-id="CHEBI:29825" relevant="false">SO2R</ne>&lt;10&gt;, wherein n is O 1 or 2;
R&lt;5&gt; and R&lt;6&gt; are independently <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.302" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.96" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.83" epochem-id="EPOCHEM:NEW:LIGAND:210" name="(CrC6) haloalkyl" comment="(C1C6) haloalkyl" chebi-id="WO2007045867:195695" relevant="false">(CrC6) haloalkyl</ne>, or R&lt;5&gt; and R&lt;6&gt; together with the atom to which they are attached form a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.919" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3364" relevant="false">cycloalkyl</ne> group; R&lt;7&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.303" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.97" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.10" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>;
R&lt;8&gt; is <ne type="LIGAND" id="WO2007045867.HC.ligand-names.950" epochem-id="EPOCHEM:NEW:LIGAND:528" name="aryl" comment="" chebi-id="CHEBI:33338" relevant="false">aryl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.978" epochem-id="EPOCHEM:NEW:LIGAND:529" name="heteroaryl" comment="" chebi-id="CHEBI:33486" relevant="false">heteroaryl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.845" epochem-id="EPOCHEM:NEW:LIGAND:523" name="aryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:456700" relevant="false">aryl-fused-heterocycloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.839" epochem-id="EPOCHEM:NEW:LIGAND:522" name="heteroaryl-fused-cycloalkyl" comment="" chebi-id="WO2007045867:476609" relevant="false">heteroaryl-fused-cycloalkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.878" epochem-id="EPOCHEM:NEW:LIGAND:524" name="heteroaryl-fused-heterocycloalkyl" comment="" chebi-id="WO2007045867:242991" relevant="false">heteroaryl-fused-heterocycloalkyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.885" epochem-id="EPOCHEM:NEW:LIGAND:526" name="aryl-fused- cycloalkyl" comment="" chebi-id="WO2007045867:764181" relevant="false">aryl-fused-cycloalkyl</ne>; and
R&lt;9&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.304" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.98" epochem-id="EPOCHEM:NEW:LIGAND:211" name="(C1-C6) alkyl" comment="" chebi-id="WO2007045867:310567" relevant="false">(C1-C6) alkyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.11" epochem-id="EPOCHEM:NEW:LIGAND:206" name="(C1-C6) haloalkyl" comment="" chebi-id="WO2007045867:89102" relevant="false">(C1-C6) haloalkyl</ne>, or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.922" epochem-id="EPOCHEM:NEW:LIGAND:527" name="cycloalkyl" comment="" chebi-id="CHEBI:3365" relevant="false">cycloalkyl</ne>.
</P>
<P>2. A compound as claimed in claim 1 wherein R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt; and R&lt;4&gt; are independently selected from <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.305" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.739" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.219" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, n- and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.689" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.781" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.522" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.270" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.282" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.537" epochem-id="EPOCHEM:NEW:LIGAND:296" name="fluoro" comment="" chebi-id="CHEBI:42645" relevant="false">fluoro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.755" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.767" epochem-id="EPOCHEM:NEW:LIGAND:378" name="bromo" comment="" chebi-id="WO2007045867:807484" relevant="false">bromo</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.479" epochem-id="EPOCHEM:NEW:LIGAND:277" name="nitrile" comment="" chebi-id="CHEBI:18379" relevant="false">nitrile</ne>
(<ne type="FORMULA" id="WO2007045867.HC.formula-names.10" epochem-id="EPOCHEM:NEW:FORMULA:152" name="CN" comment="" chebi-id="CHEBI:48819" relevant="false">CN</ne>), -S(O)<ne type="FORMULA" id="WO2007045867.HC.formula-names.81" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">nR</ne>&lt;10&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.23" epochem-id="EPOCHEM:NEW:FORMULA:155" name="SO2N" comment="" chebi-id="WO2007045867:676309" relevant="false">SO2N</ne>(R&lt;11&gt;)2, -N(R&lt;11&gt;)2, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.82" epochem-id="EPOCHEM:NEW:FORMULA:254" name="NR" comment="" chebi-id="CHEBI:32876" relevant="false">NR</ne>&lt;11&gt;<ne type="FORMULA" id="WO2007045867.HC.formula-names.101" epochem-id="EPOCHEM:NEW:FORMULA:267" name="C(O)R" comment="" chebi-id="WO2007045867:714016" relevant="false">C(O)R</ne>&lt;10&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.19" epochem-id="EPOCHEM:NEW:FORMULA:154" name="CO2R" comment="" chebi-id="WO2007045867:616448" relevant="false">CO2R</ne>&lt;11&gt;, -<ne type="FORMULA" id="WO2007045867.HC.formula-names.102" epochem-id="EPOCHEM:NEW:FORMULA:267" name="C(O)R" comment="" chebi-id="WO2007045867:714016" relevant="false">C(O)R</ne>&lt;10&gt;, and -OR&lt;12&gt; wherein each R&lt;10&gt; is independently selected from <ne type="LIGAND" id="WO2007045867.HC.ligand-names.740" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.220" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, n- and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.690" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>; <ne type="LIGAND" id="WO2007045867.HC.ligand-names.782" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne> <ne type="LIGAND" id="WO2007045867.HC.ligand-names.523" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.271" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.283" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.290" epochem-id="EPOCHEM:NEW:LIGAND:104" name="cyclopentyl" comment="" chebi-id="WO2007045867:427337" relevant="false">cyclopentyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.296" epochem-id="EPOCHEM:NEW:LIGAND:106" name="cyclohexyl" comment="" chebi-id="WO2007045867:868001" relevant="false">cyclohexyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.803" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.444" epochem-id="EPOCHEM:NEW:LIGAND:265" name="pyridyl" comment="" chebi-id="WO2007045867:44079" relevant="false">pyridyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.342" epochem-id="EPOCHEM:NEW:LIGAND:221" name="thienyl" comment="" chebi-id="CHEBI:37991" relevant="false">thienyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.394" epochem-id="EPOCHEM:NEW:LIGAND:247" name="furanyl" comment="" chebi-id="CHEBI:24131" relevant="false">furanyl</ne>, and each R&lt;11&gt; is independently selected from <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.306" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.741" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.221" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, n- and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.691" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.783" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.524" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.272" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.284" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.291" epochem-id="EPOCHEM:NEW:LIGAND:104" name="cyclopentyl" comment="" chebi-id="WO2007045867:427337" relevant="false">cyclopentyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.297" epochem-id="EPOCHEM:NEW:LIGAND:106" name="cyclohexyl" comment="" chebi-id="WO2007045867:868001" relevant="false">cyclohexyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.696" epochem-id="EPOCHEM:NEW:LIGAND:303" name="cyclopropylmethyl" comment="" chebi-id="WO2007045867:77384" relevant="false">cyclopropylmethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.698" epochem-id="EPOCHEM:NEW:LIGAND:304" name="cyclopentylmethyl" comment="" chebi-id="WO2007045867:191940" relevant="false">cyclopentylmethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.700" epochem-id="EPOCHEM:NEW:LIGAND:305" name="cyclohexylmethyl" comment="" chebi-id="WO2007045867:83357" relevant="false">cyclohexylmethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.702" epochem-id="EPOCHEM:NEW:LIGAND:306" name="cyclopropylethyl" comment="" chebi-id="WO2007045867:960526" relevant="false">cyclopropylethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.704" epochem-id="EPOCHEM:NEW:LIGAND:307" name="cyclopentylethyl" comment="" chebi-id="WO2007045867:676448" relevant="false">cyclopentylethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.706" epochem-id="EPOCHEM:NEW:LIGAND:308" name="cyclohexylethyl" comment="" chebi-id="WO2007045867:954418" relevant="false">cyclohexylethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.804" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.445" epochem-id="EPOCHEM:NEW:LIGAND:265" name="pyridyl" comment="" chebi-id="WO2007045867:44079" relevant="false">pyridyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.343" epochem-id="EPOCHEM:NEW:LIGAND:221" name="thienyl" comment="" chebi-id="CHEBI:37991" relevant="false">thienyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.395" epochem-id="EPOCHEM:NEW:LIGAND:247" name="furanyl" comment="" chebi-id="CHEBI:24131" relevant="false">furanyl</ne>.
</P>
<P>3. A compound as claimed in claim 1 wherein R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt; and R&lt;4&gt; are independently selected from <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.307" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.756" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne>.
</P>
<P>4. A compound as claimed in claim 1 wherein R&lt;1&gt;, R&lt;3&gt; and R&lt;4&gt; are each <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.308" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne> and R&lt;2&gt; is <ne type="LIGAND" id="WO2007045867.HC.ligand-names.757" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne>.
</P>
<P>5. A compound as claimed in any of the preceding claims wherein R&lt;5&gt; and R&lt;6&gt; are independently selected from <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.309" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.742" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.222" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, n- and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.692" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.784" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.525" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.273" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne>, and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.285" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>.
</P>
<P>6. A compound as claimed in any of claims 1 to 4 wherein R&lt;5&gt; and R&lt;6&gt; together with the atom to which they are attached form a <ne type="LIGAND" id="WO2007045867.HC.ligand-names.274" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.292" epochem-id="EPOCHEM:NEW:LIGAND:104" name="cyclopentyl" comment="" chebi-id="WO2007045867:427337" relevant="false">cyclopentyl</ne> or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.298" epochem-id="EPOCHEM:NEW:LIGAND:106" name="cyclohexyl" comment="" chebi-id="WO2007045867:868001" relevant="false">cyclohexyl</ne> ring.
</P>
<P>7. A compound as claimed in any of claims 1 to 4 wherein both of R&lt;5&gt; and R&lt;6&gt; are <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.310" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>.
</P>
<P>8. A compound as claimed in any of the preceding claims wherein R&lt;7&gt; is selected from <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.311" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.743" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.223" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, n- and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.693" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.785" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.526" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>.
</P>
<P>9. A compound as claimed in any of claims 1 to 7 wherein R&lt;7&gt; is <ne type="LIGAND" id="WO2007045867.HC.ligand-names.744" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>.
</P>
<P>10. A compound as claimed in any of the preceding claims wherein R&lt;8&gt; is optionally substituted <ne type="LIGAND" id="WO2007045867.HC.ligand-names.805" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.711" epochem-id="EPOCHEM:NEW:LIGAND:140" name="naphthyl" comment="" chebi-id="WO2007045867:301239" relevant="false">naphthyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.719" epochem-id="EPOCHEM:NEW:LIGAND:309" name="quinolinyl" comment="" chebi-id="WO2007045867:478166" relevant="false">quinolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.446" epochem-id="EPOCHEM:NEW:LIGAND:265" name="pyridyl" comment="" chebi-id="WO2007045867:44079" relevant="false">pyridyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.344" epochem-id="EPOCHEM:NEW:LIGAND:221" name="thienyl" comment="" chebi-id="CHEBI:37991" relevant="false">thienyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.396" epochem-id="EPOCHEM:NEW:LIGAND:247" name="furanyl" comment="" chebi-id="CHEBI:24131" relevant="false">furanyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.723" epochem-id="EPOCHEM:NEW:LIGAND:310" name="azolyl" comment="" chebi-id="WO2007045867:653414" relevant="false">azolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.359" epochem-id="EPOCHEM:NEW:LIGAND:228" name="thiazolyl" comment="" chebi-id="WO2007045867:487041" relevant="false">thiazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.761" epochem-id="EPOCHEM:NEW:LIGAND:376" name="diazolyl" comment="" chebi-id="WO2007045867:486335" relevant="false">diazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.353" epochem-id="EPOCHEM:NEW:LIGAND:226" name="imidazolyl" comment="" chebi-id="WO2007045867:176925" relevant="false">imidazolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.415" epochem-id="EPOCHEM:NEW:LIGAND:259" name="tetrahydroquinolinyl" comment="" chebi-id="WO2007045867:903584" relevant="false">tetrahydroquinolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.419" epochem-id="EPOCHEM:NEW:LIGAND:260" name="indolinyl" comment="" chebi-id="WO2007045867:725815" relevant="false">indolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.424" epochem-id="EPOCHEM:NEW:LIGAND:261" name="benzodioxinyl" comment="" chebi-id="WO2007045867:180049" relevant="false">benzodioxinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.428" epochem-id="EPOCHEM:NEW:LIGAND:262" name="benxodioxolyl" comment="" chebi-id="WO2007045867:530861" relevant="false">benxodioxolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.432" epochem-id="EPOCHEM:NEW:LIGAND:263" name="dihydrobenzofuranyl" comment="" chebi-id="WO2007045867:234633" relevant="false">dihydrobenzofuranyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.437" epochem-id="EPOCHEM:NEW:LIGAND:264" name="isoindolonyl" comment="" chebi-id="WO2007045867:590048" relevant="false">isoindolonyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.420" epochem-id="EPOCHEM:NEW:LIGAND:260" name="indolinyl" comment="" chebi-id="WO2007045867:725815" relevant="false">indolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.425" epochem-id="EPOCHEM:NEW:LIGAND:261" name="benzodioxinyl" comment="" chebi-id="WO2007045867:180049" relevant="false">benzodioxinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.763" epochem-id="EPOCHEM:NEW:LIGAND:377" name="benzodioxolyl" comment="" chebi-id="WO2007045867:434800" relevant="false">benzodioxolyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.433" epochem-id="EPOCHEM:NEW:LIGAND:263" name="dihydrobenzofuranyl" comment="" chebi-id="WO2007045867:234633" relevant="false">dihydrobenzofuranyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.438" epochem-id="EPOCHEM:NEW:LIGAND:264" name="isoindolonyl" comment="" chebi-id="WO2007045867:590048" relevant="false">isoindolonyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.333" epochem-id="EPOCHEM:NEW:LIGAND:219" name="tetrahydronaphthyl" comment="" chebi-id="WO2007045867:131223" relevant="false">tetrahydronaphthyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.336" epochem-id="EPOCHEM:NEW:LIGAND:220" name="indanyl" comment="" chebi-id="WO2007045867:990977" relevant="false">indanyl</ne>.
</P>
<P>11. A compound as claimed in any of claims 1 to 9 wherein R&lt;8&gt; is optionally substituted <ne type="LIGAND" id="WO2007045867.HC.ligand-names.806" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>.
</P>
<P>12. A compound as claimed in claim 10 or claim 11 wherein any optional substitutents present in R&lt;8&gt; are selected from <ne type="LIGAND" id="WO2007045867.HC.ligand-names.538" epochem-id="EPOCHEM:NEW:LIGAND:296" name="fluoro" comment="" chebi-id="CHEBI:42645" relevant="false">fluoro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.758" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.807" epochem-id="EPOCHEM:NEW:LIGAND:382" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.486" epochem-id="EPOCHEM:NEW:LIGAND:280" name="methanesulfonyl" comment="" chebi-id="WO2007045867:560731" relevant="false">methanesulfonyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.488" epochem-id="EPOCHEM:NEW:LIGAND:281" name="4-ethanesulfonylphenyl" comment="" chebi-id="WO2007045867:89974" relevant="false">4-ethanesulfonylphenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.786" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.482" epochem-id="EPOCHEM:NEW:LIGAND:278" name="morpholine-4-sulfonyl" comment="" chebi-id="WO2007045867:954655" relevant="false">morpholine-4-sulfonyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.484" epochem-id="EPOCHEM:NEW:LIGAND:279" name="pyrrolidine-1-carbonyl" comment="" chebi-id="WO2007045867:270811" relevant="false">pyrrolidine-1-carbonyl</ne>, and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.490" epochem-id="EPOCHEM:NEW:LIGAND:282" name="cyclobutylcarbamoyl" comment="" chebi-id="WO2007045867:828402" relevant="false">cyclobutylcarbamoyl</ne>. 13. A compound as claimed in any of claims 1 to 9 wherein R&lt;8&gt; is selected from <ne type="LIGAND" id="WO2007045867.HC.ligand-names.533" epochem-id="EPOCHEM:NEW:LIGAND:295" name="A- chlorophenyl" comment="4-chlorophenyl" chebi-id="WO2007045867:424096" relevant="false">A- chlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.492" epochem-id="EPOCHEM:NEW:LIGAND:283" name="2-chlorophenyl" comment="" chebi-id="WO2007045867:60121" relevant="false">2-chlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.494" epochem-id="EPOCHEM:NEW:LIGAND:284" name="4-(trifluoromethyl)phenyl" comment="" chebi-id="WO2007045867:81738" relevant="false">4-(trifluoromethyl)phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.495" epochem-id="EPOCHEM:NEW:LIGAND:285" name="4-(methylsulfonyl)phenyl" comment="" chebi-id="WO2007045867:303620" relevant="false">4-(methylsulfonyl)phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.532" epochem-id="EPOCHEM:NEW:LIGAND:294" name="A- fluorophenyl" comment="4-fluorophenyl" chebi-id="WO2007045867:39643" relevant="false">A- fluorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.498" epochem-id="EPOCHEM:NEW:LIGAND:286" name="2-naphthyl" comment="" chebi-id="WO2007045867:92913" relevant="false">2-naphthyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.501" epochem-id="EPOCHEM:NEW:LIGAND:287" name="1 -naphthyl" comment="" chebi-id="WO2007045867:273857" relevant="false">1 -naphthyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.504" epochem-id="EPOCHEM:NEW:LIGAND:288" name="2,3-dichlorophenyl" comment="" chebi-id="WO2007045867:371207" relevant="false">2,3-dichlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.508" epochem-id="EPOCHEM:NEW:LIGAND:289" name="8-quinolinyl" comment="" chebi-id="WO2007045867:2417" relevant="false">8-quinolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.511" epochem-id="EPOCHEM:NEW:LIGAND:290" name="3,5- dichlorophenyl" comment="" chebi-id="WO2007045867:704605" relevant="false">3,5- dichlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.514" epochem-id="EPOCHEM:NEW:LIGAND:291" name="3,4-dichlorophenyl" comment="" chebi-id="WO2007045867:840420" relevant="false">3,4-dichlorophenyl</ne>. 14. A compound as claimed in any of the preceding claims wherein R&lt;9&gt; is selected from <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.312" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.745" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.224" epochem-id="EPOCHEM:NEW:LIGAND:125" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, n- or <ne type="LIGAND" id="WO2007045867.HC.ligand-names.694" epochem-id="EPOCHEM:NEW:LIGAND:18" name="iso-propyl" comment="" chebi-id="WO2007045867:371215" relevant="false">iso-propyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.788" epochem-id="EPOCHEM:NEW:LIGAND:380" name="trifluoromethyl" comment="" chebi-id="WO2007045867:274104" relevant="false">trifluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.527" epochem-id="EPOCHEM:NEW:LIGAND:292" name="difluoromethyl" comment="" chebi-id="WO2007045867:11038" relevant="false">difluoromethyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.275" epochem-id="EPOCHEM:NEW:LIGAND:105" name="cyclopropyl" comment="" chebi-id="CHEBI:30364" relevant="false">cyclopropyl</ne> and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.286" epochem-id="EPOCHEM:NEW:LIGAND:148" name="cyclobutyl" comment="" chebi-id="CHEBI:30376" relevant="false">cyclobutyl</ne>.
</P>
<P>15. A compound as claimed in any of claims 1 to 13 wherein R&lt;9&gt; is <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.313" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>.
</P>
<P>16. A compound as claimed in claim 1 wherein R&lt;1&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt; and R&lt;9&gt; are each <ne type="CHEMICAL" id="WO2007045867.HC.chemical-names.314" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne>, R&lt;2&gt; is <ne type="LIGAND" id="WO2007045867.HC.ligand-names.759" epochem-id="EPOCHEM:NEW:LIGAND:375" name="chloro" comment="" chebi-id="CHEBI:47853" relevant="false">chloro</ne>, R&lt;7&gt; is <ne type="LIGAND" id="WO2007045867.HC.ligand-names.746" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, and R&lt;8&gt; is selected from <ne type="LIGAND" id="WO2007045867.HC.ligand-names.529" epochem-id="EPOCHEM:NEW:LIGAND:293" name="4-chlorophenyl" comment="" chebi-id="WO2007045867:173177" relevant="false">4-chlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.493" epochem-id="EPOCHEM:NEW:LIGAND:283" name="2-chlorophenyl" comment="" chebi-id="WO2007045867:60121" relevant="false">2- chlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.530" epochem-id="EPOCHEM:NEW:LIGAND:284" name="4-(trifluoromethyl)phenyl" comment="" chebi-id="WO2007045867:81738" relevant="false">4-(trifluoromethyl)phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.531" epochem-id="EPOCHEM:NEW:LIGAND:285" name="4-(methylsulfonyl)phenyl" comment="" chebi-id="WO2007045867:303620" relevant="false">4-(methylsulfonyl)phenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.642" epochem-id="EPOCHEM:NEW:LIGAND:298" name="4-fluorophenyl" comment="" chebi-id="WO2007045867:53461" relevant="false">4-fluorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.643" epochem-id="EPOCHEM:NEW:LIGAND:299" name="Z- naphthyl" comment="2-naphthyl" chebi-id="WO2007045867:763753" relevant="false">Z- naphthyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.502" epochem-id="EPOCHEM:NEW:LIGAND:287" name="1 -naphthyl" comment="" chebi-id="WO2007045867:273857" relevant="false">1-naphthyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.505" epochem-id="EPOCHEM:NEW:LIGAND:288" name="2,3-dichlorophenyl" comment="" chebi-id="WO2007045867:371207" relevant="false">2,3-dichlorophenyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.509" epochem-id="EPOCHEM:NEW:LIGAND:289" name="8-quinolinyl" comment="" chebi-id="WO2007045867:2417" relevant="false">8-quinolinyl</ne>, <ne type="LIGAND" id="WO2007045867.HC.ligand-names.512" epochem-id="EPOCHEM:NEW:LIGAND:290" name="3,5- dichlorophenyl" comment="" chebi-id="WO2007045867:704605" relevant="false">3,5-dichlorophenyl</ne>, and <ne type="LIGAND" id="WO2007045867.HC.ligand-names.515" epochem-id="EPOCHEM:NEW:LIGAND:291" name="3,4-dichlorophenyl" comment="" chebi-id="WO2007045867:840420" relevant="false">3,4- dichlorophenyl</ne>.
</P>
<P>17. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims together with one or more pharmaceutically acceptable carriers.
</P>
<P>18. The use of a compound as claimed in any of claims 1 to 16 in the manufacture of a composition for treatment of a condition responsive to modulation of CRTH2 receptor activity.
</P>
<P>19. A method of treatment of a condition responsive to modulation of CRTH2 receptor activity, comprising administering to a patient suffering such condition an effective amount of a compound as claimed in any of claims 1 to 16. 20. The use as claimed in claim 18 or a method as claimed in claim 19 wherein the condition is selected from asthma, chronic obstructive pulmonary disease, allergic airway syndrome, bronchitis, cystic fibrosis, emphysema and rhinitis. 21. The use as claimed in claim 18 or a method as claimed in claim 19 wherein the condition is selected from psoriasis, atopic and non-atopic dermatitis Crohn's disease, ulcerative colitis, and irritable bowel disease.
</P></DIV>
</BODY>
</PAPER>
